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“Coronary heart disease is now the leading cause of death worldwide; it is on the rise 
and has become a true pandemic that respects no borders”
 (World Health Organization, 2009) 
Cardiovascular disease (CVD) is the leading cause of death in the Western world, with 
CVD accounting for 32% of all deaths in the United States in 2009 1. In the Netherlands, 
mortality rates are comparable, with 30% of total deaths being attributable to CVD in 2012 
2. Coronary artery disease (CAD) is one of the most common types of CVD and accounted 
for nearly half of all cardiovascular deaths, and 1 of every 6 deaths in the United States in 
2009 1. In the Netherlands, CAD accounted for 25% of all cardiovascular deaths in 2012 
2. Over the past decades, mortality rates have declined considerably due to improved 
treatment options, resulting in an increased number of patients living longer with CAD 1, 
3. Hence, CAD imposes a high burden on patients, caregivers, and the health care system 
worldwide 4. Despite the decline in mortality rates, CAD is still expected to be the leading 
cause of death worldwide in 2030 5, and is number one on the list of projected top 10 
diseases with the largest disease burden worldwide in 2020 6.
CAD, generally caused by atherosclerosis, refers to abnormalities in the coronary 
arteries that facilitate the supply of blood and oxygen to the heart 7, 8. Due to plaque growth 
inside the lumen of coronary arteries, they may become narrowed, which may lead to 
ischemic chest pain (i.e., angina pectoris). If a coronary artery becomes fully blocked due 
to plaque rupture and the subsequent formation of thrombosis, this may result in an acute 
coronary syndrome (ACS), such as myocardial infarction (MI) 7, 8. In 2009, the prevalence 
of CAD in the Netherlands was estimated at 5% in men and 3% in women, whereas the 
annual incidence was 6 per 1000 men and 4 per 1000 women of the Dutch population 9.
CORONARY REVASCULARIZATION PROCEDURES
In patients with CAD, coronary revascularization is a common procedure to treat narrowed 
or obstructed arteries in order to restore coronary blood flow. Coronary artery bypass graft 
(CABG) surgery and percutaneous coronary intervention (PCI) comprise the 2 primary 
means of such revascularization 10, 11. 
Since its introduction in 1968, CABG surgery rapidly became the treatment of 
choice for patients with CAD needing revascularization. During CABG surgery, narrowed 
or obstructed coronary arteries are bypassed by grafting vessels from elsewhere in the 
body 12. Usually, “on-pump” CABG surgery is performed, with cardiopulmonary bypass (or 
heart-lung machine) taking over heart and lung functioning during surgery to maintain 
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blood and oxygen circulation throughout the body 13. Over the past decades, there has 
been growing interest in performing CABG on a beating heart, also referred to as “off-
pump surgery” 14. 
PCI was introduced by Andreas Grüntzig in 1977 and is a less invasive, non-
surgical revascularization procedure 15. During the first PCI procedures, balloon dilatation 
was used to dilate the narrowed or obstructed coronary artery, this way restoring 
coronary blood flow. In 1986, this dilatation procedure was revolutionalized by inserting 
a “bare”-metal stent in the artery to retain the dilated vessel open (Figure 1). In 2000, the 
PCI procedure was further improved by the development of the so-called “drug-eluting 
stent”(DES), which releases a drug in the dilated artery to block cell growth and to reduce 
the risk for restenosis (i.e., recurrent narrowing or obstruction of the artery) 16. Previously, 
restenosis occurred in 30-50% of patients treated with PCI without stenting, whereas this 
risk decreased to 10-30% with bare-metal stenting. The introduction of DES has further 
decreased the risk for restenosis and the need for repeated revascularization as compared 
with bare-metal stenting 17. 
Figure 1. Schematic representation of a PCI procedure
Illustrator: Auke Herrema
A.            Deflated ballon inserted in the affected artery via a cathether
B.            Balloon dilatation





When PCI was first introduced, this method was thought to be appropriate only 
for patients with single-vessel disease (i.e., no more than 1 coronary artery being narrowed 
or obstructed) 15. Increased experience with this non-surgical procedure and improved 
technology expanded its use to patients with more complex CAD, such as multi-vessel 
disease 18. Today, PCI is the most frequently used revascularization strategy in CAD, with 
MI, unstable angina pectoris, and stable angina pectoris being common indications 10, 
11. In 2012, 45.305 CAD patients were treated with PCI in the Netherlands, versus 11.240 
patients undergoing CABG surgery in that same year 2 (Figure 2). 




(i.e., CABG and valve surgeries)
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RISK FACTORS FOR CORONARY ARTERY DISEASE
Traditional risk factors
Hypertension, hypercholesterolemia, smoking, diabetes mellitus, abdominal obesity, 
physical inactivity, and unhealthy diet have been established as the most important 
modifiable risk factors for incident CAD and poor prognosis in patients with established 
CAD, whereas non-modifiable risk factors include age, male gender, and a family history 
of CAD 1, 19, 20. Several risk estimation algorithms, such as the Systematic COronary 
Risk Evaluation (SCORE) algorithm, have been developed to identify persons at high 
cardiovascular risk 19, 21. With regard to the prognostic impact of obesity in patients with 
established CAD, evidence is still inconclusive, as some studies show better survival rates 
for overweight or obese CAD patients, a phenomenon referred to as the “obesity paradox” 
22, 23. So far, it remains unclear how this phenomenon may be explained. 
Psychological risk factors
In addition to traditional biomedical risk factors, there has been growing interest in the 
role of psychological factors in CAD 19, 24. Psychological distress is a rather broad concept 
and refers to a wide range of episodic (e.g., anxiety and depression) and chronic stressors 
(e.g., personality). Psychological distress is highly prevalent in patients with established 
CAD, affecting 1 in 4 patients, and has been linked to increased cardiovascular morbidity 
and mortality 25, 26 and poorer patient-reported outcomes, such as impaired health status 
and quality of life 27-29. Health status refers to the patient’s perception of the impact of 
disease or treatment on functional limitations, symptoms, and quality of life, in which 
quality of life is the discrepancy between actual and desired function 30. In initially healthy 
persons, psychological distress has been linked to a higher risk for incident CAD 24.
The identification of patients at high-risk for psychological distress is essential, 
as it may enhance secondary prevention efforts and point to targets for intervention. 
The 2012 European Guidelines for Prevention of Cardiovascular Diseases of the European 
Society of Cardiology state that psychological factors should be assessed in patients with 
established CAD but also in those at risk for incident CAD 19. The guidelines specifically refer 
to anxiety, depression, and the distressed (Type D) personality in their list of recommended 
psychological risk factors to screen for, which will be discussed in more detail in the 
subsequent sections. Although over the past decades a vast amount of research focused 
on the impact of psychological distress on incident CAD as well as its prognostic impact 
in patients with established CAD, the level of evidence remains moderate (i.e., class IIa 




The role of negative emotions 
Most studies on the association between psychological distress and CAD have focused 
on the role of depression. According to the Diagnostic and Statistic Manual of Mental 
Disorders, Fifth Edition (DSM-5), depression is characterized by low mood and/or a loss of 
interest or pleasure in daily activities. These symptoms are often accompanied by a change 
in appetite or weight, insomnia or hypersomnia, psychomotor agitation or retardation, 
fatigue or loss of energy, feelings of worthlessness and guilt, concentration problems, and 
suicidal ideation. The presence of at least 5 out of 9 symptoms for most of the day, nearly 
every day, and for at least 2 weeks, warrants a diagnosis of major depressive disorder 
(MDD) 31. 
The prevalence of depression is high in CAD. Around 20% of patients suffer 
from MDD after an MI 32, whereas self-reported depressive symptoms are prevalent in 
25-50% of CAD patients 26, 32, 33. These rates are approximately 3 times higher than rates 
reported in the general population 32. A recent meta-analysis confirmed that depression is 
associated with a 1.6 to 2.7-fold increased risk for all-cause mortality and adverse cardiac 
events up to 2 years post-MI, independent of disease severity 26. Besides, depression has 
been associated with impaired health status 27, 29, 34, poor adherence to treatment 35, 36, and 
increased health care consumption 37 in patients with established CAD. 
Anxiety comprises the second most frequently studied psychological distress 
factor in the context of CAD. Anxiety refers to feelings of fear, worry, and uneasiness in 
response to a perceived threat 31, often resulting from a sense of being unable to predict, 
control, or obtain a desired outcome 38. Anxiety is often accompanied by increased 
activity of the autonomic nervous system and ranges along a continuum from normal 
to pathological 31. Pathological anxiety, or anxiety disorders, include among others 
generalized anxiety disorder, panic disorder, agoraphobia, post-traumatic stress disorder, 
specific phobia, and social phobia 31. 
Around 45% of patients with CAD present with an anxiety disorder at some 
point in their life 39, whereas self-reported anxiety symptoms are observed in 20-60% of 
CAD patients 25. Although anxiety is highly prevalent in patients with CAD, its impact on 
prognosis is less clear. According to recent meta-analyses, anxiety is associated with a 1.2 
to 1.7-fold increased risk of cardiovascular morbidity and mortality in CAD patients who 
suffered an MI 25. However, in other studies no such associations 40, 41 or even protective 
effects of anxiety on survival were reported in patients with established CAD 42-44. The 
better survival rates in anxious patients may be attributed to a more optimal help-seeking 
pattern for somatic complaints in (non-phobic) anxious patients. It is known that anxious 
patients are more likely to receive coronary angiography even in the presence of less 
severe or insignificant CAD, which could facilitate earlier initiation of adequate treatment. 
Further, in contrast to depressed patients, anxious patients may be more motivated to 
17
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control their CAD risk factors and have a better adherence to treatment 37, 42, 43. However, 
evidence on this topic is scarce and conflicting, as poor adherence to treatment and life 
style recommendations has also been reported in anxious MI patients 45, 46. Finally, like 
depression, anxiety has been associated with poorer patient-reported outcomes in 
patients with CAD, including impaired health status and quality of life 27, 29, 47.
Type D personality
Besides episodic stressors, such as anxiety and depression, personality traits have been 
linked to CAD outcomes. Type D personality is a commonly investigated trait in this context, 
which originates from clinical and research work on Belgian CAD patients attending cardiac 
rehabilitation 48. The construct focuses on the differential effect of individual coping styles 
on emotional and physical health 49, and how the interaction between different personality 
traits may affect prognosis 50. Type D personality is composed of 2 broad personality traits: 
Negative affectivity (NA) and social inhibition (SI). Individuals scoring high on negative 
affectivity tend to experience negative emotions (e.g., feeling down in the dumps) across 
time and situations, while individuals scoring high on social inhibition tend not to express 
these negative emotions in social situations out of fear of rejection or disapproval 48. 
Type D personality is prevalent in 25-37% of CAD patients 48, 51. Evidence suggests 
that CAD patients with a Type D personality are 1.4 to 3.7 times more likely to die and to 
experience adverse cardiac events as compared with non-Type D patients 52, 53. Further, 
Type D personality is associated with increased anxiety and depression 54-56, impaired 
health status 28, and poor medication adherence 57, 58. However, in a recent meta-analysis, 
the authors concluded that although there is a significant association between Type D 
personality and prognosis in cardiac patients, the strength of this effect has been declining 
over the years and that therefore, the effect of Type D might have been overestimated in 
previous studies 59. Further, an effect for Type D personality on prognosis was mainly found 
in CAD patients with acute coronary syndromes, such as post-MI and CABG patients, but 
not in heart failure patients 59.  
Another avenue to pursue: The role of positive emotions
In contrast to the vast amount of research focusing on the impact of negative emotions 
on CAD outcomes, the role of positive emotions has received less attention 60, 61. Positive 
affect refers to mood states such as joy, activity, and cheerfulness 62, and is not merely the 
opposite of negative affect 63, as both types of affect can be present simultaneously 64. High 
levels of positive affect have been associated with a decrease in hospital readmissions 
in patients with established CAD 65, lower incident hypertension 66, and lower incident 
CAD 67, while studies on the association between positive affect and survival have shown 




reduced positive affect) on CAD outcomes, indicating that anhedonia is associated with a 
higher risk for mortality and adverse cardiac events up to 2 years follow-up 60, 70 as well as 
with poorer patient-reported outcomes, such as impaired health status 71, 72. 
Potential underlying mechanisms
Several potential pathways have been proposed as underlying mechanisms for the 
relationship between psychological distress and poor prognosis in CAD. Biological 
pathways include the hypothalamus-pituitary-adrenal axis 73, 74, autonomic nervous system 
functioning 75, 76, coronary plaque burden 77, 78, and inflammation 79. In addition, behavioral 
pathways have been suggested, with psychologically distressed patients being less likely 
to engage in optimal health-related behaviors, such as exercising, quitting smoking, and 
adhering to dietary advice 75, 80, 81. These potential pathways largely remain speculative, 
as few studies have examined these pathways as potential links between psychological 
distress and prognosis in CAD, and results being inconsistent.
CURRENT KNOWLEDGE GAPS 
Although considerable literature is available on the role of psychological distress in 
CAD, demonstrating that negative emotions, such as anxiety, depression, and Type D 
personality, are highly prevalent in CAD patients and associated with adverse clinical and 
patient-reported outcomes, several knowledge gaps can be identified. 
There is a gap in our understanding of the impact of psychological distress on 
long-term prognosis in CAD patients, as on average follow-up durations of previous 
studies ranged between 1.5 and 2.5 years 25, 26. Further, there has been a tendency in the 
literature to focus on one psychological risk factor at a time, which has also been labeled 
as the 'risk factor of the month approach' 82. The question remains whether psychological 
distress factors, such as anxiety and depression, exert an independent effect on prognosis 
in CAD or whether other psychological factors may explain some of the variance of these 
associations, as they are often inter-related and co-occur 82, 83. In addition, the majority of 
studies focusing on the prognostic impact of episodic psychological risk factors do not take 
into account the role of more stable factors, such as personality 83. Finally, the mechanisms 
through which psychological distress may lead to poorer prognosis in CAD remain unclear, 
warranting more research, as this knowledge may facilitate the development of successful 
psychological intervention trials in the future.
From a methodological point of view, we know little about the occurrence 
of attrition bias in studies on patients with CAD and the associated consequences 
for conclusions drawn. The majority of previous studies examining the prevalence 
of psychological factors and their impact on clinical outcome in CAD patients used a 
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prospective cohort design in combination with standardized and validated questionnaires 
as the primary methodology 25, 26, 28, 59. A potential attrition bias can be introduced if 
patients who complete the study (“completers”) versus patients who are lost to follow-up 
(“drop-outs”) differ systematically on baseline characteristics, exposure to risk factors, or 
outcome variables 84, jeopardizing the conclusions drawn - as there may be an over- or 
underestimation of the true effect - and the generalizability 85. However, we know little 
about differences between completers and drop-outs, as most previous prospective 
studies do not report drop-out rates, reasons for drop-out, or compare the characteristics 
of drop-outs versus completers 86.
So far, the majority of previous studies on psychological distress in CAD have 
focused on post-MI, CABG, or general CAD patients. Despite PCI being currently the 
most commonly used coronary revascularization procedure, few studies have focused 
on the patient perspective in PCI. Although MI patients account for a substantial part of 
the PCI population, unstable and stable angina pectoris are also common indications. A 
previous study in admitted unstable angina pectoris patients identified depression in 41% 
of patients and showed that depressed angina patients were more than 6 times more 
likely to experience an adverse cardiac event as compared with non-depressed patients 
87. Little is known about the impact of psychological distress in PCI patients, including 
broad indications ranging from stable and unstable angina to MI, and whether it is similar 
to that reported in post-MI, CABG, and general CAD populations, or whether disease- and 
treatment-specific processes play a role in this context. 
THE CURRENT DISSERTATION: FOCUS ON PATIENTS TREATED WITH PCI
The current dissertation extends previous research by focusing on the psychological well-
being of patients treated with PCI and the impact of psychological distress on long-term 
survival in this specific patient group. Further, the current dissertation will briefly tap into 
potential underlying mechanisms that may explain the link between psychological distress 
and poorer prognosis in patients treated with PCI and addresses the issue of attrition bias 
in prospective cohort studies and its potential consequences for study conclusions. 
Except for Chapter 10, all studies presented in this dissertation are based on data 
collected in the Erasmus MC, Rotterdam, the Netherlands. In total, 4 cohorts of patients 
treated with PCI between 2001 and 2011 are included (Table 1). In Chapter 10, data from 
the national Danish Heart Registry was used to identify patients admitted to Danish 
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BMS = Bare-metal stent, DS14 = Type D scale, EES = everolimus-eluting stent, HADS = Hospital Anxiety and 
Depression Scale, PES = paclitaxel-eluting stent, PHQ-9 = 9-item Patient Health Questionnaire, RRP10 = 
Remembered Relationship with Parents scale, SES = sirolimus-eluting stent, SF-36 = 36-item Short-Form Health 
Survey, STAI-S = State measure of the State-Trait Anxiety Inventory
* Data was partly gathered by Nikki Damen from Sept 2010 – May 2012
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Aims and outline of this dissertation
As aforementioned, indications for PCI include MI, unstable angina pectoris, and stable 
angina pectoris 10. One might expect that MI patients undergoing a PCI procedure 
experience higher levels of anxiety and depression than those with unstable angina 
pectoris or stable angina pectoris, due to the more acute nature of the cardiac event. To 
date, little is known about the influence of indication for PCI on psychological distress 54. 
Hence, the aim of Chapter 2 is to examine the association between indication for PCI (i.e., 
MI, unstable angina pectoris, or stable angina pectoris) and anxiety and depression levels 
in the first year post-PCI. 
When examining anxiety and depression levels in cardiac patients this is generally done by 
means of incidence and prevalence rates 88, or changes in overall mean scores over time 54. 
However, these approaches mask intra-individual changes over time and, consequently, 
potential differential risks of adverse health outcomes may be overlooked 89. Chapter 3 
reports on changes in anxiety and depression over a 12-month period post-PCI using an 
intra-individual approach, and identifies the demographic and clinical correlates of these 
changes. 
Although substantial research has focused on the association between depression and 
mortality in CAD, only a paucity of studies examined the impact of depression on long-
term mortality (≥5 years), with results being inconsistent 33, 42, 90. To our knowledge, no such 
studies are available in PCI patients. Hence, in Chapter 4 we study the association between 
depression and long-term mortality with a median follow-up duration of 7 years post-PCI. 
Given that there has been a tendency in the literature to focus on one psychological risk 
factor at a time, also called 'risk factor of the month approach' 82, we also examine whether 
the effect of depression on mortality is independent of anxiety and Type D personality. In 
relation to Chapter 4, a letter to the editor and our reply have been added at the end of 
the chapter. 
A paucity of studies focused on the impact of anhedonia on short-term prognosis 60, 70, 
but it is not yet known whether anhedonia is associated with long-term prognosis. Hence, 
in Chapter 5, the impact of anhedonia on long-term mortality with a median follow-up 
duration of 7 years post-PCI is presented. 
Medical explanations, such as differences in medication prescriptions 23, 91, do not provide 
a clear understanding of the obesity paradox, which refers to the better survival rates 
reported in overweight or obese CAD patients 27, 28. Impaired health status has been linked 




obesity and health status 94, 95, but the role of health status in the context of obesity and 
mortality in CAD has not yet been examined. Hence, in Chapter 6 we pursue health status 
as a potential explanation for the obesity paradox in patients treated with PCI.
Both Type D personality and dysfunctional parenting styles, like overprotection or coldness, 
are associated with anxiety and depression 54, 96. As parenting styles have been related to 
personality development 97, 98, dysfunctional parenting styles may also be associated with 
Type D personality, which in turn may increase the risk for anxiety and depression. Chapter 
7 examines whether remembered parenting is associated with anxiety and depression in 
cardiac patients and whether Type D personality mediates this relationship. 
Chapter 8 elaborates on inflammation and coronary plaque burden as potential 
mechanisms underlying the relationship between psychological distress and prognosis 
in patients treated with PCI. More specifically, in this cross-sectional study we examined 
whether psychological distress is associated with selected inflammatory markers or the 
extent of coronary plaque burden, as measured by intravascular ultrasound 99.
In the majority of previous studies as well as in the current dissertation, the prospective 
cohort design in combination with standardized and validated questionnaires has been 
the primary methodology used to examine a link between psychological factors and CAD 
outcomes 25, 26, 28, 59. Chapter 9 investigates the possible occurrence and consequence of 
attrition bias in a prospective cohort study by examining differences in socio-demographic, 
clinical, and psychological (i.e., anxiety, depression, and Type D personality) baseline 
characteristics, and 4-year risk for all-cause mortality between completers and drop-outs 
at 12 months in patients treated with PCI.
Besides PCI, CABG surgery is a commonly performed coronary revascularization strategy 
10, 11. Little is known about potential differences in patient well-being between CABG 
and PCI patients. A more invasive procedure may be associated with increased use of 
psychopharmaca. Hence, the aim of Chapter 10 is to prospectively examine differences in 
antidepressant and anxiolytic medication use between CABG and PCI patients up to 12 
months post-index event, using data from the national Danish Heart Registry. 
Finally, in Chapter 11 the main findings of this dissertation are discussed and implications 
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Percutaneous coronary intervention (PCI) is one of the mainstays of treatment for patients 
with coronary artery disease (CAD). Indications for PCI include myocardial infarction (MI), 
unstable angina pectoris (UAP), and stable angina pectoris (SAP). Previous studies have 
demonstrated that PCI indication is associated with different cardiovascular morbidity 
and mortality rates 1, 2. 
Anxiety and depression are prevalent in 25-50% of CAD patients 3-5 and are 
associated with poor prognosis 3, 4, impaired health-related quality of life (HRQOL) 5, and 
increased health-care consumption 4. A paucity of studies examined the association 
between indication for treatment and levels of psychological distress in cardiac patients, 
with these studies mainly focusing on acute coronary syndrome (ACS) 6-8 and implantable 
cardioverter defibrillator (ICD) patients 9, and results being inconsistent. 
Although some studies focusing on predictors of anxiety and depression post-PCI 
included PCI indication in their multivariable models 10, 11, the independent contribution 
of this factor on psychological distress levels over time is still unclear. One might expect 
that MI patients undergoing PCI experience higher levels of anxiety and depression than 
those with UAP or SAP, due to the more acute nature of the cardiac event. If confirmed, this 
could point to targets for the identification and management of psychological distress 
in PCI patients. Hence, the aim of the current prospective cohort study was to examine 
the association between indication for PCI (i.e., PCI for MI, UAP, or SAP, respectively) and 
anxiety and depression levels in the first year post-PCI. 
Our sample comprised 791 consecutive patients (76.9% men; mean age 63.3±10.7 
years, range [30-87] years) who underwent PCI between July 1, 2003 and September 14, 
2006 at the Erasmus MC, Rotterdam, the Netherlands. At baseline (i.e., 4 weeks post-PCI) 
and 12 months post-PCI, patients completed the Dutch version of the Hospital Anxiety and 
Depression Scale (HADS) to assess symptoms of anxiety and depression 12. Information on 
socio-demographic and clinical variables was systematically collected at the time of the 
index-PCI (baseline) and recorded in our institutional database. 
The association between indication for PCI and anxiety and depression levels was 
examined by analysis of variance (ANOVA) for repeated-measures with indication (i.e., MI, 
UAP, and SAP) entered as a between-subject factor. Analysis of covariance (ANCOVA) for 
repeated measures was conducted to adjust for the potential confounding effects of socio-
demographic (i.e., gender and age) and clinical characteristics (i.e., multi-vessel disease, 
cardiac history, hypertension, diabetes mellitus, family history of CAD, self-reported 
smoking, body mass index (BMI), and prescribed cardiac discharge medications (i.e., 
ACE-inhibitors, beta-blockers, calcium-antagonists, diuretics, oral nitrates, and statins)). 
Covariates were selected a priori based on the literature 1, 7. 
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In the current study, 19.3% (153/791) of patients was treated with PCI because 
of MI, 34.0% (269/791) due to UAP, and 46.6% (369/791) due to SAP. Mean anxiety and 
depression scores stratified by indication for PCI are shown in Figure 1. ANOVA for 
repeated measures showed that patients treated with PCI due to MI, UAP, or SAP did not 
differ significantly on anxiety (F2-783=.85, p=.43) and depression (F2-788=.67, p=.51) levels. 
The interaction effect of indication for PCI by time (F2-783=.35, p=.71 for anxiety and 
F2-788=.35, p=.71 for depression levels, respectively) and the main effect of time (F1-783=.04, 
p=.84 for anxiety and F1-788=.04, p=.84 for depression levels, respectively) were also not 
significant. This indicates that the anxiety and depression levels were generally stable over 
time, and independent of indication for PCI. Our main results did not change in adjusted 
analyses (Table 1). 


















Table 1. Indication for PCI and anxiety and depression levels
Anxiety Depression
F p F p
ANOVA for repeated measures
Indication for PCI a .85 .43 .67 .51
Time .04 .84 .04 .84
Indication for PCI * Time .35 .71 .35 .71
ANCOVA for repeated 
measures
Indication for PCI a .55 .58 .65 .52
Indication for PCI * Time .93 .39 .53 .59
Male gender 9.00 .003** .80 .37
Age 18.77 <.001*** .01 .92
Multi-vessel disease .00 .98 .40 .53
Cardiac history b 1.12 .29 2.98 .085
Hypertension 2.23 .14 .25 .62
Diabetes mellitus 1.47 .23 1.88 .17
Family history of CAD .02 .89 .94 .33
Self-reported smoking .75 .39 4.41 .036*
BMI 3.79 .052 .00 .99
ACE-inhibitors 2.02 .16 .63 .43
Beta-blockers .71 .40 4.18 .041*
Calcium-antagonists .10 .76 2.43 .12
Diuretics 2.10 .15 4.68 .031*
Oral nitrates 1.04 .31 .43 .51
Statins .02 .90 .02 .89
*p≤.05; ** p≤.01; ***p≤.001
a Percutaneous coronary intervention (PCI) for myocardial infarction (MI), unstable angina pectoris (UAP), 
or stable angina pectoris (SAP)
b Previous MI, PCI, or coronary artery bypass graft (CABG) surgery 
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease
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The current study showed that indication for PCI was not systematically associated 
with anxiety and depression, which is in line with the findings from previous studies in 
ACS 6, 8 and ICD 9 patients. Although one study demonstrated that ACS patients presenting 
with UAP had a significantly poorer HRQOL 7 months after their index-hospitalization as 
compared to patients presenting with MI 6, our study results did not corroborate this 
finding. This discrepancy may be explained by the focus on HRQOL rather than anxiety/
depression, and the focus on ACS patients.
Although we expected MI patients undergoing PCI to experience higher levels of 
anxiety and depression than UAP or SAP patients, the current study did not confirm this 
hypothesis. It is plausible that especially psychological factors related to the subjective 
experience of the cardiac event are predictive of psychological distress in the long-term 
rather than objective measures of disease severity 8. Previous studies have identified several 
psychological correlates of anxiety and depression in CAD, including the distressed (Type 
D) personality (i.e., the combination of negative affectivity and social inhibition traits) 11, 
13 and acute distress and fear of dying 8. Given that anxiety and depression are associated 
with adverse clinical and patient-reported outcomes in CAD patients 4, 5 and tend to be 
stable over time 10, 11, it is recommended that future research and clinical practice focus on 
the early identification of patients at high-risk for psychological distress and look beyond 
factors related to disease severity and treatment. 
Limitations of the current study should be acknowledged. First, no information 
on left ventricular ejection fraction was collected, which is an important risk factor for poor 
prognosis in CAD 4. Second, no information on participation in cardiac rehabilitation and 
prescription of psychotropic medication was collected. Third, 31.5% of patients completing 
the HADS at baseline did not complete the HADS at 12 months. Possibly, a sampling bias 
occurred with those patients scoring higher on anxiety or depression being more likely to 
drop-out, as has been found in other studies 14. Finally, as anxiety and depression levels 
were only assessed at 2 time points, mixed modelling was not feasible on our data. 
In conclusion, in the current study patients treated with PCI for MI, UAP, or SAP 
did not differ in their anxiety and depression levels. Future research and clinical practice 
should focus on the early identification of patients at high-risk for psychological distress, 
and look beyond factors related to disease severity and treatment.
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Background: Only a paucity of studies focused on intra-individual changes in anxiety 
and depression over time and its correlates in cardiac patients, which may contribute to 
the identification of high-risk patients and point to targets for intervention. We examined 
changes in anxiety and depression over a 12-month period and the socio-demographic 
and clinical correlates of change scores using an intra-individual approach in patients 
treated with percutaneous coronary intervention (PCI). 
Methods: Consecutive PCI patients (N=715) completed the Hospital Anxiety and 
Depression Scale (HADS) at baseline and 12 months post-PCI. Individual change scores 
were calculated and in secondary analyses, 3 categories of change were identified (i.e., 
stable, improved, and deteriorated anxiety or depression).
Results: The mean individual change was -.16 (±3.0) for anxiety and -.02 (±2.8) for 
depression. In linear regression analyses, baseline anxiety levels (B=-.25, 95%CI [-.30 - -.20], 
p<.001) and baseline depression levels (B=-.28, 95%CI [-.33 - -.22], p<.001) were significant 
correlates of individual change scores. Secondary analyses showed that anxiety remained 
stable in 76.4% (546/715) of patients, while depression remained stable in 81.4% (582/715) 
of patients. 
Conclusions: The findings of the current study showed that levels of anxiety and depression 
remained stable in the majority of PCI patients from the index-PCI to 12 months post-
PCI. Future studies using an intra-individual approach are warranted to further examine 
individual changes in anxiety and depression over time in CAD, and PCI in particular, as a 
means to bridge the gap between research and clinical practice. 
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INTRODUCTION
Anxiety and depression are common in patients with established coronary artery 
disease (CAD) 1, with prevalence rates ranging from 20-50% for anxiety 2, 3 and 30-60% 
for depression 4-6, respectively. Both anxiety and depression have been associated with 
increased cardiovascular morbidity and mortality 7-9, increased health care consumption 
2, 3, and impaired health-related quality of life 10. Generally, anxiety and depression in CAD 
have been examined by means of incidence and prevalence rates 2, 9, or changes in overall 
mean scores over time 11, 12. However, these approaches mask intra-individual changes 
over time and, consequently, potential differential risks of adverse health outcomes may 
be overlooked 7, 12-14.
Given that anxiety and depression are associated with poor prognosis in CAD 
7-9, knowledge of the correlates of changes in anxiety and depression may contribute to 
the identification of high-risk patients 15 and point to targets for intervention 16. Only a 
paucity of studies have focused on intra-individual changes in anxiety and depression 
over time and its correlates in cardiac patients using different statistical approaches, with 
these studies focusing on implantable cardioverter defibrillator (ICD) patients 17, 18, post-
myocardial infarction (MI) patients 7, 14, patients admitted for elective coronary artery 
bypass grafting (CABG) surgery 9, 12, 14, and a specific subsample of exhausted patients 
treated with percutaneous coronary intervention (PCI) 15. Hence, the aims of the current 
study in patients treated with PCI were to 1) examine changes in anxiety and depression 
over time using an intra-individual approach, and 2) examine the socio-demographic and 
clinical correlates of changes in anxiety and depression over a 12-month period.
METHODS
Our sample comprised 715 consecutive patients (75.8% men; mean age 63.6±10.8 years, 
range [30-87] years) treated with PCI at the Erasmus MC, Rotterdam, the Netherlands. 
The Dutch version of the 14-item Hospital Anxiety and Depression Scale (HADS) was 
used to assess levels of anxiety and depression at baseline (i.e., 4 weeks post PCI) and 
at 12 months post-PCI 19. The HADS anxiety and depression subscale scores range from 
0 to 21, with a higher score indicating higher levels of distress. Given the 2 time points, 
individual change scores were calculated using the absolute difference between levels of 
anxiety and depression at baseline and 12-month follow-up. Linear regression analyses 
were used to examine correlates of these individual change scores. A priori, we decided 
to enter gender, age, indication for PCI (stable angina/unstable angina vs. myocardial 
infarction (MI)), multi-vessel disease (multi-vessel disease vs. single-vessel disease/no 




(hypertension, hypercholesterolemia, family history of CAD, self-reported smoking, and 
diabetes mellitus) as potential correlates of change based on the literature 15, 16. Moreover, 
in order to correct for regression to the mean, we adjusted for baseline levels of anxiety 
and depression 20. Prescribed cardiac medications were not considered, as there is no 
evidence to suggest that they have an influence on anxiety and depression scores. 
In secondary analyses, established cut-off scores of the HADS (i.e., scores ranging 
from 0 to 7 indicating normal levels, scores ranging from 8 to 11 indicating mild to 
moderate levels, and scores ≥12 indicating severe levels of anxiety and depression) were 
used to identify 3 categories of change in anxiety and depression (i.e., stable, improved, 
and deteriorated) 21. Using logistic regression analyses, we focused on correlates of 
deteriorated anxiety and depression using stable/improved as the reference category. 
The study protocol was approved by the medical ethics committee of the 
participating hospital and conducted according to the Helsinki declaration 22. Patients 
participated on a voluntary basis, and were able to withdraw from the study at any 
moment, without this decision having implications for future medical treatment. Every 
patient provided informed consent.
RESULTS
The mean anxiety and depression scores at baseline for the total sample were 5.3 (±3.7) 
and 4.4 (±3.8), while 12-month mean scores were 5.1 (±4.0) and 4.4 (±3.8). The mean 
individual change in anxiety scores was -.16 (±3.0), while the mean individual change in 
depression scores was -.02 (±2.8). Overall, univariable and multivariable analyses yielded 
similar results. In multivariable linear regression analyses, only baseline anxiety levels 
(B=-.25 95%CI [-.30 - -.20], p<.001) and baseline depression levels (B=-.28, 95%CI [-.33 - 
-.22], p<.001) were significantly associated with individual change scores in anxiety and 
depression over the 12-month follow-up period (Table 1), with higher baseline levels 
associated with less of a change in anxiety and depression scores over time. 
As listed in Tables 2a and 2b, anxiety remained stable in 76.4% (546/715) of patients, 
while depression remained stable in 81.4% (582/715) of patients. Anxiety improved in 
10.9% (78/715) of patients and in 12.7% (91/715) of patients anxiety deteriorated. In 9.0% 
(64/715) of patients depression improved and in 9.7% (69/715) of patients depression 
deteriorated. In multivariable logistic regression analyses, baseline levels of anxiety were 
highly associated with deteriorations in anxiety (OR=1.11, 95%CI [1.04-1.18], p=.001), as 
were baseline levels of depression (OR=1.09, 95%CI [1.03-1.16], p=.005) (Table 1). 
39


















































































































































































































































































































































































































































































































































































































































































































































































































































Intra-individual changes in anxiety and depression
Table 2a. Stability of anxiety over time during the 12-month follow-up period a








12-month levels of 
anxiety b
Normal levels 470 (65.7)c 53 (7.4)d 13 (1.8)d
Mild to moderate 
levels 
57 (8.0)e 53 (7.4)c 12 (1.7)d
Severe levels 12 (1.7)e 22 (3.1)e 23 (3.1)c
a Results are presented as n (%) unless otherwise stated.
b Levels of anxiety were based on established cut-off scores of the HADS, with scores ranging from 0 to 7 indicating 
normal levels, scores ranging from 8 to 11 indicating mild to moderate levels, and scores ≥12 indicating severe 
levels of anxiety 21
c Stable anxiety: 546/715= 76.4%
d Improved anxiety: 78/715= 10.9% 
e Deteriorated anxiety: 91/715= 12.7%
Table 2b. Stability of depression over time during the 12-month follow-up period a








12-month levels of 
depression b
Normal levels 512 (71.6)c 41 (5.7)d 5 (0.7)d
Mild to moderate 
levels 
49 (6.9)e 55 (7.7)c 18 (2.5)d
Severe levels 7 (1.0)e 13 (1.8)e 15 (2.1)c
a Results are presented as n (%) unless otherwise stated.
b Levels of depression were based on established cut-off scores of the HADS, with scores ranging from 0 to 7 
indicating normal levels, scores ranging from 8 to 11 indicating mild to moderate levels, and scores ≥12 indicating 
severe levels of depression 21
c Stable depression: 582/715= 81.4%
d Improved depression: 64/715= 9.0% 





Our study demonstrated that the majority of patients did not experience significant 
changes in levels of anxiety and depression from the index-PCI to 12-month follow-up 
(i.e., 76.4% for anxiety and 81.4% for depression, respectively). A stable pattern of anxiety 
and depression was demonstrated previously in ICD patients 17, 18, post-MI patients 7, 
patients admitted for elective CABG surgery 9, and exhausted PCI patients 15. In the current 
study, anxiety deteriorated in 12.7% of patients, whereas in 9.7% of patients depression 
deteriorated, which is in line with previous studies 9, 23. 
Baseline levels of anxiety and depression were associated with psychological 
distress levels over time, indicating that the higher the baseline levels, the lower the 
change in anxiety and depression scores over time. In contrast to previous studies, in 
the current study none of the included socio-demographic and clinical variables were 
associated with individual changes in anxiety and depression 12, 14, 15. However, these 
previous studies did not focus on intra-individual changes over time, with the possibility 
that correlates of mean scores and trajectories may be different than correlates of change 
scores. Future studies are warranted to further examine intra-individual changes in anxiety 
and depression over time and its correlates in the context of CAD, and PCI in particular, 
since clinically relevant intra-individual change standards and knowledge of the correlates 
of change may contribute to the identification of high-risk patients and provide targets 
for interventions 13, 18.
Strengths of the study include the novel approach of examining intra-individual 
changes in anxiety and depression rather than focusing on between-group differences 
over time, the relatively large sample size, and the use of a validated and standardized 
questionnaire to assess levels of anxiety and depression 19. However, some limitations 
must be acknowledged. First, subclinical levels of anxiety and depression were assessed 
using self-reports rather than a clinical diagnostic interview. Second, 31% of patients 
completing the HADS at baseline did not complete the HADS at 12 months. Possibly, a 
sampling bias occurred with those patients scoring higher on depression being more 
likely to drop-out (t(1035)= -2.71, 95%CI [-1.21- -.19], p=.01). Finally, information on history 
of anxiety and depression, participation in cardiac rehabilitation, and use of psychotropic 
medication was not collected, and therefore, we were not able to control statistically for 
these variables in multivariable analyses.
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In conclusion, the findings of the current study showed that levels of anxiety 
and depression remained stable in the majority of PCI patients from the index-PCI to 
12 months post-PCI. Future studies using an intra-individual approach are warranted to 
further examine individual changes in anxiety and depression over time and the potential 
implications for morbidity and mortality in CAD, and PCI in particular, as a means to bridge 
the gap between research and clinical practice. 
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Background: Depression has been associated with poor prognosis in patients with 
coronary artery disease (CAD), but little is known about the impact of depression on long-
term mortality. We examined whether depression was associated with 7-year mortality in 
patients treated with percutaneous coronary intervention (PCI), after adjusting for socio-
demographic and clinical characteristics, anxiety, and the distressed (Type D) personality.
Methods: The sample comprised a cohort of consecutive PCI patients (N=1234; 72.0% 
men; mean age 62.0±11.1 years, range [26-90] years) from the Rapamycin-Eluting Stent 
Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. At baseline (i.e., 6 
months post-PCI), patients completed the Hospital Anxiety and Depression Scale (HADS) 
to assess anxiety and depression and the Type D scale (DS14) to assess Type D personality. 
The endpoint was defined as all-cause mortality. 
Results: The prevalence of depression (HADS-D≥8) was 26.2% (324/1236). After a median 
follow-up of 7.0±1.6 years, 187 deaths (15.2%) from any cause were recorded. The incidence 
of all-cause mortality in depressed patients was 23.5% (76/324) versus 12.2% (111/910) in 
non-depressed patients. Cumulative hazard functions differed significantly for depressed 
versus non-depressed patients (log-rank X2=25.57, p<.001). In multivariable analysis, 
depression remained independently associated with all-cause mortality (HR=1.63; 95%CI 
[1.05-2.71], p=.038), after adjusting for socio-demographic and clinical characteristics, 
anxiety, and Type D personality. 
Conclusions: Depression was independently associated with a 1.6-fold increased risk for 
7-year mortality, above and beyond anxiety and Type D personality. Future studies are 
warranted to further elucidate the potential pathways linking depression to long-term 
mortality following PCI.
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INTRODUCTION
Depression is common in patients with coronary artery disease (CAD), with prevalence 
rates ranging between 25-50% 1-5. Depression is associated with an increased risk for all-
cause and cardiac mortality, independent of disease severity 6-9. Previous studies with 
follow-up durations ranging from 1 to 3.5 years have shown that depressed patients had 
a 1.2 to 3.7-fold increased risk for death as compared with non-depressed patients after 
myocardial infarction (MI) 1, 6, 8, 10-13. These findings were replicated in samples of patients 
who underwent coronary artery bypass graft (CABG) surgery 2, 14 or percutaneous coronary 
intervention (PCI) 9, and in heart failure patients 3, 7. Recent meta-analyses have confirmed 
the prognostic association between depression and mortality in cardiac patients 15-18.
As depression tends to be stable over time 14, 19, 20, it is possible that depression 
is also predictive of long-term mortality (≥5 years). To date, only a paucity of studies 
in post-MI patients 4, 21, CABG patients 5, 14, and patients referred for exercise testing 22 
have examined the impact of depression on long-term mortality. In 3 of these studies, 
a significant association between depression and long-term mortality was found 5, 14, 21, 
whereas in 2 other studies depression was associated with short-term but not long-term 
prognosis 4, 22. 
In the context of CAD, there has been a tendency to focus on one risk factor at a 
time, which has also been labeled as the ‘risk factor of the month approach’ 23, 24. The question 
remains whether depression exerts an independent effect on prognosis or whether other 
psychological risk factors, like anxiety and the distressed (Type D) personality (i.e., the 
combined tendency to experience negative emotions and to inhibit self-expression 25), 
may explain some of the variance in the association between depression and mortality. 
Hence, the aim of the current study was to examine whether depression is 
associated with 7-year mortality in patients treated with PCI, after adjusting for socio-
demographic and clinical characteristics, anxiety, and Type D personality.
METHODS
Participants and procedure
The study sample comprised a cohort of consecutive CAD patients treated with PCI, with 
either sirolimus-eluting stenting (SES) or bare-metal stenting (BMS), between September 
2, 2001 and November 14, 2002 at the Erasmus MC, Rotterdam, the Netherlands, as part 
of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) 
registry. The design of the RESEARCH registry has been published previously 26, 27. In brief, 




“real world” of interventional cardiology. Hence, no exclusion criteria were applied for 
patients entering the registry, and all PCI patients were eligible for enrolment regardless 
of anatomical or clinical presentation 26. 
At 6 months post-PCI (referred to as baseline in the remainder of the paper), all 
living patients were asked to complete a set of standardized and validated psychological 
questionnaires. Due to logistic reasons and in accordance with previous studies on 
long-term clinical outcomes in PCI patients, assessment at 6 months was chosen so as 
to represent patients in a stable condition, as the risk for restenosis is increased in the 
0-6 month period post-PCI 28. All patients were prospectively followed for adverse clinical 
events. The study protocol was approved a priori by the medical ethics committee of 
the Erasmus MC, Rotterdam, and the study was conducted according to the Helsinki 
Declaration 29. Every patient provided informed consent. 
Measures
Socio-demographic and clinical characteristics
Socio-demographic characteristics included gender and age. Clinical characteristics 
included type of stent (BMS vs. SES implantation), multi-vessel disease (multi-vessel 
disease vs. single-vessel disease/no vessel disease), body mass index (BMI), cardiac history 
(i.e., previous MI, CABG surgery, or PCI), indication for PCI (stable angina/silent ischemia, 
unstable angina, or MI), renal failure (i.e., glomular filtration rate (GFR) <15) 30, CAD risk 
factors (i.e., hypertension, hypercholesterolemia, diabetes mellitus, family history of CAD, 
and self-reported smoking), and prescribed cardiac discharge medications (i.e., aspirin, 
ACE-inhibitors, beta-blockers, calcium-antagonists, diuretics, oral nitrates, and statins). 
Information on clinical variables was prospectively collected at the time of the index-PCI/
baseline and recorded in the institutional database.
Anxiety and depression
Patients completed the Dutch version of the Hospital Anxiety and Depression Scale (HADS) 
at baseline to assess symptoms of anxiety and depression 31, 32. Both subscales consist 
of 7 items that are answered on a 4-point Likert scale ranging from 0 to 3 31. A cut-off 
score ≥8 on each subscale represents clinically relevant levels of anxiety and depression 
33. The HADS has demonstrated to be a valid screening tool for detecting symptoms of 
anxiety and depression 33, 34 and has been shown to predict mortality in patients referred 
for exercise testing 22. The internal consistency has been demonstrated previously with 
Cronbach’s alpha of .83 for the anxiety subscale (HADS-A) and .82 for the depression 
subscale (HADS-D) 33. In the current study, the correlation between both subscales was .69 
and Cronbach’s alpha was .85 for both HADS-A and HADS-D. 
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Type D personality
At baseline, Type D personality was assessed with the 14-item Type D scale (DS14) that 
comprises 2 subscales, negative affectivity (e.g., “I often feel unhappy”) and social inhibition 
(e.g., “I am a closed kind of person”), each consisting of 7 items. Items are scored on a 
5-point Likert scale ranging from 0 (“false”) to 4 (“true”). Based on findings from the Item 
Response Theory 35, a standardized cut-off score ≥10 on both subscales is used to identify 
individuals with a Type D personality. Previous research suggested that the co-occurrence 
of negative affectivity and social inhibition, rather than the single traits, predicts adverse 
events in PCI patients 36. Assessment of Type D with the DS14 is internally consistent 37, not 
confounded by disease severity 38, 39, and relatively stable over time 38, 39. 
Endpoint
The endpoint was defined as all-cause mortality. Deaths (n=54) occurring between PCI and 
psychological assessment were excluded as an endpoint from the analyses. Information on 
survival status was obtained from the Municipal Civil Registries in May 2009. The median 
follow-up period for all-cause mortality was 7.0±1.6 years (range [.7-8.6] years). Survival 
status at follow-up was known for all patients (100%). Information on cause of death was 
requested from the Central Bureau of Statistics (CBS) of the Netherlands and was divided 
into cardiac death (i.e., death due to arrhythmias, myocardial infarction, heart failure, or 
sudden cardiac death) and non-cardiac death (i.e., death due to cancer or other causes). 
Statistical analyses
Group differences between depressed and non-depressed patients were examined using 
the Chi-square test for nominal variables and Student’s t-test for independent samples 
for continuous variables. Cumulative survival curves for depression (i.e., absent versus 
present, cut-off score ≥8) were constructed using the Kaplan-Meier method. The log-
rank test was used to compare cumulative survival curves between groups. Univariable 
and multivariable Cox regression models were used to examine the effect of depression 
on all-cause mortality. Covariates were entered into the model using the Enter method, 
thereby reducing the risk of overfitting 40. In multivariable analysis, we adjusted for socio-
demographic characteristics (i.e., gender and age), clinical characteristics (i.e., type of 
stent, multi-vessel disease, cardiac history, indication for PCI, renal failure, hypertension, 
hypercholesterolemia, diabetes mellitus, family history of CAD, self-reported smoking, 
BMI, and prescribed cardiac medications), anxiety, and Type D personality. Covariates 
were selected a priori based on the literature 1, 5, 9, 41, 42. Since almost all patients (i.e., 95%) 




In addition, a multivariable Cox regression model was conducted to examine 
whether continuous depression scores were associated with all-cause mortality. Further, 
a univariable Cox regression model was conducted to examine the relationship between 
depression and cardiac mortality in addition to all-cause mortality. 
Hazard Ratios (HRs) with their corresponding 95% CIs were reported for Cox 
regression analyses. All results were based on 2-tailed tests and a p-value <.05 was used 
to indicate statistical significance. All statistical analyses were performed using SPSS for 
Windows 17.0 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Patient characteristics
Of 1675 eligible patients treated with PCI in the study period, 54 died within 6 months. 
The remaining 1621 patients were asked to participate in the study, of which 387 did not 
return the questionnaire at baseline (76.1% response rate). Thus, final analyses were based 
on data from 1234 patients (72.0% men; mean age 62.0±11.1 years, range [26-90] years). 
In Figure 1, a flowchart of the patient selection is provided. No systematic differences 
between participants (N=1234) and non-participants (n=387) were found, except for non-
participants more often having diabetes mellitus as compared with participants (21.0% 
vs. 15.0%, p<.05).
The prevalence of depression was 26.3% (324/1234). At follow-up, 187 deaths 
(15.2%) from any cause were recorded. Patient characteristics stratified by depression are 
presented in Table 1. Depressed and non-depressed patients differed on some baseline 
characteristics, with depressed patients more often being female, older, having a cardiac 
history, diabetes mellitus, and anxiety, but less often having a family history of CAD and 
being prescribed statins. 
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Figure 1. Flowchart of patient selection
a before questionnaire completion at baseline
n = 1675










Did not return 
questionnaire at baseline















Male gender 888 (72.0) 203 (62.7) 685 (75.3) <.001***
Age, mean (SD) 62.0 (11.1) 63.4 (11.7) 61.5 (10.9) .012*
Clinical characteristics
Sirolimus-eluting stent 703 (57.0) 197 (60.8) 506 (55.6) .12
Multi-vessel disease 666 (54.0) 190 (58.6) 476 (52.3) .057
Cardiac history b 695 (57.3) 203 (64.2) 492 (54.9) .005**
Indication for PCI .27
   Stable angina/ Silent ischemia 623 (50.7) 172 (53.4) 451 (49.7)
   Unstable angina 438 (35.6) 114 (35.4) 324 (35.7)
   MI 168 (13.7) 36 (11.2) 132 (14.6)
Renal failure 42 (5.4) 11 (5.2) 31 (5.4) 1.00
Hypertension 513 (41.6) 150 (46.3) 363 (39.9) .054
Hypercholesterolemia 997 (80.9) 259 (79.9) 738 (81.2) .68
Diabetes Mellitus 185 (15.0) 67 (20.7) 118 (13.0) .001***
Family history of CAD 358 (29.0) 78 (24.1) 280 (30.8) .026*
Self-reported smoking 371 (30.1) 105 (32.4) 266 (29.3) .32
BMI, mean (SD) 27.1 (5.2) 27.3 (5.3) 27.0 (5.2) .50
Cardiac medication
Aspirin 1162 (94.9) 301 (93.8) 861 (95.3) .34
ACE-inhibitors 402 (32.8) 101 (31.5) 301 (33.3) .59
Beta-blockers 815 (66.6) 201 (62.6) 614 (68.0) .092
Calcium-antagonists 619 (50.6) 168 (52.3) 451 (49.9) .50
Diuretics 184 (15.0) 59 (18.4) 125 (13.8) .062
Oral nitrates 187 (15.3) 60 (18.7) 127 (14.1) .059
Statins 894 (73.0) 211 (65.7) 683 (75.6) .001***
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Anxiety (i.e., HADS-A ≥8 ) 359 (29.1) 236 (73.1) 123 (13.5) <.001***
Type D personality 353 (29.2) 104 (32.5) 249 (28.0) .15
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease,  HADS-A 
= Hospital Anxiety and Depression Scale - Anxiety
Symptoms of depression and all-cause mortality
The incidence of all-cause mortality at follow-up (median follow-up period 7.0±1.6 years, 
range [.7-8.6] years) in depressed patients was 23.5% (76/324) versus 12.2% (111/910) 
in non-depressed patients (Figure 2). Cumulative hazard functions differed significantly 
for depressed versus non-depressed patients (log-rank X2=25.57, p<.001). In univariable 
Cox regression analysis, depression was associated with a cumulative increased risk 
for all-cause mortality (HR=2.09; 95%CI [1.56-2.80], p<.001) (Figure 3). In multivariable 
Cox regression analysis, depression remained independently associated with all-cause 
mortality (HR=1.63; 95%CI [1.05-2.71], p=.038), after adjusting for socio-demographic 
and clinical characteristics, anxiety, and Type D personality (Table 2). Male gender, older 
age, hypercholesterolemia, and diabetes mellitus were significantly associated with an 
increased risk for all-cause mortality as well, whereas the prescription of statins was 
associated with a reduced risk for all-cause mortality. No significant effects were found for 
anxiety and Type D personality in relation to the endpoint. 
Additional analysis examining the impact of depression on all-cause mortality 
using a continuous score of depression yielded similar results as compared to the analysis 
using a dichotomized depression score (results not shown). Cause of death was known for 
a subset of patients (n=830). The incidence of cardiac mortality at follow-up in depressed 
patients was 7.6% (15/197) versus 4.9% (31/633) in non-depressed patients. In univariable 
Cox regression analysis, depression was not significantly related to cardiac mortality 





Figure 2. Proportion of all-cause mortality at follow-up stratified by depression 
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Male gender 2.21 1.30 – 3.78 .004**
Age 1.08 1.05 – 1.10 <.001***
Clinical characteristics
Sirolimus-eluting stent .76 .48 - 1.19 .23
Multi-vessel disease 1.25 .79 – 1.96 .34
Cardiac history a 1.25 .79 – 1.99 .34
Indication for PCI
   Unstable angina .84 .54 – 1.31 .44
   MI 1.18 .57 – 2.45 .65
Renal failure .94 .39 – 2.27 .89
Hypertension 1.15 .74 – 1.79 .53
Hypercholesterolemia 1.95 1.05 – 3.61 .034*
Diabetes mellitus 1.85 1.14 – 2.99 .013*
Family history of CAD .70 .40 – 1.23 .21
Self-reported smoking 1.33 .80 – 2.23 .27
BMI 1.01 .97 – 1.05 .60
Cardiac medication
ACE-inhibitors 1.40 .89 – 2.19 .15
Beta-blockers .83 .52 – 1.32 .43
Calcium-antagonists 1.18 .77 – 1.82 .45
Diuretics 1.54 .94 – 2.53 .086
Oral nitrates .89 .51 – 1.54 .67
Statins .40 .23 - .69 .001***
Psychological characteristics
Depression (i.e., HADS-D ≥8) 1.63 1.05 – 2.71 .038*
Anxiety (i.e., HADS-A ≥8) .92 .52 – 1.62 .77
Type D personality 1.19 .76 – 1.85 .45
*p≤.05; ** p≤.01; ***p≤.001; a Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or 
coronary artery bypass graft (CABG) surgery; ACE = angiotensin-converting enzyme, BMI = body mass index 
(kg/m2), CAD = coronary artery  disease, HADS-A = Hospital Anxiety and Depression Scale - Anxiety, HADS-D = 
Hospital Anxiety  and Depression Scale - Depression
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DISCUSSION
To our knowledge, this is the first study to report on the relationship between depression 
and long-term mortality in patients treated with PCI and to examine whether this 
relationship is independent of anxiety and Type D personality. After a median follow-up of 
7 years, depression was independently associated with a 1.6-fold increased risk for all-cause 
mortality in patients who survived the first 6 months post-PCI, after adjusting for relevant 
socio-demographic and clinical characteristics, anxiety, and Type D personality. Further, 
male gender, older age, hypercholesterolemia, and diabetes mellitus were significantly 
associated with an increased risk for all-cause mortality, whereas the prescription of 
statins was associated with a reduced risk for all-cause mortality. No significant effects 
were found for anxiety and Type D personality in relation to the endpoint. 
The results of the current study corroborate those of previous studies in cardiac 
patients, demonstrating that depression is independently associated with an increased 
risk for short-term mortality 1, 2, 6-9, 12, 13. The impact of depression on long-term mortality (≥5 
years) has been studied previously, with these studies mainly focusing on post-MI patients 
4, 21, CABG patients 5, 14, and patients referred for exercise testing 22, rather than PCI patients. 
The results of 3 of these previous studies were in line with the current study, showing 
a significant association between depression and long-term mortality 5, 14, 21, whereas 
other studies demonstrated that depression was significantly associated with short-term 
prognosis but not with long-term prognosis 4, 22. These discrepancies may be explained by 
differences in the patient population (284 post-MI patients and 5057 patients referred for 
exercise testing, respectively) and the assessment of depression using other instruments 
than the HADS (e.g., Beck Depression Inventory (BDI)). 
In the context of CAD, there has been a tendency to focus on one risk factor at a 
time, which has also been labeled as the ‘risk factor of the month approach’ 23, 24. Hence, 
the question remains whether depression exerts an independent effect on prognosis or 
whether other psychological risk factors, like anxiety and Type D personality, may explain 
some of the variance in the association between depression and mortality. With the 
current study, we were able to demonstrate that depression may exert an independent 
effect on outcomes, as depression remained independently associated with 7-year all-
cause mortality, even when adjusting for related constructs, such as anxiety and Type D 
personality. Previous studies on the impact of anxiety and Type D personality on prognosis 
in CAD have shown mixed results 3, 10, 25, 43, 44, with these studies mainly focusing on short-
term prognosis. In order to draw firm conclusions, future research should seek to further 
disentangle the different psychological constructs that have been related to cardiac 




Examining the impact of not only multiple psychological risk factors but also their co-
occurrence seems worthwhile, as risk factors tend to cluster together and may dispose 
patients to a higher risk 24, 45. 
There are several potential pathways through which depression may have an 
adverse influence on prognosis in patients with CAD. First, depressed patients may be less 
likely to engage in optimal health-related behaviors, such as exercising, quitting smoking, 
and adhering to dietary constrictions and the prescribed medication regimen 9, 14, 46. 
However, the current study did not support this notion, as there were no differences in 
smoking status and BMI between depressed and non-depressed patients. Unfortunately, 
no other health-related behaviors were assessed in the current study. Second, depression 
may alter the activity of the sympathetic nervous system in turn leading to increases 
in heart rate and blood pressure 46. The hypothalamus-pituitary-adrenal axis may also 
be involved, as depression may induce hypercortisolemia 47, 48. Finally, an increase in 
inflammatory markers, such as interleukin (IL)-6 and C-reactive protein (CRP), in depressed 
patients may provide another explanation for the adverse effect of depression on CAD 
prognosis 14, 49. These potential pathways largely remain speculative as few studies have 
examined these pathways as potential links between depression and prognosis in CAD. 
However, knowledge of the pathways that may explain the association 
between depression and mortality is essential for secondary prevention. So far, results of 
psychological intervention trials have shown mixed results. Some trials demonstrated that 
cognitive-behavioral therapy and antidepressants could (modestly) reduce symptoms of 
depression in CAD patients, but this did not translate into enhanced survival 50, 51, whereas 
2 recent trials showed that treatment of depression was associated with a reduction in 
cardiovascular morbidity and mortality 52, 53. Future research into the depression construct 
is needed to identify optimal targets for intervention. For instance, there is increasing 
evidence that specific symptoms of depression are more cardiotoxic than others 9, 54, 55. Also, 
previous studies suggest that incident depression is predictive of impaired cardiovascular 
prognosis rather than recurrent depressive episodes 56, 57. 
The limitations of the current study must be acknowledged. First, no information 
on left ventricular ejection fraction (LVEF) was collected, which is an important risk factor 
for poor prognosis in CAD 10. However, in multivariable analysis we adjusted for multi-
vessel disease and cardiac history as indicators of disease severity. Second, no information 
on participation in cardiac rehabilitation and prescription of psychotropic medication was 
collected. Hence, we could not adjust for these potential confounders in multivariable 
analyses. Third, except for information on smoking and BMI, which might potentially 
impinge on the relationship between depression and prognosis, we had no information 
on health-related behaviors, such as adherence to medication. Fourth, information on 
renal failure was only collected for 783 patients. Finally, 26.3% (441/1675) of the eligible 
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PCI patients were not included in the study due to death within 6 months (n=54) or non-
response to the HADS questionnaire (n=387). 
Strengths of the study comprise the prospective study design with a median 
follow-up duration of 7 years, the large sample size, and the focus on PCI patients. Previous 
studies on the role of psychological factors in CAD have mainly been conducted in post-MI 
patients. Moreover, given the paucity of studies on the relationship between depression 
and long-term prognosis, the findings of the current study add to our understanding of 
the impact of depression on long-term cardiovascular health outcomes. 
In conclusion, the current study showed that after a median follow-up of 7 
years, depression was independently associated with a 1.6-fold increased risk for all-
cause mortality in patients who survived the first 6 months post-PCI, after adjusting for 
socio-demographic and clinical characteristics, anxiety, and Type D personality. No effect 
was found for anxiety and Type D personality on all-cause mortality. Future studies are 
warranted to further elucidate the impact of depression on long-term mortality and to 
examine the potential pathways explaining this link. 
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I read the recently published article by Damen et al. 1 about depression as a significant 
predictor of 7-year all-cause mortality in patients with percutaneous coronary 
intervention. They used the Hospital Anxiety and Depression Scale (HADS) to assess 
anxiety and depression and the Type D scale (DS14) to assess Type D personality. As a 
conclusion, depression was significantly associated with a 1.6-fold increased risk of 
mortality by multivariable Cox regression analysis. Other risk factors were male, age, 
hypercholesterolemia, diabetes mellitus, and statin medication.
The number of events was satisfactory for the analysis, and tools for identifying 
psychological characteristics were appropriate with valid evidence. The authors concluded 
that further elucidation is needed to understand the potential pathways linking depression 
to long-term mortality following PCI.
I have two queries on their article. First, Grande et al. recently conducted a meta-
analysis using 12 prospective studies on prognostic ability of Type D personality in patients 
with cardiovascular disease 2. Although odds ratio of Type D scale for the prognosis 
decreased overtime, significant association between Type D personality and prognosis 
was observed. Six studies out of 12 used depression scale score as a psychological variable 
to adjust the statistical model. The discrepancy should be explored as a further study. 
Second, Romppel et al. reported a 6-year longitudinal study to know the 
association between Type D personality and depressive symptoms for cardiac patients 
3. Depressive symptoms were assessed by a subscale of HADS (HADS-D), and they used 
HADS-D both at baseline and follow-up studies. Although Type D personality measured 
by DS14 was significantly associated with HADS-D at follow-up study, the relationship 
between DS14 and HADS-D at baseline was weak. This means that there is a possibility 
of change in the state of depression in patients with percutaneous coronary intervention 
at baseline, which was conducted by Damen et al. 1. Not only for baseline study, but also 
another opportunity to conduct depression survey is needed to know the persistency of 
depression during follow-up period. As the effect of depression on mortality for cardiac 
patient is important from the view point of preventive cardiology, further study is needed 
to clarify the association.
The author of this manuscript has certified that he comply with the principles of ethical 
publishing in the International Journal of Cardiology.
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In our recent study on the relationship between depression and 7-year mortality in patients 
treated with percutaneous coronary intervention (PCI), we adjusted for the distressed 
(Type D) personality in multivariable analyses. As Dr. Kawada correctly stated in his letter 
to the editor 1, we did not find a significant association between Type D personality and 
all-cause mortality, which is in contrast to some 2-5 but not all previous studies 6-8. In the 
meta-analysis by Grande et al., the authors concluded that although there is a significant 
association between Type D personality and prognosis in cardiac patients, the strength of 
this effect has been declining over the years and that therefore, the effect of Type D might 
have been overestimated in previous studies 9. 
In our view, it is possible that Type D personality might affect prognosis in specific 
cardiac populations, but that this effect might not generalize to all groups. As discussed 
in the meta-analysis by Grande et al., an effect for Type D personality on prognosis was 
mainly found in patients with acute coronary syndrome (ACS), such as post myocardial 
infarction (MI) and coronary artery bypass graft (CABG) surgery patients, but not in heart 
failure (HF) patients 9. Given these findings, Type D personality may mainly exert an effect 
on patients in the early stages of disease, whereas no or smaller effects are found in end-
stage heart disease, such as HF. 
With our study, we were not able to confirm the findings of an earlier study of 
the RESEARCH registry, in which a significant association was found between Type D 
personality and the composite endpoint of cardiac mortality and MI 10. An association 
between cardiac-related endpoints and Type D personality was also confirmed in other 
previous studies 2, 4, 5.  However, in the present study the endpoint was all-cause mortality 
at 7-year follow-up. It is plausible that Type D personality is more related to cardiac causes 
of death rather than to all-cause mortality 7. Future studies are needed to contribute to a 
better understanding of the role of personality characteristics in the context of CAD.
We further agree with Dr. Kawada that it is important to look at the persistence of 
depressive symptoms and their effect on prognosis in CAD rather than only at baseline or 
a one-time snapshot. We have previously demonstrated that levels of depression remain 
stable over time for the majority of PCI patients (around 80%) 11, which was also found in 
other cardiac patient groups, including ICD 12, 13, post-MI 14, and CABG patients 15. Our study 
was underpowered to look at the prognostic value of persistent depressive symptoms, so 
future studies on this topic are warranted.
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Aims: Negative mood states (e.g., anxiety and depression) have been associated with 
increased cardiovascular morbidity and mortality in coronary artery disease (CAD), but 
little is known about the impact of positive emotions on these health outcomes. We 
examined whether anhedonia (i.e., reduced positive affect) was associated with 7-year 
mortality in patients treated with percutaneous coronary intervention (PCI).
Methods: Consecutive PCI patients (N=1206; 71.5% men; mean age 62.0±11.1 years) from 
the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) 
registry completed the Hospital Anxiety and Depression Scale (HADS) to assess anhedonia 
at baseline. Anhedonia was defined as a score ≤7 (i.e., 1 SD below the mean) on the positive 
affect scale of the HADS. The endpoint was defined as all-cause mortality. 
Results: The prevalence of anhedonia was 23.7% (286/1206). After a median follow-
up of 7.0±1.6 years, 186 deaths (15.4%) from any cause were recorded. The incidence 
of mortality in anhedonic patients was 22.7% (65/286) versus 13.2% (121/920) in non-
anhedonic patients (HR=1.66; 95%CI [1.19-2.32], p=.003). Cumulative hazard functions 
were significantly different for anhedonic versus non-anhedonic patients (log-rank 
X2=16.61, p<.001). In multivariable analysis, anhedonia remained independently 
associated with all-cause mortality (HR=1.51; 95%CI[1.03-2.22], p=.036), after adjusting 
for socio-demographic and clinical characteristics, and negative and relaxed affect.
Conclusion: Anhedonia was independently associated with a 1.5-fold increased risk for all-
cause mortality in patients who survived the first 6 months post-PCI. Enhancing positive 
emotions, in addition to reducing negative emotions, may constitute an important target 
for future psychological intervention trials in CAD patients.
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INTRODUCTION
Negative mood states, like anxiety and depression, have been associated with increased 
cardiovascular morbidity and mortality in coronary artery disease (CAD) 1-3. Only a paucity 
of studies focused on the impact of positive emotions on these outcomes 4, 5. Positive 
affect refers to mood states such as joy, activity, and cheerfulness 6, and is not merely the 
opposite of negative affect 7, as both types of affect can be present simultaneously 8. 
High levels of positive affect have been associated with a decrease in hospital 
readmissions in patients with CAD 9, lower incident hypertension 10, a dampened 
physiological stress response 11, and lower incident CAD 12, whereas studies on the 
association between positive affect and survival showed mixed results 5, 13. Anhedonia 
(i.e., reduced positive affect) has been shown to independently predict all-cause 
mortality and major adverse clinical events (i.e., myocardial infarction, hospitalization, or 
coronary revascularization) 1 year after an acute cardiac event 14. In patients treated with 
percutaneous coronary intervention (PCI), anhedonia was associated with an increased 
risk for the composite of death and myocardial infarction (MI) 2 years post-index event 4. 
In addition, anhedonia has been associated with poor patient-reported outcomes, such 
as poor health status 15, 16.
It is not yet known whether anhedonia is associated with long-term mortality in 
addition to short-term mortality in CAD patients. Therefore, the aim of the current study 
was to examine whether anhedonia is associated with 7-year mortality in patients treated 
with PCI with drug-eluting stenting.
METHODS
Participants and procedure
The study sample comprised consecutive patients treated with PCI, with either 
sirolimus-eluting stenting (SES) or bare-metal stenting (BMS), between September 2, 
2001 and November 14, 2002 at the Erasmus MC, Rotterdam, the Netherlands, as part 
of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) 
registry. The design of the RESEARCH registry has been published previously 17, 18. In brief, 
the registry was designed to evaluate the efficacy and safety of SES implantation in the 
“real world” of interventional cardiology. Hence, no exclusion criteria were applied for 
patients entering the registry, and all PCI patients were eligible for enrolment regardless 
of anatomical or clinical presentation 18, 19. 
At 6 months post-PCI (referred to as baseline in the remainder of the paper), 
all living patients were asked to complete a standardized and validated psychological 




term clinical outcomes in PCI patients, assessment at 6 months was chosen so as to 
represent patients in a stable condition, as the risk for restenosis is increased in the 0-6 
month period post-PCI 20. All patients were prospectively followed for adverse clinical 
events. The study protocol was approved by the medical ethics committee of the Erasmus 
MC, Rotterdam, and the study was conducted according to the Helsinki Declaration 21. 
Every patient provided informed consent. 
Measures
Socio-demographic and clinical characteristics
Socio-demographic variables included gender and age. Clinical variables included type 
of stent (BMS vs. SES implantation), multi-vessel disease (multi-vessel disease vs. single-
vessel disease/no vessel disease), body mass index (BMI), cardiac history (i.e., previous MI, 
coronary artery bypass graft (CABG) surgery, or PCI), indication for PCI (stable angina/silent 
ischemia, unstable angina, or MI), CAD risk factors (i.e., hypertension, hypercholesterolemia, 
diabetes mellitus, family history of CAD, and self-reported smoking), and prescribed cardiac 
discharge medications (i.e., aspirin, ACE-inhibitors, beta-blockers, calcium-antagonists, 
diuretics, oral nitrates, and statins). Information on clinical variables was prospectively 
collected at the time of the index-PCI and recorded in the institutional database.
Anhedonia
Reduced positive affect, or anhedonia, was assessed using the Hospital Anxiety and 
Depression Scale (HADS) at baseline. The HADS consists of 14 items that are scored on 
a 4-point Likert scale ranging from 0 to 3 22, 23. Previous research to determine the factor 
structure of the HADS supported the ability of this questionnaire to assess (the absence 
of ) positive affect in CAD 4, 22, 24-27. Three of the previous studies were conducted in 
independent cohorts of patients with CAD (i.e., 355 post-MI patients 24, 875 PCI patients 4, 
and 534 PCI patients 27, respectively) and indicated that 3 distinct factors can be identified: 
Positive affect, negative affect, and relaxed affect. The study by Denollet and colleagues 
in PCI patients was also based on data from the RESEARCH registry, but focused on a 
subset of patients with a 2-year follow-up. In line with these previous studies, the positive 
affect scale was computed by summing up 4 items (i.e., items 2, 4, 6, and 12) (range [0-
12], mean=9.4±2.8). Anhedonia was defined as a score ≤7 (i.e., 1 SD below the mean) 
on the positive affect scale. The mean scores on the negative affect scale (range [0-12], 
mean=3.1±2.8) and the relaxed affect scale (range [0-9], mean=6.5±2.1) were in line with 
those reported previously 4, 24,27 . The positive affect scale was strongly correlated with the 
negative affect and the relaxed affect scales (r=-.59 and r=.57, respectively), whereas the 
negative affect scale showed a large inverse correlation with the relaxed affect scale (r=-
.54).
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The 3 derived HADS subscales were shown to be internally consistent, with 
Cronbach’s alpha ranging from .72 for the relaxed affect subscale to .86 for the positive 
affect and the negative affect scales, which was also consistent with previous findings 4, 
24, 27.
Endpoint
The endpoint was defined as all-cause mortality. Deaths (n=54) occurring between PCI and 
psychological assessment were excluded as an endpoint from the analyses. Information 
on survival status was obtained from the Municipal Civil Registries in May 2009. The 
median follow-up period for all-cause mortality was 7.0±1.6 years (range [.7-8.0] years). 
Information on survival status at follow-up was complete (100%) for all patients. 
Statistical analyses
Missing values on the HADS
In the current study, the proportion of patients with a missing score on 1 of the 14 items of 
the HADS questionnaire was in the range from .2-1.8%. For the 4-item scales positive affect 
and negative affect, missing values were extrapolated with the mean score of completed 
items when there was a response missing on a maximum of 2 items. For the 3-item scale 
relaxed affect, missing values were extrapolated with the mean score when there was a 
response missing on a maximum of 1 item. After extrapolating the missing responses on 
the 3 HADS subscales, all patients could be included in the analyses.
General analyses
Group differences were examined using the Chi-square test for nominal variables and 
Student’s t-test for independent samples for continuous variables. Cumulative survival 
curves for anhedonia (i.e., absent versus present) were constructed using the Kaplan-
Meier method. The log-rank test was used to compare cumulative survival curves 
between groups. Univariable and multivariable Cox regression models were used to 
examine the effect of anhedonia on all-cause mortality. Covariates were entered into the 
model using the Enter method, thereby reducing the risk of overfitting 28. In multivariable 
analysis, we adjusted for socio-demographic characteristics (i.e., gender and age), clinical 
characteristics (i.e., type of stent, multi-vessel disease, cardiac history, indication for 
PCI, hypertension, hypercholesterolemia, diabetes mellitus, family history of CAD, self-
reported smoking, BMI, and prescribed cardiac medications), and negative and relaxed 
affect. Covariates were selected a priori based on the literature 4, 14, 29, 30. Since almost all 
patients (i.e., 95%) were prescribed aspirin, we did not add aspirin as a covariate to the 
multivariable model. To be able to compare our results with findings of previous studies, 




Hazard Ratios (HRs) with their corresponding 95% CIs were reported for Cox 
regression analyses. All results were based on 2-tailed tests and a p-value <.05 was used 
to indicate statistical significance. All statistical analyses were performed using SPSS for 
Windows 17.0 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Patient characteristics
Of 1675 eligible patients treated with PCI in the study period, 54 died within 6 months. The 
remaining 1621 patients were asked to participate in the study, of which 415 patients did 
not return the questionnaire at baseline (74.4% response rate). Final analyses were based 
on data from 1206 patients (71.5% men; mean age 62.0±11.1 years, range [26-90] years). 
In Figure 1, a flowchart of the patient selection is provided. No systematic differences 
between participants and non-participants were found, except for non-participants more 
often having diabetes mellitus as compared with participants (21.0% vs. 14.8%, p<.05). 
In the current sample, the prevalence of anhedonia was 23.7% (286/1206). 
At follow-up, 186 deaths (15.4%) from any cause were recorded. Patient characteristics 
stratified by anhedonia are presented in Table 1. Anhedonic and non-anhedonic patients 
differed on some baseline characteristics, with anhedonic patients more often being 
female, older, having a cardiac history, and diabetes mellitus, but less often having a family 
history of CAD and being prescribed statins. Negative affect was more often present in 
anhedonic patients, whereas relaxed affect was less often present than in non-anhedonic 
patients (all ps<.05).
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Figure 1. Flowchart of patient selection
a before questionnaire completion at baseline
n = 1675










Did not return 
questionnaire at baseline















Male gender 862 (71.5) 186 (65.0) 676 (73.5) .007**
Age, mean (SD) 62.0 (11.1) 63.6 (11.3) 61.6 (11.0) .006**
Clinical characteristics
Sirolimus-eluting stent 701 (58.1) 180 (62.9) 521 (56.6) .069
Multi-vessel disease 654 (54.2) 164 (57.3) 490 (53.3) .25
Cardiac history b 680 (57.4) 182 (65.2) 498 (55.0) .003**
Indication for PCI .23
   Stable angina/ Silent ischemia 609 (50.7) 152 (53.3) 457 (49.9)
   Unstable angina 430 (35.8) 103 (36.1) 327 (35.7)
   MI 162 (13.5) 30 (10.5) 132 (14.4)
Hypertension 503 (41.7) 132 (46.2) 371 (40.4) .096
Hypercholesterolemia 974 (80.8) 227 (79.4) 747 (81.3) .53
Diabetes mellitus 178 (14.8) 57 (19.9) 121 (13.2) .006**
Family history of CAD 348 (28.9) 66 (23.1) 282 (30.7) .016*
Self-reported smoking 365 (30.3) 93 (32.5) 272 (29.6) .39
BMI, mean (SD) 27.1 (5.2) 27.1 (5.2) 27.1 (5.2) .99
Negative affect 1006 (83.5) 285 (99.7) 721 (78.5) <.001***
Relaxed affect 985 (81.8) 158 (55.6) 827 (89.9) <.001***
Cardiac medication
Aspirin 1135 (94.9) 268 (94.0) 867 (95.2) .55
ACE-inhibitors 391 (32.7) 84 (29.5) 307 (33.7) .21
Beta-blockers 796 (66.6) 180 (63.2) 616 (67.6) .19
Calcium-antagonists 605 (50.6) 144 (50.5) 461 (50.6) 1.00
Diuretics 180 (15.1) 45 (15.8) 135 (14.8) .76
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease
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Anhedonia and all-cause mortality
The incidence of all-cause mortality at follow-up in anhedonic patients was 22.7% (65/286) 
versus 13.2% (121/920) in non-anhedonic patients. Cumulative hazard functions differed 
significantly for anhedonic versus non-anhedonic patients (log-rank X2=16.61, p<.001). In 
univariable Cox regression analysis, anhedonia was associated with a cumulative increased 
risk for all-cause mortality (HR=1.66; 95%CI [1.19-2.32], p=.003) (Figure 2). In multivariable 
Cox regression analysis, anhedonia remained independently associated with all-cause 
mortality (HR=1.51; 95%CI [1.03-2.22], p=.036), after adjusting for socio-demographic and 
clinical characteristics, and negative and relaxed affect (Table 2). Male gender, older age, 
and diabetes mellitus were significantly associated with an increased risk for all-cause 
mortality as well, whereas the prescription of beta-blockers and statins were associated 
with a decreased risk for all-cause mortality. 
































Table 2. Associates of all-cause mortality (adjusted analysis)
HR 95%CI p
Anhedonia 1.51 1.03 – 2.22 .036*
Male gender 2.12 1.40 – 3.20 <.001***
Age 1.07 1.05 – 1.09 <.001***
Sirolimus-eluting stent .73 .51 - 1.03 .071
Multi-vessel disease 1.31 .92 – 1.86 .14
Cardiac history a 1.32 .91 – 1.91 .14
Indication for PCI
   Unstable angina .83 .59 – 1.18 .30
   MI .93 .51 – 1.67 .80
Hypertension 1.10 .78 – 1.54 .59
Hypercholesterolemia 1.27 .81 – 2.00 .30
Diabetes Mellitus 1.70 1.14 – 2.52 .009**
Family history of CAD .90 .59 – 1.35 .60
Self-reported smoking 1.07 .72 – 1.60 .74
BMI, mean (SD) .99 .95 – 1.03 .50
Negative affect 1.13 .72 – 1.77 .59
Relaxed affect 1.23 .78 – 1.95 .38
ACE-inhibitors 1.21 .85 – 1.74 .29
Beta-blockers .70 .49 - .99 .044*
Calcium-antagonists 1.30 .93 – 1.81 .13
Diuretics 1.25 .83 – 1.90 .29
Oral nitrates 1.03 .68 – 1.57 .88
Statins .55 .35 - .81 .003**
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease
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DISCUSSION
Studies on the relationship between psychological factors and cardiovascular morbidity 
and mortality in CAD have primarily focused on the role of negative mood states 1-3. In 
contrast, little is known about the impact of positive emotions on CAD prognosis 4, 5. To 
our knowledge, this is the first study to report on the relationship between anhedonia 
(i.e., reduced positive affect) and long-term mortality in patients treated with PCI. After 
a median follow-up of 7 years, anhedonia was independently associated with a 1.5-fold 
increased risk for all-cause mortality, after adjusting for socio-demographic and clinical 
characteristics, and negative and relaxed affect in patients who survived the first 6 months 
post-PCI.
The results of the current study are in line with previous studies, demonstrating 
that anhedonia is independently associated with the combined endpoint of major 
adverse clinical events and all-cause mortality 1 year after an acute cardiac event 14, and 
the composite of death and MI 2 years post-PCI 4. Other studies in CAD showed that 
anhedonia is associated with poor health status 15, 16, whereas a high level of positive affect 
is associated with a decrease in hospital readmissions 9, lower incident hypertension 10, a 
dampened physiological stress response 11, and lower incident CAD 12. However, the current 
findings also extend previous research by showing that anhedonia is not only associated 
with short-term but also with long-term prognosis in CAD. In addition, anhedonia exerted 
an independent effect on prognosis above and beyond negative affect, supporting the 
notion that positive and negative affect are not merely opposites on the same continuum 
7. Future studies on the combined effects of positive and negative affect are warranted to 
contribute to a better understanding of the role of different types of affect in the context 
of CAD 16.
In the current study, we replicated findings on the underlying factorial structure 
of the HADS. Originally, this instrument was developed to assess symptoms of anxiety and 
depression 22, 23, but evidence suggests that a subset of the HADS items can also be used 
as a valid and reliable measure of anhedonia 4, 24, 27. In line with these previous findings, 
we identified 3 distinct subscales of the HADS: Positive affect, negative affect, and relaxed 
affect. Hence, with the HADS it is possible to assess several different psychological 
constructs without increasing patient burden, making it a useful instrument for clinical 
practice 16. 
There are several potential pathways through which anhedonia may have an 
adverse influence on CAD prognosis. First, anhedonic patients may be less likely to engage 
in optimal health-related behaviors, such as exercising, quitting smoking, and adhering to 
dietary constrictions 4, 6. However, the current study did not support this notion, as there 




patients. Unfortunately, no other health-related behaviors were assessed in the current 
study. Second, anhedonia may alter the activity of the sympathetic nervous system in turn 
leading to increases in heart rate and blood pressure 6, 11. The hypothalamus-pituitary-
adrenal axis may also be involved, as anhedonia may induce hypercortisolemia 11. Finally, 
an increase in inflammatory markers, such as interleukin (IL)-6 and C-reactive protein 
(CRP), in anhedonic patients may provide another explanation for the adverse effect of 
anhedonia on CAD prognosis 31. These potential pathways remain speculative as they are 
yet to be tested empirically in future research in this patient population. 
Limitations of the current study must be acknowledged. First, no information on 
left ventricular ejection fraction (LVEF) was collected, which is an important risk factor for 
poor prognosis in CAD 3. However, in multivariable analysis we adjusted for multi-vessel 
disease and cardiac history as indicators of disease severity. Second, no information on 
participation in cardiac rehabilitation and prescription of psychotropic medication was 
collected. Hence, we could not adjust for these potential confounders in multivariable 
analysis. Third, except for information on smoking and BMI, which might potentially 
impinge on the relationship between anhedonia and prognosis, we had no information 
on health-related behaviors. Fourth, only information on all-cause mortality was collected 
and not the specific cause of death. Finally, 28.0% (469/1675) of the eligible PCI patients 
were not included in the study due to death within 6 months (n=54) or non-response to 
the HADS questionnaire (n=415).
Strengths of the study comprise the prospective design with a median follow-up 
duration of 7 years, the large sample size, the focus on PCI patients and positive emotions, 
in addition to negative emotions. Previous studies on the role of psychological factors in 
CAD have mainly been conducted in post-MI patients rather than PCI patients, focusing 
mainly on the role of negative emotions (e.g., anxiety and depression). Given the paucity 
of studies on the relationship between (reduced) positive emotions and prognosis, the 
findings of the current study add to the understanding of the impact of different types of 
emotions on cardiovascular health outcomes. 
Future studies are warranted to further examine the impact of anhedonia on 
adverse health outcomes. If the findings of the current study are confirmed, anhedonia 
may provide a new target for cardiac rehabilitation and psychological intervention trials. 
Up to now, trials have mainly focused on the detrimental effects of negative emotions on 
CAD prognosis, and their efficacy remains unclear 32-34. The results of the current study 
confirm and extend the findings of previous studies, indicating that anhedonia is also 
of importance in the context of CAD both for short- and long-term prognosis. Therefore, 
psychological interventions should not only target the reduction of negative emotions, 
but also seek to enhance positive emotions. The first results in this area are promising,
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with cognitive-behavioral therapy having been shown to improve positive affect in older 
depressed patients at increased cardiovascular risk 35, and mindfulness-based stress 
reduction programs improving positive affect in medically ill patients 36.
Future studies should also seek to further disentangle the different psychological 
constructs that have been related to cardiac outcomes. Despite overlap between the 
different psychological constructs, there is not likely to be one unifying feature that 
covers all psychological effects on outcome. Furthermore, psychological constructs are 
also not necessarily interchangeable and may exert independent effects on outcomes. 
This independency was also demonstrated in the current study, in which anhedonia 
remained an independent predictor of all-cause mortality, even when adjusting for the 
related constructs negative and relaxed affect. To expand our knowledge of the role of 
psychological factors in CAD, a paucity of recent studies has shifted focus towards the co-
occurrence of psychological risk factors rather than single risk factors alone, as risk factors 
tend to cluster together 37, 38. For example, in implantable cardioverter defibrillator (ICD) 
patients the clustering of device-related concerns and Type D personality (“the distressed 
personality type”) was associated with a higher mortality risk as compared to the presence 
of none or only one of these risk factors 39. Hence, the impact of clustering of psychological 
risk factors on cardiac prognosis needs further investigation. 
In conclusion, the current study showed that after a median follow-up of 7 
years, anhedonia is independently associated with a 1.5-fold increased risk for all-cause 
mortality, after adjusting for socio-demographic and clinical characteristics, and negative 
and relaxed affect in patients who survived the first 6 months post-PCI. Future studies are 
warranted to further determine the impact of anhedonia on adverse health outcomes, and 
long-term mortality in particular. Enhancing positive emotions, in addition to reducing 
negative emotions, may constitute an important target for cardiac rehabilitation and 
future psychological intervention trials in CAD patients.
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Obesity, health status, and 7-year 
mortality in percutaneous coronary 
intervention: In search of an 
explanation for the obesity paradox
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Background: Obesity is a growing health problem and is associated with adverse 
outcomes in coronary artery disease (CAD). However, recent studies have shown better 
survival in cardiovascular patients with overweight or obesity, which has been referred 
to as the “obesity paradox”. As there is not a clear understanding of the phenomenon, 
we examined the association between body mass index (BMI) and all-cause mortality in 
patients treated with percutaneous coronary intervention (PCI) at 7-years follow-up, and 
the potential role of health status in explaining the obesity paradox.
Methods: Consecutive PCI patients (72.5% men; mean age 62.0±11.2 years, range [27-
90] years) from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital 
(RESEARCH) registry completed the 36-item Short-Form Health Survey (SF-36) to assess 
health status at baseline. Patients were classified into a normal weight, overweight, or 
obesity group. 
Results: The prevalence of normal weight was 34.7% (354/1019), whereas overweight 
was found in 45.9% (468/1019) of patients, and 19.3% (197/1019) was obese. After a 
median follow-up of 7.0±1.7 years, 163 deaths (16.0%) from any cause were recorded. 
Cumulative hazard functions differed significantly for the obese and overweight group as 
compared to the normal weight group (log-rank X2=6.59, p<.05). In multivariable analysis, 
overweight but not obesity was associated with a lower risk for all-cause mortality (HR=.60; 
95%CI [.42-.86], p=.005). Additionally, after adding the 8 health status SF-36 domains to 
the multivariate model, the association between overweight and mortality remained 
unchanged.
Conclusion: In the current study, overweight but not obesity was associated with a lower 
risk for 7-year mortality in PCI patients. Health status as measured with the SF-36 did not 
seem to play a role in explaining the obesity paradox.
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INTRODUCTION
Obesity is a growing epidemic, with prevalence rates in the general population ranging 
from 32% in men to 36% in women 1. In coronary artery disease (CAD), obesity is prevalent 
in about 30% of patients 2 and is associated with potential risk for cardiovascular morbidity 
and mortality 3, 4. However, evidence for a link between obesity and cardiovascular 
prognosis is based on a small number of studies, with results being mixed, as some 5 but 
not all studies support such a relationship 6. Moreover, recent studies have demonstrated 
that there may not be a linear and straightforward relationship between overweight and 
obesity and mortality, as some studies show better survival in cardiovascular patients with 
overweight or obesity. This phenomenon is referred to as the “obesity paradox” 6-9. 
In an attempt to explain the obesity paradox, studies have primarily focused 
on potential differences in the prescription of guideline-based medications 2, 7. A higher 
prevalence of invasive treatment has also been observed in obese patients with CAD 2. 
Nevertheless, we still do not have a clear understanding of the obesity paradox.
Patient-reported health status might be another avenue to pursue in order to 
elucidate factors that may impinge on or help explaining the obesity paradox. A recent 
systematic review demonstrated that poor health status in CAD and congestive heart 
failure increases the risk of mortality and hospital readmissions, independent of indicators 
of disease severity and socio-demographic and clinical characteristics 10. Also a recent 
paper from our research group found an association between poor health status and 
higher mortality 11. A paucity of studies focused on the association between obesity and 
health status 12-15, but the role of health status in the context of obesity and mortality in 
CAD has not yet been examined. 
Hence, in the current study we examined 1) the association between body 
mass index (BMI) and all-cause mortality in patients treated with percutaneous coronary 




The study sample comprised consecutive CAD patients treated with PCI, with either 
sirolimus-eluting stenting (SES) or bare-metal stenting (BMS), between October 16, 2001 
and October 15, 2002 at the Erasmus MC, Rotterdam, the Netherlands, as part of the 
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. 
The design of the RESEARCH registry has been published elsewhere 16. In brief, the registry 




interventional cardiology. Hence, no exclusion criteria were applied for patients entering 
the registry, and all PCI patients were eligible for enrolment regardless of anatomical or 
clinical presentation 17.
At 6 months post-PCI (referred to as baseline in the remainder of the paper), 
all living patients were asked to complete a standardized and validated health status 
measure. In accordance with previous studies, assessment at 6 months was chosen so as 
to represent patients in a stable condition, as the risk for restenosis is increased in the 0-6 
month period post-PCI 18. All patients were prospectively followed-up for adverse clinical 
events. 
Socio-demographic and clinical characteristics
Socio-demographic variables included gender and age. Clinical variables were obtained 
from patients’ medical records at the time of the index-PCI and included BMI (i.e., weight 
in kilograms divided by the square of the height in meters), type of stent (SES vs. BMS 
implantation), multi-vessel disease (multi-vessel disease vs. single-vessel disease/no 
vessel disease), indication for PCI (stable angina/silent ischemia, unstable angina, or 
myocardial infarction (MI)), cardiac history (i.e., previous MI, coronary artery bypass 
graft (CABG) surgery, or PCI), CAD risk factors (i.e., hypertension, hypercholesterolemia, 
diabetes mellitus, family history of CAD, and self-reported smoking) and prescribed cardiac 
discharge medications (i.e., ACE-inhibitors, beta-blockers, calcium-antagonists diuretics, 
oral nitrates, and statins). Information on clinical variables was prospectively collected at 
the time of the index-PCI and recorded in the institutional database.
Health status
Health status was assessed at baseline, 12, and 36 months post-PCI, using the 36-item 
Short-Form Health Survey (SF-36) 19. The SF-36 consists of 36 items that contribute to 8 
health status domains (i.e., physical functioning, role physical functioning, role emotional 
functioning, mental health, vitality, social functioning, bodily pain, and general health). 
Scale scores are obtained by summing the items together within a domain, dividing this 
outcome by the range of scores, and then transforming the raw scores to a scale from 0 
to 100 19. A higher score on the SF-36 subdomains represents better functioning. A high 
score on the bodily pain scale indicates freedom from pain. The scale has good reliability 
with Cronbach’s alpha ranging from .65 to .96 for all subscales 20.  
Endpoint
The primary endpoint was defined as all-cause mortality. Deaths (n=54) occurring 
between PCI and psychological assessment were excluded as an endpoint from the 
analyses. Information on survival status was obtained from the Municipal Civil Registries 
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in May 2009. The median follow-up period for all-cause mortality was 7.0±1.7 years (range 
[.8-9.4 years]). Information on survival status at follow-up was complete for 1007 patients 
(98.8%). 
Informed consent
The study protocol was approved by the medical ethics committee of the Erasmus MC, 
Rotterdam, and conducted according to the Helsinki Declaration 21. Every patient provided 
informed consent. 
Statistical analyses
Prior to statistical analyses, we dichotomized all 8 health status domains, as suggested 
by others, in order to enhance clinical interpretability 22, 23. The lowest tertile was used 
to indicate poor health status and the 2 highest tertiles to indicate good health status. 
Categorization of BMI was adopted from the World Health Organization and defined as 
normal weight (18.5 to 24.9 kg/m²), overweight (25 to 29.9 kg/m²), and obese (≥30 kg/m²) 
24, 25. For all analyses, normal weight was used as the reference group. 
Group differences were examined using the Chi-square test (Fisher’s exact test 
if appropriate) for nominal variables, while one-way ANOVA was used for continuous 
variables. Cumulative survival curves for BMI classes were constructed using the Kaplan-
Meier method. The log-rank test was used to compare cumulative survival curves between 
groups. Univariable and multivariable Cox regression models were used to examine the 
effect of BMI on all-cause mortality. Covariates were entered into the model using the Enter 
method, thereby reducing the risk of overfitting 26. In multivariable analysis, we adjusted 
for socio-demographic and clinical characteristics (i.e., gender, age, type of stent, multi-
vessel disease, indication for PCI, cardiac history, CAD risk factors, and prescribed cardiac 
medications). Covariates were selected a priori based on the literature 10, 11, 27-29. Health 
status was added to the final model to examine the role of health status in explaining the 
obesity paradox. 
Hazard Ratios (HRs) with their corresponding 95% CIs were reported for Cox 
regression analyses. All results were based on 2-tailed tests and a p-value <.05 was used 
to indicate statistical significance. All statistical analyses were performed using SPSS for 






Of 1675 eligible patients treated with PCI in the study period, 54 patients died within 6 
months. Of the remaining 1621 patients asked to participate in the study, 602 did not 
return the questionnaire at baseline (62.9% response rate). Final analyses were based on 
data from 1019 patients (72.5% men; mean age 62.0±11.2 years, range [27-90] years). 
No systematic differences between participants and non-participants were found on 
baseline characteristics, except for non-participants more often having diabetes mellitus 
as compared with participants (21.0% vs. 14.8%, p<.05). 
In the current sample, the prevalence of normal weight was 34.7% (354/1019), 
overweight was found in 45.9% (468/1019) of patients, whereas 19.3% (197/1019) was 
obese. At follow-up, 163 deaths (16.0%) from any cause were recorded. Patient baseline 
characteristics stratified by the 3 BMI categories are presented in Table 1. Overweight and 
obese patients were more likely to be younger as compared with the reference BMI group. 
Furthermore, obese patients were more likely to be female, smoke, have diabetes mellitus, 
and be prescribed diuretics.
BMI and all-cause mortality
The incidence of all-cause mortality at follow-up was 7.1% (72/1019) in the normal weight 
group versus 6.3% (64/1019) in the overweight group and 3.0% (31/1019) in the obesity 
group. Cumulative hazard functions differed significantly for the obese and overweight 
group as compared to the normal weight group (log-rank X2=6.59, p<.05). In univariable 
Cox regression analysis, overweight was significantly associated with a cumulative 
decreased risk for all-cause mortality (HR=.71; 95%CI [.51-.97], p=.030), whereas obesity 
was not (HR=.96; 95%CI [.64-1.42], p=.82) (Figure 1). After adjusting for socio-demographic 
and clinical characteristics, overweight remained associated with a lower risk for all-cause 
mortality (HR=.60; 95%CI [.42-.86], p=.005), whereas no association was found between 
obesity and mortality (HR=.87; 95%CI [.55-1.37], p=.55) (Table 2).
BMI, all-cause mortality, and health status
In a final model, each of the 8 health status subdomains was added to the multivariable 
Cox regression analysis. After adjusting for socio-demographic and clinical characteristics, 
and the health status subdomains, the association between overweight and mortality 
remained unchanged (Table 2). 
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Male gender 72 70 76 68 .005**
Age, mean (SD) 62 (11.2) 63 (11.4) 63 (11.2) 60 (10.6) .005**
Clinical characteristics
Multi-vessel disease 54 52 57 53 .44
Cardiac history b 59 57 59 61 .71
Indication for PCI .66
   Stable angina/ Silent ischemia 51 51 50 55
   Unstable angina 37 36 39 34
   MI 12 13 12 11
Hypertension 29 32 28 25 .24
Hypercholesterolemia 59 56 59 61 .45
Diabetes mellitus 15 10 16 24 <.001***
Family history of CAD 15 14 15 17 .60
Self-reported smoking 42 35 42 54 <.001***
BMI, mean (SD) 27 (5.1) 23 (1.4) 27 (1.4) 34 (7.1) <.001***
Cardiac medication
Aspirin 95 94 95 95 .87
ACE-inhibitors 33 31 33 38 .20
Beta-blockers 67 66 67 68 .88
Calcium-antagonists 51 51 50 55 .54
Diuretics 15 12 15 22 .008**
Oral nitrates 17 18 15 19 .41
Statins 73 73 73 72 .96
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as % unless otherwise stated
b Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery




































Obesity 191 182 173 166
Reference
HR=.71; 95%CI [.51-.97], p=.030
HR=.96; 95%CI [.64-1.42], p=.82
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Table 2. Association between BMI, health status, and all-cause mortality (adjusted analyses a)
HR 95%CI p
BMI (without SF-36 subdomains)
18.5 – 24.9 Reference
25.0 – 29.9 .60 .42 - .86 .005**
≥30.0 .87 .55 – 1.37 .55
BMI (including SF-36 subdomains)
Physical functioning
18.5 – 24.9 Reference
25.0 – 29.9 .59 .41 – .86 .005**
≥30.0 .78 .78 – 1.25 .30
Social functioning
18.5 – 24.9 Reference
25.0 – 29.9 .62 .43 – .89 .009**
≥30.0 .85 .54 – 1.34 .49
Role physical functioning
18.5 – 24.9 Reference
25.0 – 29.9 .64 .44 – .94 .024*
≥30.0 .89 .55 – 1.43 .63
Role emotional functioning
18.5 – 24.9 Reference
25.0 – 29.9 .62 .42 – .91 .015*
≥30.0 .88 .54 – 1.41 .59
Mental health
18.5 – 24.9 Reference
25.0 – 29.9 .59 .41 – .85 .005**
≥30.0 .87 .55 – 1.38 .56
Vitality
18.5 – 24.9 Reference
25.0 – 29.9 .57 .39 – .82 .003**







18.5 – 24.9 Reference
25.0 – 29.9 .62 .43 – .88 .008**
≥30.0 .80 .51 – 1.27 .35
General health
18.5 – 24.9 Reference
25.0 – 29.9 .62 .43 – .89 .010**
≥30.0 .82 .51 – 1.32 .41
*p≤.05; ** p≤.01; ***p≤.001
a Adjusted for: Gender, age, hypercholesterolemia, hypertension, diabetes mellitus, smoking, family history of 
CAD, cardiac history, indication for PCI, multi-vessel disease, type of stent, aspirin, ACE-inhibitors, beta-blockers, 
calcium antagonists, diuretics, oral nitrates, and statins
BMI = body mass index (kg/m2), SF-36 = 36-item Short-Form Health Survey
DISCUSSION
To our knowledge, this is the first study which examined whether the paradoxical 
association between BMI and mortality could be explained by health status. After a median 
follow-up of 7 years, overweight but not obesity was associated with a lower risk for all-
cause mortality in patients treated with PCI, after adjusting for socio-demographic and 
clinical characteristics. We found no evidence that health status played a role in explaining 
the obesity paradox.
The results of the current study are in line with previous studies, demonstrating 
that overweight was associated with a decrease in mortality risk. A large meta-analysis 
conducted by Romero-Corral et al. 30 selected 40 studies with a total of 250.152 patients 
who underwent either PCI or CABG surgery. Results showed that overweight was 
associated with the lowest risk for total and cardiovascular mortality as compared with 
normal weight. In contrast to our findings, mildly obese patients also had lower mortality 
rates as compared with the normal weight group. Several other studies investigated the 
relationship between BMI and mortality. Most of them consistently showed an “obesity 
paradox” after PCI, with better survival in obese patients 5, 6, 9, 31, 32. However, in our PCI 
cohort, only overweight but not obesity was associated with lower all-cause mortality 
as compared with patients with a normal weight. These discrepancies may possibly be 
attributed to bigger sample sizes (ranging from 2.099 up to 95.435 PCI patients) 5, 6, 9, 31, 32 
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or differences in the follow-up duration, as the follow-up duration in previous studies was 
mainly limited to 1 year 5, 9.
In an attempt to explain the obesity paradox, previous studies in cardiac patients 
have mainly focused on medical factors, but results are inconclusive. For example, 
some studies examined the possible influence of guideline-based medications. These 
studies argued that higher BMI is associated with increased use of guideline-based 
medications, such as aspirin, beta-blockers, statins, and renin-angiotensin antagonists 
during hospitalization and at discharge. Hence, overweight and obese patients may 
receive more optimal medical treatment, which might contribute to improved long-term 
outcomes 2, 9. Further, more severe hypercholesterolemia and higher levels of serum low-
density lipoproteins in obese patients have been examined as potential explanations for 
the obesity paradox 33. Other mechanisms like plasma renin levels, increased release of 
inflammatory cytokines, adinopectin secretion, and physical well-being could also be part 
of the explanation 34-37. However, there is still not a clear understanding of the obesity 
paradox. 
As previously shown, health status is an important outcome measure in CAD. 
Schenkeveld et al. 11 showed that poor health status is associated with adverse outcomes 
after PCI. Moreover, a recent meta-analysis showed that poor health status is associated 
with higher all-cause and cardiac mortality in CAD patients 10. These findings were 
confirmed in other studies in patients undergoing cardiac intervention or surgery 38-40. 
Several studies focused on the relation between BMI and health status, with most of them 
showing a negative relationship 12-15, 27, 41. However, these studies were mainly focusing on 
heart failure patients 12, maintenance hemodialysis patients 15, 41, or the general population 
13, but not PCI patients. These studies did not examine the role of health status as a possible 
explanation of the obesity paradox either.
The present study did not find evidence for health status as a possible explanation 
of the obesity paradox. There are some mechanisms which could be of importance in 
explaining our results. First, health status is probably a modifiable risk factor. Several 
mechanisms might be responsible for a connection between adverse clinical outcome 
and poor health status (i.e., demographic, physiological, and biomechanical mechanisms). 
Second, health status not only differs by level of obesity, but also by gender and age 13. 
However, we adjusted for these factors in our multivariable models and no changes were 
observed. Finally, weight loss could result in significant improvements in health status, as 
measured with the SF-36 and the Kellner Symptom Questionnaire 42-44. Future studies are 
warranted to more precisely investigate the complex nature of the obesity paradox and 
the factors that could play a role in explaining the paradox, taking socio-demographic, 





Limitations of the current study must be acknowledged. First, data on abdominal obesity, 
as measured by waist circumference and waist/hip ratio, was not available. A recent 
meta-analysis showed that central obesity was associated with higher mortality in CAD, 
whereas total obesity (BMI) was not 45. Therefore, future research should focus on the 
different aspects of obesity rather than total obesity alone. Second, the SF-36 is a generic 
measure of health status, which may be less sensitive to tap into patients’ health status 
than the disease-specific measures used in previous studies 10. Third, we only included 
patients who returned the SF-36 questionnaire. This might have influenced our results. 
Finally, our study population was not sufficiently large to perform subgroup analyses for 
extreme BMI’s (i.e., ≤20 and ≥40). Therefore, we cannot deduce if our results show similar 
trends in these groups.
Conclusion
The current study showed that after a median follow-up of 7 years, overweight but not 
obesity was associated with lower mortality. In the current study health status did not 
seem to play a role in explaining the obesity paradox. 
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The distressed (Type D) personality 
mediates the relationship between 
remembered parenting and 
psychological distress in cardiac     
patients
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Objective: Both the distressed (Type D) personality (i.e., the combination of negative 
affectivity and social inhibition traits) and dysfunctional parenting styles are associated with 
anxiety and depression. As parenting styles have been related to personality development, 
dysfunctional parenting styles may also be associated with Type D personality. We 
examined whether remembered parenting was associated with anxiety and depression in 
cardiac patients and whether Type D personality mediated this relationship. 
Methods: Our sample comprised 435 patients treated with percutaneous coronary 
intervention (PCI) and 123 patients with congestive heart failure (CHF). Patients completed 
the Hospital Anxiety and Depression Scale (HADS), Type D Scale (DS14), and Remembered 
Relationship with Parents (RRP10) scale. 
Results: Remembered parenting was significantly associated with higher anxiety and 
depression levels and with Type D personality. In multivariable linear regression analyses, 
Type D personality accounted for 25-29% of the variance in anxiety and 23-46% of 
the variance in depression, while remembered parenting was no longer significantly 
associated with these domains. Sobel tests and bootstrapping indicated that Type D 
personality mediated the relationship between remembered parenting and anxiety and 
depression. 
Conclusion: Type D personality mediated the relationship between remembered 
parenting and anxiety and depression in both PCI and CHF patients. 
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INTRODUCTION
The distressed (Type D) personality (i.e., the combination of negative affectivity and social 
inhibition traits) is a risk factor for anxiety and depression 1-4, poor health status and quality 
of life 5-7, and morbidity and mortality in patients with cardiovascular disease 8-11, as also 
confirmed in recent meta-analyses 12, 13. Type D individuals experience a broad range of 
negative emotions and tend to inhibit these emotions in social interaction 14, 15.
Several links have been identified that may explain the association between 
Type D personality and adverse health outcomes in cardiac patients, and include both 
behavioral and biological pathways. Type D patients are less likely to engage in optimal 
health-related behaviors, such as exercising and quitting smoking 14, 16, 17, and are also less 
likely to consult their health care provider despite worrying more about their symptoms 
18. Biological pathways include immune activation 19, 20, dysfunctional stress reactivity 21, 22, 
and disturbances in cortisol regulation 23, 24. 
However, knowledge of the mechanisms involved in the development of Type 
D personality itself is largely lacking. A recent study suggested that the characteristics 
of Type D personality may in part be attributed to genetic factors, as the heritability for 
Type D was found to be 52% 25. Regarding environmental factors, remembered parenting 
may be of importance, as dysfunctional parenting styles, like overprotection or coldness, 
have been related to neuroticism 26-28, negative affectivity 29, and adult shyness 29. These 
personality traits are closely related to the 2 core components of the Type D construct. 
In addition, previous studies have indicated that dysfunctional parenting styles 
are associated with an increased risk for anxiety and depression 30-34. Furthermore, 
dysfunctional parenting styles have been related to cardiovascular outcomes. Results 
from the Adverse Childhood Experiences (ACE) study showed that adverse childhood 
experiences, including household dysfunction, neglect, and abuse, are related to an 
increased risk for ischemic heart disease 35, 36. Another study with a 35-year follow-up 
showed that dysfunctional parenting styles were associated with an increased risk for 
incident coronary artery disease (CAD) 37.
Because both Type D personality and dysfunctional parenting styles are related 
to psychological distress and dysfunctional parenting styles may also be associated 
with Type D personality, Type D may mediate the relationship between remembered 
dysfunctional parenting and anxiety and depression. Personality factors, such as self-
esteem, emotional stability, and self-discipline, have been investigated as a mediating 
mechanism in the relationship between dysfunctional parenting styles and depression 
38-40. In a recent population-based study, Type D mediated the relationship between 
remembered parenting and perceived health 41, whereas another study demonstrated the 





Although both dysfunctional parenting styles and Type D personality have been 
related to adverse cardiovascular outcomes, to date no study examined this mediation 
model in cardiac patients. Hence, the aim of the current study was to examine whether 
remembered parenting is associated with anxiety and depression in cardiac patients, and 
whether Type D personality mediates this relationship. To examine whether the effects 
differ between stages of heart disease, we used 2 cohorts of cardiac patients, patients 
treated with percutaneous coronary intervention (PCI) and congestive heart failure (CHF) 
patients.
METHODS
Participants and procedure 
The study sample included 558 cardiac patients. The first cohort comprised 435 consecutive 
patients treated with percutaneous coronary intervention (PCI) to reflect early-stage 
heart disease. Patients were treated with PCI between February 2, 2006 and September 
14, 2006 at the Erasmus MC, Rotterdam, the Netherlands. In all patients, the paclitaxel-
eluting stent (PES) was used as the default strategy. No exclusion criteria were applied 
and all PCI patients were eligible for enrolment regardless of their anatomical, clinical, 
or psychological presentation. One month post-PCI, patients were asked to complete a 
set of standardized and validated psychological questionnaires, as preliminary evidence 
suggests that psychological assessment at the time of the index-PCI may be less optimal 
than 1 month post-procedure 43.
To represent end-stage heart disease, the second cohort comprised 123 patients 
receiving a first-time cardiac resynchronization therapy defibrillator (CRT-D) between 
January 21, 2009 and August 9, 2010 at the University Medical Center Utrecht (UMCU), 
the Netherlands. All patients participated in the ongoing “The influence of PSYchological 
factors on health outcomes in HEART failure patients treated with CRT: A prospective, 
single-center, observational study (PSYHEART-CRT)”. The PSYHEART-CRT study was 
primarily designed to examine whether psychological factors moderate the effect of 
objectively assessed CRT response on patient-reported outcomes in CHF patients. 
Exclusion criteria were age <18 or >85 years, a history of psychiatric illness other than 
affective/anxiety disorders, cognitive impairments (e.g., dementia), on the waiting list 
for heart transplantation, and insufficient knowledge of the Dutch language. We did not 
exclude patients with a history of affective/anxiety disorders, as we were particularly 
interested in patients with increased levels of depression and anxiety, irrespective of the 
fact if this had been diagnosed as a disorder. One day prior to implantation, patients were 
asked to complete a set of standardized and validated psychological questionnaires. 
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The current study was approved by the medical ethics committee of the respective 
hospitals and was conducted in accordance with the Helsinki Declaration 44. All patients 
provided informed consent. 
Measures
Socio-demographic and clinical characteristics of PCI patients
Socio-demographic characteristics included gender and age. Clinical characteristics 
included multi-vessel disease (multi-vessel disease vs. single-vessel disease/no vessel 
disease), body mass index (BMI), cardiac history (i.e., previous myocardial infarction (MI), 
coronary artery bypass graft (CABG) surgery, or PCI), indication for PCI (stable angina/silent 
ischemia, unstable angina, or MI), CAD risk factors (i.e., hypertension, diabetes mellitus, 
family history of CAD, and self-reported smoking), and prescribed cardiac discharge 
medications (i.e., aspirin, ACE-inhibitors, beta-blockers, calcium-antagonists, diuretics, 
oral nitrates, and statins). Information on socio-demographic and clinical characteristics 
was obtained from patients’ medical records.
Socio-demographic and clinical characteristics of CHF patients
Socio-demographic characteristics included gender and age. Clinical characteristics 
included etiology (ischemic vs. non-ischemic), implantable cardioverter defibrillator 
(ICD) indication (primary vs. secondary prevention), New York Heart Association (NYHA) 
functional class, left ventricular ejection fraction (LVEF), BMI, cardiac history (i.e., previous 
MI, CABG, or PCI), smoking, and prescribed cardiac medications at hospital admission for 
CRT-D implantation. Information on socio-demographic and clinical characteristics was 
obtained from patients’ medical records. 
Type D personality
In both cohorts, Type D personality was assessed with the 14-item Type D scale (DS14) 
that comprises 2 subscales, negative affectivity (NA) (e.g., “I often feel unhappy”) and 
social inhibition (SI) (e.g., “I am a closed kind of person”), each consisting of 7 items. Items 
are scored on a 5-point Likert scale ranging from 0 (“false”) to 4 (“true”). Based on findings 
from the Item Response Theory 45, a standardized cut-off score ≥10 on both subscales is 
used to identify individuals with a Type D personality. However, previous studies indicated 
that Type D personality is better represented as a continuous construct 46 and could be 
derived from the interaction effect of the NA and SI subscales 24, 47. In the current study, we 
used this interaction term as a continuous measure of Type D personality in all analyses. In 
the cohort of PCI patients, Cronbach’s alpha was .86 for NA and .85 for SI, whereas in the 





All patients completed the Dutch version of the Hospital Anxiety and Depression Scale 
(HADS) to assess symptoms of anxiety and depression 48, 49. Both subscales consist of 
7 items that are answered on a 4-point Likert scale ranging from 0 to 3 48. The HADS 
has demonstrated to be a valid screening tool for detecting symptoms of anxiety and 
depression 50, 51, and has been shown to predict mortality in patients referred for exercise 
testing 52. The internal consistency has been demonstrated previously, with Cronbach’s 
alpha of .83 for the anxiety subscale (HADS-A) and .82 for the depression subscale (HADS-D) 
50. In the current study, in the cohort of PCI patients Cronbach’s alpha was .85 for HADS-A 
and .81 for HADS-D, whereas in the cohort of CHF patients, Cronbach’s alpha was .83 for 
HADS-A and .82 for HADS-D.
Remembered parenting
The Remembered Relationship with Parents (RRP10) scale was used to retrospectively 
assess perceptions of parental care 34. This self-report instrument assesses caregiving 
processes with an emphasis on deficiencies in emphatic relationships between parents 
and child. Respondents are asked to describe the relationship with their parents while 
growing up on a 5-point Likert scale ranging from 0 ("false") to 4 ("true"). The RRP10 
consists of 2 subscales, alienation from parents and control by parents. Alienation refers 
to respondents’ perception of dysfunctional communication and intimacy with their 
parents (e.g., “I often felt that my parents did not understand me”), while control refers 
to the respondent’s perception of an overprotective parenting style (e.g., “I wished my 
parents would worry less about me”). Remembered alienation and control were assessed 
with reference to the father and mother separately. However, in the current study the 
combined score of both parents was used to assess alienation and control (score range 
[0-40]). A higher score on both parenting scales indicates worse remembered parenting 
while growing up. Because of the non-pathological focus, the RRP10 is suitable for use in 
non-psychiatric populations and in epidemiological and clinical research 41. The RRP10 has 
a good factor structure, internal consistency (Cronbach’s alpha = .83-.86), and convergent 
validity with the Parenting Bonding Instrument (PBI) 34, 41, 53. In the current study, in the 
cohort of PCI patients Cronbach’s alpha was .90, whereas in the cohort of CHF patients, 
Cronbach’s alpha was .89.
Statistical analyses
Before investigating whether Type D personality, as represented by the interaction term 
of NA and SI, mediated the relationship between remembered parenting and anxiety and 
depression, we examined whether the assumptions underlying the mediation model 
according to Baron and Kenny 54 were fulfilled: 1) remembered parenting had to be related 
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to anxiety and depression, 2) remembered parenting had to be associated with the 
mediator Type D personality, and 3) Type D personality had to be associated with anxiety 
and depression, after adjusting for remembered parenting (Figure 1). Type D personality 
was considered a mediator if it accounted for a significant part of the relation between 
remembered parenting and anxiety and depression 54. The assumptions for mediation 
were tested with a series of linear regression models. In general, with mediation we meant 
to state that the direct effect of remembered parenting on psychological distress might 
be weakened by an indirect effect via Type D personality. 
To allow for a more direct test of the mediation effect, Sobel tests were used 55. 
Sobel tests, which are products of coefficient tests for the mediating variable effect, are 
used to test the significance of the mediating variable effect by dividing the estimate 
of the mediating variable effect by its standard error and comparing this value to a 
standard normal distribution. In contrast with causal step methods (e.g., the Baron and 
Kenny approach), Sobel tests are less prone to Type I errors and have more statistical 
power to detect mediation if present 56. To further test the robustness of our mediation 
model, bootstrapping, using 5000 sample replicates, was performed 57. Bootstrapping 
is especially suitable for small sample sizes and avoids the assumption that the indirect 
effects are normally distributed. Indirect effects are unstandardized coefficients, which are 
significant when the 95% confident interval does not contain zero. 
In additional multivariable linear regression analyses, we examined whether 
Type D personality remained significantly associated with anxiety and depression, after 
adjusting for socio-demographic and clinical variables. In the PCI cohort, we adjusted 
for all baseline characteristics listed in Table 1, except for aspirin as almost all patients 
(i.e., 95%) were prescribed aspirin. In the CHF cohort, we adjusted for gender, age, NYHA 
functional class, LVEF, etiology, and diabetes mellitus. Covariates were selected a priori 
based on the literature 58-60. The assumption of multicollinearity was checked for all 
separate multivariable linear regression models.
Sobel tests and bootstrapping were performed with SPSS macros by Preacher 
and Hayes 57, 61 (http://www.afhayes.com/spss-sas-and-mplus-macros-and-code.html), as 
SPSS does not provide the possibility to directly test the mediation effect. For all other 




Figure 1. Mediation model for parental alienation and control, Type D personality, and anxiety and 
depression
RESULTS
Characteristics of PCI patients
Of the 869 eligible patients treated with PCI in the study period, 29 died within 4 weeks. 
The remaining 840 were asked to participate in the study, of which 297 did not return the 
questionnaire at baseline (64.6% response rate). Of the remaining 543 patients, 108 did not 
complete the HADS, DS14, or RRP10. Final analyses were based on data from 435 patients 
(77.5% men; mean age 62.6±10.7 years, range [30-91] years). In the current study, the 
mean scores for NA and SI were 8.2±6.2 and 9.1±6.4, respectively. Patient characteristics 
for the total sample of PCI patients are presented in Table 1. 
Characteristics of CHF patients
Of the 182 eligible patients implanted with a CRT-D in the study period, 35 refused to 
participate and 8 patients did not return the questionnaire at baseline (76.4% response 
rate). Of the remaining 139 patients, 16 did not complete the HADS, DS14, or RPP10. Final 
analyses were based on 123 patients (71.5% men; mean age 65.3±10.5 years, range [30-
84] years). In the current study, the mean scores for NA and SI were 8.4±6.4 and 9.1±5.8, 
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Male gender 336 (77.4) 88 (71.5)
Age, mean (SD) 62.6 (10.7) 65.3 (10.5)
Clinical characteristics
Cardiac history b 164 (38.5) 59 (48.4)
Hypertension 208 (53.1) 47 (38.2)
Diabetes mellitus 76 (17.5) 24 (19.5)
Self-reported smoking 114 (29.1) 17 (13.8)
BMI, mean (SD) 27.3 (3.9) 27.3 (5.5)
Multi-vessel disease 221 (51.0) -
Family history of CAD 208 (53.1) -
Indication for PCI
   Stable angina/ Silent ischemia 174 (40.7) -
   Unstable angina 110 (25.8) -
   MI 143 (33.5) -
Ischemic etiology - 64 (52.0)
CRT-D for primary prevention - 98 (79.7)
NYHA functional class III or IV - 99 (80.5)
LVEF, mean (SD) - 24.6 (8.5)
Cardiac medication
Aspirin 423 (97.7) 38 (30.9)
ACE-inhibitors 70 (16.2) 82 (66.7)
Beta-blockers 302 (69.7) 94 (76.4)
Calcium-antagonists 5 (1.2) 9 (7.3)
Diuretics 4 (.9) 105 (85.4)
Oral nitrates 61 (14.1) 21 (17.1)
Statins 362 (83.6) 74 (60.2)
a Results are presented as n (%) unless otherwise stated; b Previous myocardial infarction (MI), percutaneous 
coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery; ACE = angiotensin-converting 
enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease, CRT-D = cardiac resynchronization 




Type D, parenting, and distress in PCI patients
In PCI patients, we tested the hypothesis that Type D personality mediated the 
relationship between remembered parenting and anxiety and depression, using a series 
of linear regression analyses. Results indicated that parental alienation and control were 
associated with both more anxiety (p<.001) and depression (p<.001) (Table 2). The second 
assumption underlying the mediation model was also fulfilled: Parental alienation and 
control were significantly related to Type D personality (p<.001) (Table 2). Multivariable 
linear regression analyses showed that Type D personality was significantly associated with 
both higher anxiety (p<.001) and depression (p<.001), when adjusting for remembered 
alienation and control (Table 2). Once Type D personality was included in the model, the 
effect of the remembered relationship with parents on anxiety and depression was no 
longer significant, indicating mediation. 
Sobel tests confirmed that Type D personality significantly mediated the 
relationship between remembered parenting and anxiety (z’=7.58, p<.001 for alienation 
and z’=6.88, p<.001 for control, respectively) and depression (z’=7.20, p<.001 for 
alienation and z’=6.47, p<.001 for control, respectively). In addition, bootstrapping further 
confirmed the mediation model with significant indirect effects of Type D personality on 
the relationship between remembered parenting and anxiety (indirect effect=.08, SE=.01, 
95%CI [.06-.12] for alienation and indirect effect=.08, SE=.01, 95%CI [.06-.11] for control, 
respectively) and depression (indirect effect=.09, SE=.01, 95%CI [.06-.12] for alienation 
and indirect effect=.08, SE=.01, 95%CI [.06-.11] for control, respectively).
In extended multivariable linear regression analyses, Type D personality remained 
significantly associated with higher levels of anxiety and depression (β=.56, p<.001, 
∆R2=.26 and β=.54, p<.001, ∆R2=.24, respectively), after adjusting for socio-demographic 
and clinical variables. Female gender (β=.11, p=.002) and diabetes mellitus (β=.09, p=.038) 
were associated with higher levels of anxiety, whereas higher age (β=.12, p=.007), diabetes 
mellitus (β=.11, p=.020), and smoking (β=.12, p=.014) were associated with higher levels 
of depression. In all multivariable linear regression models, the assumption of non-
multicollinearity was met.
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Type D, parenting, and distress in CHF patients
In CHF patients, parental alienation and control were significantly associated with more 
anxiety (p<.001) and depression (p<.01) (Table 2). Parental alienation and control were 
also significantly related to Type D personality (p<.001) (Table 2). Once again, Type D 
personality was significantly associated with both higher anxiety (p<.001) and depression 
(p<.001), when adjusting for parental alienation and control (Table 3). Once Type D 
personality was included in the model, the effect of remembered parenting on anxiety 
and depression was no longer significant, indicating mediation. 
Sobel tests confirmed that Type D mediated the relationship between remembered 
parenting and anxiety (z=3.67, p<.001 for alienation and z=3.37, p<.001 for control, 
respectively) and depression (z=3.67, p<.001 for alienation and z=3.58, p<.001 for control, 
respectively). In addition, bootstrapping further confirmed the mediation model with 
significant indirect effects of Type D personality on the relationship between remembered 
parenting and anxiety (indirect effect=10, SE=.03, 95%CI [.05-.15] for alienation and 
indirect effect=.09, SE=.03, 95%CI [.04-16] for control, respectively) and depression 
(indirect effect=.11, SE=.02, 95%CI [.07-.16] for alienation and indirect effect=.11, SE=.04, 
95%CI [.05-.18] for control, respectively).
In extended multivariable regression analyses, Type D personality remained 
significantly associated with higher levels of anxiety and depression (β=.45, p<.001, 
∆R2=.16 and β=.57, p<.001, ∆R2=.26, respectively), after adjusting for remembered 
parenting, age, gender, NYHA functional class, LVEF, etiology, and diabetes. None of 
the socio-demographic and clinical variables were significantly associated with anxiety, 
whereas higher NYHA functional class was associated with higher levels of depression 
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DISCUSSION
To our knowledge, this is the first study to report on the role of Type D personality as a 
mediator between remembered parenting and anxiety and depression in cardiac patients. 
In both PCI and CHF patients, remembered dysfunctional parenting was significantly 
associated with higher anxiety and depression levels as well as with Type D personality. 
In multivariable linear regression analyses, Type D personality accounted for 25-29% of 
the variance in anxiety and 23-46% of the variance in depression, while remembered 
parenting was no longer significantly associated with any of these symptoms. Sobel 
tests and bootstrapping confirmed the finding that Type D personality mediated the 
relationship between remembered parenting and anxiety and depression in both PCI and 
CHF patients. 
The current study corroborates the findings of previous studies, demonstrating 
that personality factors may mediate the relationship between parenting styles and 
depression 38-40. In line with a recent study in the general Dutch population, we found 
that Type D personality mediated the relationship between remembered parenting 
and psychological distress 41. However, the current study extends previous research by 
showing that this mediation model is also applicable to cardiac patients. 
A paucity of studies have examined the association between parenting styles and 
personality development, showing that dysfunctional parenting styles, like overprotection 
and coldness, are related to the development of for example neuroticism 26-28 and negative 
affectivity 29. This is the first study to show that there is a link between remembered 
parenting and Type D personality in cardiac patients, with Type D patients reporting 
significantly more alienation from and control by parents than non-Type D patients. Given 
that Type D personality has been associated with a 2-fold increased risk for poor physical 
and mental health status and a more than 3-fold increased risk for poor prognosis in CAD 12, 
13, future longitudinal studies are warranted to examine whether dysfunctional parenting 
styles may contribute to the development of Type D personality. 
Information on genetic and environmental factors that contribute to the 
development of Type D personality is important for developing appropriate intervention 
trials that target this personality disposition in patients with established cardiovascular 
disease. To our knowledge, only one recent psychological intervention trial in Dutch 
community residents specifically targeted Type D personality. In this study, a mindfulness-
based stress reduction intervention was designed to reduce the NA and SI characteristics 
of Type D personality. After the 8-week intervention, the intervention group showed a 
significant decrease in both NA and SI dimensions, although change in Type D caseness 
did not differ between groups 62. In post-MI patients, a psychological intervention trial 




and levels of psychological distress, including Type D personality 63. Results of the current 
study suggest that when designing a behavioral intervention for Type D patients, it may 
also be important to take remembered parenting into account. 
The limitations of the current study must be acknowledged. First, the cross-
sectional study design does not allow for causal inferences about the relationship between 
remembered parenting, Type D personality, and anxiety and depression. A so-called recall 
bias may arise, as it is possible that childhood memories are influenced by the patient’s 
personality and current feelings of distress. For example, given the high levels of SI in Type 
D patients, these patients may report that they feel more alienated from their parents 
as compared with patients with lower levels of SI. This should be investigated further. 
Second, patients who indicated that there was only maternal or paternal parenting were 
excluded from the analyses. This was the case in 7.7% (42/543) of PCI patients and 10.1% 
(14/139) of CHF patients. Third, data on Type D personality and anxiety and depression 
was obtained from self-report questionnaires and therefore, common method variance 
may have contributed to the significant results. However, we only used validated and 
reliable questionnaires to assess the psychological constructs studied, which have been 
used frequently in different cardiovascular patient groups 1, 64. Finally, in contrast to the 
current study, previous studies mainly used the PBI to assess remembered parenting 
rather than the RRP10. However, it has been shown that the RRP10 has good convergent 
validity with the PBI 34, 41, 53. 
In conclusion, the current study showed that Type D personality mediated the 
relationship between remembered parenting and anxiety and depression in patients 
treated with PCI and CHF patients. Hence, in psychological intervention trials targeting 
Type D personality, it may be important to address remembered parenting. Future studies 
using a longitudinal design are warranted to examine the directionality of the relationship 
between remembered parenting, Type D personality, and psychological distress in cardiac 
patients.
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burden in patients treated with 
percutaneous coronary intervention
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Background: Psychological distress is associated with poor prognosis in patients with 
coronary artery disease (CAD). Both inflammation and the extent of coronary plaque 
burden are proposed as possible underlying mechanisms. We examined whether anxiety, 
depression, and the distressed (Type D) personality were associated with inflammatory 
markers and the extent of coronary plaque burden, as represented by intravascular 
ultrasound (IVUS), in patients treated with percutaneous coronary intervention (PCI).
Methods: The study sample of this cross-sectional study comprised 183 patients 
undergoing PCI. Blood samples for determining the inflammatory markers C-reactive 
protein (CRP), tumor-necrosis factor alpha (TNF-α), soluble TNF-α receptor 2 (sTNF-R2), 
interferon-gamma (IFN-γ), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-18 (IL-18), 
and vascular cell adhesion molecule-1 (VCAM-1) were collected, and the extent of plaque 
burden was assessed by IVUS of a non-culprit coronary artery. Psychological distress was 
examined by the State measure of the State-Trait Anxiety Inventory (STAI-S), the Patient 
Health Questionnaire (PHQ-9), and the Type D scale (DS14).
Results: In multivariate analyses, consistent, but inverse associations were found between 
anxiety, Type D personality, negative affectivity (NA), and social inhibition (SI) and ln-
transformed CRP level, whereas SI was associated with lower ln-transformed TNF-α levels. 
Both anxiety and NA were inversely associated with IVUS-derived coronary plaque burden. 
No significant associations were found for depression. Psychological distress accounted 
for 2-7% of the variance in inflammatory marker levels and coronary plaque burden. 
Conclusion: Our results do not support inflammation and the extent of coronary plaque 
burden as likely mechanisms underlying the relationship between psychological distress 
and cardiovascular disease. 
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INTRODUCTION
Psychological distress, such as anxiety, depression, and the distressed (Type D) personality 
(i.e., the combination of negative affectivity and social inhibition traits 1) is prevalent in 
25-50% of patients with coronary artery disease (CAD) and associated with increased 
cardiovascular morbidity and mortality 1-4. Both inflammation and the extent of 
atherosclerosis have been associated with the onset and progression of CAD 5-10. These 
phenomena are also proposed as possible mechanisms linking psychological distress to 
poorer prognosis in CAD patients, although results are inconsistent.
Previous studies indicated that depressed or anxious CAD patients have higher 
levels of inflammatory markers, including C-reactive protein (CRP) 11-15 and interleukin-6 
(IL-6) 11, 14, with these findings being confirmed in a meta-analysis 16. In addition, Type D 
personality has been associated with higher levels of tumor-necrosis factor alpha (TNF-α), 
soluble TNF-α receptors 1 (sTNF-R1) and 2 (sTNF-R2), and lower levels of anti-inflammatory 
marker interleukin-10 (IL-10) in heart failure patients 17, 18. However, other studies found 
no significant positive 19-22 or inverse associations 23 between psychological distress and 
inflammatory markers in CAD. 
There is some evidence from population-based studies linking anxiety, depression, 
and personality traits to the presence, development, and progression of atherosclerosis 24-
27, while negative findings are also reported 28-32. In the latter studies, different standardized 
methods were used to assess the extent of atherosclerosis, including carotid intima-media-
thickness (IMT) 25-27, 30-32, coronary artery calcification (CAC) 28, 29, and the Ankle-Brachial 
Index (ABI) 24, 26. A relatively novel, intra-coronary imaging technique to obtain specific 
and detailed information on the extent of atherosclerosis and morphology is intravascular 
ultrasound (IVUS). By means of IVUS, specific and detailed information on the extent of 
coronary plaque burden can be obtained 33. 
To our knowledge no study has reported on the association between 
psychological distress and IVUS-derived measures of coronary plaque burden. In addition, 
evidence on the association between psychological distress, inflammation, and the extent 
of atherosclerosis in CAD remains inconclusive. Hence, the aims of the current study were 
to examine whether anxiety, depression, and Type D personality were associated with 1) 
inflammatory markers (i.e., CRP, TNF-α, sTNF-R2, interferon-gamma (IFN-γ), interleukin-8 
(IL-8), IL-10, interleukin-18 (IL-18), and vascular cell adhesion molecule-1 (VCAM-1)), and 
2) IVUS plaque burden, in patients treated with percutaneous coronary intervention (PCI) 






The current study was embedded in the European Collaborative Project on Inflammation 
and Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-
IVUS) study. The design of the ATHEROREMO-IVUS study has been published previously 33. In 
brief, patients who underwent diagnostic coronary angiography or PCI for acute coronary 
syndrome (ACS) or stable angina pectoris were enrolled in ATHEROREMO-IVUS. Blood 
samples to assess inflammatory markers were drawn prior to the coronary catheterization 
or PCI procedure, whereas IVUS imaging of a non-culprit coronary artery to assess the 
extent of coronary plaque burden was performed subsequent to angiography or PCI. 
Between November, 2008 and January, 2011, a total of 581 patients, of which 
440 PCI patients, were enrolled in ATHEROREMO-IVUS in the Erasmus MC, Rotterdam, the 
Netherlands. During the study period, as part of an evaluation of our cardiac rehabilitation 
program, 256 patients who underwent PCI were asked to complete a set of standardized 
and validated psychological questionnaires within 4 weeks post-procedure (referred to as 
baseline in the remainder of the paper). Preliminary evidence suggests that psychological 
assessment at the time of the index-PCI may be less optimal than 1 month post-procedure 
34. Our study sample comprised the 183 responders (response rate 71%), who had complete 
data on blood samples, IVUS imaging, and psychological assessment.
The ATHEROREMO-IVUS study protocol was approved by the medical ethics 
committee of the Erasmus MC, Rotterdam, and the study was conducted according to the 
Helsinki Declaration 35. Every patient provided written informed consent.
Measures
Socio-demographic and clinical characteristics
Socio-demographic characteristics included gender and age. Clinical characteristics 
included multi-vessel disease (multi-vessel disease vs. single-vessel disease/no vessel 
disease), body mass index (BMI), cardiac history (i.e., previous myocardial infarction (MI), 
coronary artery bypass graft (CABG) surgery, or PCI), indication for PCI (stable angina/
silent ischemia, unstable angina, or MI), renal impairment, peripheral artery disease 
(PAD), chronic obstructive pulmonary disease (COPD), heart failure, CAD risk factors (i.e., 
hypertension, hypercholesterolemia, diabetes mellitus, family history of CAD, and self-
reported smoking), and prescribed cardiac medications (i.e., ACE-inhibitors, aspirin, beta-
blockers, calcium-antagonists, clopidogrel, diuretics, oral anti-coagulants, oral nitrates, 
and statins). Information on clinical variables was prospectively collected at the time of 
the index-PCI and recorded into a dedicated database.
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Inflammatory markers
Blood samples to assess markers of inflammation were drawn from the arterial sheath 
prior to the PCI procedure. Within 2 hours after blood collection, blood samples were 
transported to the clinical laboratory of the Erasmus MC for further processing and 
storage at a temperature of -80oC. Inflammatory markers IFN-γ, IL-8, IL-10, IL-18, TNF-α, 
sTNF-R2, and VCAM-1 were measured in the stored EDTA-plasma samples using a validated 
multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). TNF-α, IFN- γ, IL-
8, IL-10, and IL-18 concentrations were reported in pg/ml, whereas sTNF-R2 and VCAM-1 
concentrations were reported in ng/ml. The Roche Integra high-sensitivity assay was used 
to measure serum levels of CRP (mg/l) (Clinical laboratory, Erasmus MC, Rotterdam, the 
Netherlands). 
IVUS plaque burden
Subsequent to the standard PCI procedure, IVUS imaging was used to assess the extent 
of atherosclerosis, as represented by the percentage of coronary plaque burden in a non-
culprit coronary vessel (i.e., IVUS plaque burden). Selection of the non-culprit vessel was 
predefined in the study protocol. The order of preference for selection of the non-culprit 
vessel was: 1) left anterior descending (LAD) artery, 2) right coronary artery (RCA), and 3) 
left circumflex (LCX) artery. All IVUS data was acquired with the Volcano s5/s5i Imaging 
System (Volcano Corp., San Diego, CA, USA), using a Volcano Eagle Eye Gold IVUS catheter 
(20 MHz). An automatic pullback system was used with a standard pullback speed of 0.5 
mm per second. The IVUS images were analyzed offline by an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands) that had no knowledge of the clinical data 
and inflammatory marker concentrations. The IVUS gray-scale was performed using pcVH 
2.1 and qVH software (Volcano Corp., San Diego, CA, USA). The external elastic membrane 
and luminal borders were contoured for each frame (median interslice distance 0.4 mm). 
Extent and phenotype of the coronary plaque were assessed. Plaque burden was defined 
as the plaque and media cross-sectional area divided by the external elastic membrane 
cross-sectional area and is presented as a percentage. 
Anxiety
Symptoms of anxiety were assessed at baseline with the Dutch version of the 20-item State 
measure of the State-Trait Anxiety Inventory (STAI-S) 36, a self-report instrument designed 
to measure the presence of axiety symptoms at the present moment. Each item is rated 
on a 4-point Likert scale ranging from 1 (“not at all”) to 4 (“very much so”), with a score 
range of 20–80. A high score indicates high levels of anxiety, with a score ≥40 indicating 
probable clinical levels 37. The STAI-S is a valid and reliable scale, with Cronbach’s alpha 





At baseline, patients completed the Dutch version of the 9-item Patient Health Questionnaire 
(PHQ-9), a self-report instrument that measures the frequency of depressive symptoms 
corresponding to the 9 diagnostic criteria for major depressive disorder according to the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM–IV) 38. Patients 
were asked to indicate the frequency of experiencing the 9 depressive symptoms during 
the last 2 weeks on a 4-point Likert scale ranging from 0 (“not at all”) to 3 (“nearly every 
day”), with a total score range of 0-27 39. The total score can be interpreted as indicating 
either no depression, minimal, mild, moderate, moderately severe, or severe depression. 
The PHQ-9 has demonstrated excellent validity when compared with a mental health 
interview for depression in patients with CAD 40, 41. 
Type D personality
At baseline, Type D personality was assessed with the 14-item Type D scale (DS14) that 
comprises 2 subscales, negative affectivity (NA) (e.g., “I often feel unhappy”) and social 
inhibition (SI) (e.g., “I am a closed kind of person”), each consisting of 7 items. Items are 
scored on a 5-point Likert scale ranging from 0 (“false”) to 4 (“true”). Based on findings 
from the Item Response Theory 42, a standardized cut-off score ≥10 on both subscales is 
used to identify individuals with a Type D personality. Previous research suggests that the 
co-occurrence of NA and SI, rather than the single traits, predicts adverse events in PCI 
patients 43, and both continuous subscales were examined in the present study as well. 
The DS14 is internally consistent 44, not confounded by disease severity 45, 46, and relatively 
stable over time 45, 46. 
Statistical analyses
Prior to analyses, all inflammatory markers (i.e., TNF-α, sTNF-R2, CRP, IFN-γ, IL-8, IL-10, IL-18, 
and VCAM-1) were ln-transformed, as they were not normally distributed, and verified that 
ln-transformation resulted in normal distributions. Pearson correlation coefficient was used 
to estimate the correlations of anxiety, depression, and the 2 continuous components of 
Type D personality (NA and SI), with the continuous ln-transformed inflammatory markers 
and IVUS plaque burden. 
Second, univariable and multivariable linear regression analyses were conducted 
to examine whether anxiety, depression, Type D personality, NA, and SI were associated 
with the inflammatory markers and IVUS plaque burden. In these linear models, symptoms 
of anxiety and depression and the scores on the distinct NA and SI subscales were entered 
as continuous independent variables, Type D personality as a dichotomous independent 
variable, and the continuous ln-transformed inflammatory marker concentrations 
and IVUS plaque burden as the dependent variables. In multivariable linear regression 
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analyses, we adjusted for socio-demographic characteristics (i.e., gender and age), clinical 
characteristics (i.e., multi-vessel disease, BMI, cardiac history, indication for PCI, CAD 
risk factors (i.e., hypertension, hypercholesterolemia, diabetes mellitus, family history 
of CAD, and self-reported smoking), and prescribed cardiac discharge medications (i.e., 
ACE-inhibitors, beta-blockers, calcium-antagonists, diuretics, oral nitrates, and statins)). 
Covariates were entered into the model using the Enter method, thereby reducing the 
risk of overfitting 47, and selected a priori based on the literature 11, 13, 14, 23, 48, 49. 
Separate linear models were conducted for the different inflammatory markers, 
IVUS plaque burden, and the different psychological factors (i.e., anxiety, depression, Type 
D personality, NA, and SI). All results were based on 2-tailed tests and a p-value <.05 was 
used to indicate statistical significance. All statistical analyses were performed using SPSS 
for Windows 19.0 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Patient characteristics
The study sample comprised 183 patients treated with PCI, who had complete data on 
blood samples, IVUS imaging, and psychological assessment (73.8% men; mean age 
63.7±10.9 years, range [32-88] years). The mean anxiety score at baseline was 34.9±11.6, 
whereas the mean baseline depression score was 4.7±4.5. At baseline, the prevalence of 
Type D personality was 25.1% (45/183), whereas mean baseline scores for NA and SI were 









Male gender 135 (73.8)
Age, mean (SD) 63.7 (10.9)
Clinical characteristics
Multi-vessel disease 77 (44.0)
Cardiac history b 83 (45.4)
Indication for PCI
   Stable angina/ Silent ischemia 90 (49.2)
   Unstable angina 51 (27.9)
   MI 41 (22.4)
Hypertension 90 (49.2)
Hypercholesterolemia 98 (53.6)
Diabetes mellitus 29 (15.8)
Family history of CAD 98 (53.6)
Self-reported smoking 47 (25.7)
BMI, mean (SD) 27.4 (4.0)
Renal impairment 9 (4.9)
Peripheral artery disease 14 (7.7)
Chronic obstructive pulmonary disease 11 (6.0)













Oral anti-coagulants 9 (5.0)
Oral nitrates 38 (21.1)
Statins 162 (90.0)
Inflammatory markers
CRP (mg/l), median (IQR) 1.9 (.7 - 4.5)
IFN-γ (pg/ml), median (IQR) 5.4 (3.9 - 7.7)
IL-8 (pg/ml), median (IQR) 9.2 (6.7 - 12.0)
IL-10 (pg/ml), median (IQR) 5.2 (3.1 - 10.0)
IL-18 (pg/ml), median (IQR) 162.5 (125.3 - 208.8)
TNF-α (pg/ml), median (IQR) 1.9 (1.0 - 3.0)
TNF-R2 (ng/ml), median (IQR) 4.6 (3.6 - 5.8)
VCAM-1 (ng/ml), median (IQR) 433.0 (351.0 - 513.0)
The extent of coronary plaque burden
IVUS plaque burden (%), mean  (SD) 38.0 (11.6)
Psychological factors
Anxiety, mean (SD) 34.9 (11.6)
Depression, mean (SD) 4.7 (4.5)
Type D personality 45 (25.1)
   Negative affectivity, mean (SD) 8.3 (6.0)
   Social inhibition, mean (SD) 8.0 (6.0)
a Results are presented as n (%) unless otherwise stated 
b Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery
ACE = angiotensin-converting enzyme, BMI = Body mass index (kg/m2), CAD = coronary artery disease, CRP = 
C-reactive protein, IFN-γ = interferon-gamma, IL-8 = interleukin-8, IL-10 = interleukin-10, IL-18 = interleukin-18, 
IQR = inter quartile range, IVUS = intravascular ultrasound, sTNF-R2 = soluble TNF-α receptor 2, TNF-α = tumor-




Associations between psychological distress, inflammatory markers, and IVUS plaque 
burden
Anxiety was inversely correlated with ln CRP levels (r=-.22) and IVUS plaque burden (r=-
.17). With regard to the 2 components of Type D personality, both NA and SI were inversely 
correlated with ln CRP (r=-.19 and r=-.21, respectively). Further, NA was inversely correlated 
with ln IL-8 (r=-.16) and IVUS plaque burden (r=-.18), whereas SI was inversely correlated 
with ln TNF-α (r=-.16) and ln IL-10 (r=-.19). No significant correlations were found between 
depression, the inflammatory markers, and IVUS plaque burden (Table 2).
Univariable linear regression analyses showed that anxiety was inversely 
associated with level of ln CRP (B=-.03, p=.004, R2=.05) and IVUS plaque burden (B=-.18, 
p=.025, R2=.03). In multivariable analyses, these associations remained significant after 
adjusting for socio-demographic and clinical characteristics. Type D personality was 
inversely associated with ln CRP (B=-.65, p=.009, R2=.04) and ln IL-10 (B=-.45, p=.014, 
R2=.04) in univariable analyses. In multivariable analyses, the association between Type D 
personality and ln CRP remained significant, but the inverse association with ln IL-10 was 
no longer significant (Table 3). 
With regard to the 2 components of Type D personality, NA was inversely 
associated with ln CRP (B=-.05, p=.011, R2=.04), ln IL-8 (B=-.01, p=.034, R2=.03), and IVUS 
plaque burden (B=-.34, p=.019, R2=.03) in univariable analyses. Multivariable analyses 
yielded the same results, except for the association between NA and IL-8, which was no 
longer significant after adjusting for socio-demographic and clinical characteristics. In 
addition, in multivariable analyses NA was significantly associated with higher ln VCAM-1 
levels. For SI, in univariable analyses significant inverse associations were found with ln 
CRP (B=-.05, p=.004, R2=.05), ln TNF-α (B=-.02, p=.028, R2=.03), and ln IL-10 (B=-.03, p=.021, 
R2=.04), which remained significant in multivariable analyses. No significant associations 
were found between depression and the inflammatory markers or IVUS plaque burden. 
In general, in multivariable analyses psychological distress accounted for 2-7% of the 
variance in inflammatory marker and IVUS plaque burden levels (Table 3).
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Table 2. Correlations between psychological distress, inflammatory markers, and IVUS plaque burden




Ln CRP -.22** -.10 -.19* -.21**
Ln TNF-α -.04 -.06 -.07 -.16*
Ln TNF-R2 .11 -.01 .07 .04
Ln IFN-γ -.04 .09 -.02 .03
Ln IL-8 -.05 .03 -.16* .04
Ln IL-10 .02 -.08 -.12 -.19*
Ln IL-18 -.01 -.05 -.05 -.12
Ln VCAM-1 .15 .13 .13 .12
The extent of coronary plaque 
burden
IVUS plaque burden -.17* -.10 -.18* -.02
Psychological factors
Anxiety - .57** .70** .38**
Depression - - .56** .33**
Negative affectivity (NA) - - - .45**
Social inhibition (SI) - - - 1
*p≤.05; ** p≤.01; ***p≤.001
CRP = C-reactive protein, IFN-γ = interferon-gamma, IL-8 = interleukin-8, IL-10 = interleukin-10, IL-18 = 
interleukin-18, IVUS = intravascular ultrasound, sTNF-R2 = soluble TNF-α receptor 2, TNF-α = tumor-necrosis 
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DISCUSSION
We found consistent, although small, inverse associations between psychological distress 
and serum levels of CRP and TNF-α. Anxiety and NA were inversely associated with IVUS-
derived coronary plaque burden. We consider these findings counterintuitive, as increased 
levels of distress were related to lower levels of inflammatory markers or IVUS plaque 
burden. No associations were found between depression and inflammatory markers 
or coronary plaque burden. Overall, these results do not support inflammation and the 
extent of coronary plaque burden as likely mechanisms underlying the relationship 
between psychological distress and cardiovascular disease in PCI patients.
We could not confirm the findings of previous studies in CAD patients showing 
that anxiety, depression, and Type D personality were associated with higher levels of 
inflammatory markers 11-18. Previous studies have mainly focused on CRP 11-16, IL-6 11, 14, 16, 
and TNF-α and its soluble receptors 17, 18, whereas we studied a wide variety of inflammatory 
markers, but not IL-6. In the present study, all participants were eligible for PCI, whereas 
previous studies mainly enrolled patients with stable CAD 11, 13, ACS 12, or heart failure 17, 18. 
These different clinical phenotypes may be associated with various inflammatory marker 
expressions reflecting their intrinsic pathophysiological processes. 
In the present study, anxiety, Type D personality, NA, and SI were inversely related 
with the inflammatory markers CRP and TNF-α, showing that elevated distress was related 
to lower levels of these inflammatory markers. Psychological distress was associated with 
lower levels of inflammation in one previous study, demonstrating inverse associations 
between depression and CRP, fibrinogen, and IL-6 in patients with established CAD 23. 
Psychological distress is known to be associated with increased levels of cortisol, whereas 
hypercortisolemia is known to have anti-inflammatory effects. Increased cortisol levels 
(which we did not measure) in distressed patients might have contributed to lower levels 
of inflammation 23. It might be worthwhile to evaluate this hypothesis in future studies, 
although we realize that the observed inverse effects were small and in disagreement 
with several other investigations. 
Besides these small inverse associations, in the current study no further 
significant associations were found between anxiety, depression, Type D personality, 
and the inflammatory markers. A lack of association between psychological distress and 
inflammation 19-22 has been reported previously. Inflammatory variables in the present 
study reflect a state of significant obstructive coronary occlusion, as blood samples were 
collected immediately before the PCI procedure. Distress scores were examined within 
4 weeks after the procedure, to prevent an effect of the procedure on mood states 34. A 
ceiling effect, in which the presence of psychological distress cannot further increase the 




However, this explanation seems hardly likely in the present study, given that average CRP 
levels were not extremely elevated (31.7% >3 mg/l) 50, 51.
In our study, higher levels of anxiety and NA were associated with lower coronary 
plaque burden, as measured by IVUS, whereas depression was not related to coronary 
plaque burden. The associations were small, explaining 2-3% of the variance in IVUS 
detected. IVUS-derived coronary plaque burden has not been related to distress before, 
but other studies have examined other measures of coronary plaque burden, such as 
IMT 25-27, 30-32, CAC 28, 29, or ABI 24, 26. The present findings contrast previous studies, in which 
anxiety, depression, and personality traits were significantly associated with an increased 
coronary plaque burden 24-27. At the same time, other studies did not find an association 
between psychological distress and the extent of coronary plaque burden 28-32.
The results of the current study do not support increased inflammation and the 
extent of coronary plaque burden as measured by IVUS as likely mechanisms underlying 
the relationship between psychological distress and CAD in patients with PCI. Possibly, 
other biological or behavioral mechanisms could provide a more robust explanation for 
this link, as was suggested in previous studies. For example, psychologically distressed 
patients may be less likely to engage in optimal health-related behaviors, such as 
exercising, quitting smoking, and adhering to dietary constrictions 11, 52-54. In addition, 
psychological distress may alter the activity of the autonomic nervous system, leading to 
increases in blood pressure and reduced heart rate variability 52, 55-57. Future studies should 
further investigate the potential pathways through which psychological distress may have 
an adverse influence on prognosis in patients with CAD.
Strengths of the current study include the wide variety of inflammatory markers 
assessed and the focus on the association between psychological distress and IVUS-
derived measures of coronary plaque burden. However, some limitations of the current 
study should be acknowledged. First, the cross-sectional study design does not allow for 
causal inferences about the relationship between anxiety, depression, Type D personality, 
inflammation, and IVUS plaque burden. Until now it remains unclear whether psychological 
distress may lead to increased inflammation and coronary plaque burden or whether 
it is the other way around. Future studies using a longitudinal design are warranted to 
examine the directionality of the relationship between anxiety, depression, Type D 
personality, inflammation, and IVUS plaque burden. Second, we did not have information 
on the commonly investigated inflammatory marker IL-6. Third, because inflammatory 
and atherosclerotic processes are influenced by many factors, the current study may be 
underpowered to detect the effects of psychological distress on these processes due to a 
limited sample size. 
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In conclusion, the results of the current study do not support increased 
inflammation and the extent of coronary plaque burden as likely mechanisms underlying 
the relationship between psychological distress and CAD, as inverse associations were 
found between anxiety, Type D personality, inflammation, and IVUS plaque burden in 
patients treated with PCI, whereas for depression no significant associations were found. 
Large-scale prospective studies are warranted to further disentangle the underlying 
mechanisms between psychological distress and cardiovascular disease.
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Cardiac patients who completed a 
longitudinal psychosocial study had 
a different clinical and psychosocial 
baseline profile than patients who 
dropped out prematurely
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Non-response is a serious threat to the external validity of longitudinal psychosocial studies. 
Little is known about potential systematic differences between patients with coronary 
artery disease who complete a psychosocial study and those who drop out prematurely 
due to non-response, and whether drop-outs may have a different cardiovascular risk. 
We studied a cohort of 1132 consecutive patients undergoing percutaneous coronary 
intervention (PCI). At baseline, all patients completed the Hospital Anxiety and 
Depression Scale (HADS) and the Type D Scale (DS14). At 12 months follow-up, 70.8% 
(n=802) of patients completed both questionnaires, while 29.2% (n=330) dropped out. 
We observed significant differences in socio-demographic, clinical, and psychological 
baseline characteristics between completers and drop-outs. Drop-outs were younger, 
more likely to smoke, but less often prescribed cardiovascular medications, including 
calcium-antagonists and ACE-inhibitors, as compared with completers. Drop-outs more 
often had depression, anxiety, and negative affectivity as compared with completers (all 
p-values <.05). After a median follow-up of 4 years, we found no significant differences in 
mortality risk between completers and drop-outs (6.5% versus 7.3%; adjusted HR=1.34; 
95%CI [.82-2.19], p=.24, respectively). In conclusion, a possible attrition bias occurred, as 
drop-outs and completers differed systematically on some socio-demographic, clinical, 
and psychological baseline characteristics. Despite these differences, this did not translate 
into a poorer short-term prognosis, as there were no differences in the mortality risk of 
completers versus drop-outs after a median follow-up of 4 years. In future prospective 
studies, attention should be paid to attrition bias, and its possible impact on study results 
and implications should be discussed. 
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Differences between completers and drop-outs: Attrition bias
INTRODUCTION
The prospective cohort design in combination with standardized and validated 
questionnaires has been the primary methodology used to examine a link between 
psychological factors (e.g., anxiety, depression, and the distressed (Type D) personality 
(i.e., the combination of negative affectivity and social inhibition traits 1)) and prognosis 
in coronary artery disease (CAD) 1-6. A potential attrition bias can be introduced when 
participants completing the study (“completers”) and participants who are lost to follow-
up (“drop-outs”) differ systematically on baseline characteristics, exposure to risk factors, 
or outcome variables 7. This is particularly a concern if there is a systematic loss to follow-
up related to the potential risk factor under study, jeopardizing any conclusions drawn 
- being an over- or underestimation of the true effect - and the generalizability 8. Previous 
studies have mainly focused on differences between participants and non-participants, 
finding a “healthy volunteer effect” with participants having a better general health as 
compared with non-participants 9-11, and an increased mortality risk in non-participants 
7, 10, 12-14. 
One previous study in post-myocardial infarction (MI) patients and one population-
based study focused on systematic differences in outcome between completers and 
drop-outs, demonstrating that drop-out during follow-up was associated with a higher 
mortality risk 15, 16. However, most studies do not report drop-out rates, reasons for drop-
out, or compare the characteristics of drop-outs versus completers 17. Hence, we know 
little about differences in baseline characteristics or exposure to risk factors between 
completers and drop-outs, and consequences to clinical outcome. 
To our knowledge, no study has focused on potential systematic differences 
between completers and drop-outs when examining the prevalence of psychological 
factors and their impact on clinical outcome in CAD patients. Hence, the aims of the current 
study were to examine differences in 1) socio-demographic, clinical, and psychological 
(i.e., anxiety, depression, and Type D personality) baseline characteristics, and 2) 4-year 
risk for mortality between completers and drop-outs at 12 months in patients treated 
with percutaneous coronary intervention (PCI).
METHODS
Our sample comprised 1132 consecutive patients treated with PCI between July 1, 2003 
and September 14, 2006 at the Erasmus MC, Rotterdam, the Netherlands. At baseline 
(i.e., 4 weeks post-PCI) and 12 months post-PCI, patients were asked to complete the 
Dutch version of the Hospital Anxiety and Depression Scale (HADS) to assess symptoms 




Completers were defined as patients who completed the HADS and the DS14 both at 
baseline and at 12 months post-PCI, whereas drop-outs were defined as patients who 
completed the questionnaires at baseline, but not at 12 months post-PCI. Patients who 
dropped out of the study due to death between baseline and 12 months post-PCI were 
excluded from the analyses. 
Differences in socio-demographic, clinical and psychological baseline 
characteristics between completers and drop-outs were examined using the Chi-square 
test for nominal variables and Student’s t-test for independent samples for continuous 
variables. Differences in all-cause mortality between completers and drop-outs were 
examined using the Kaplan-Meier method and univariable and multivariable Cox regression 
models. In multivariable analysis, we adjusted for socio-demographic (i.e., gender and 
age), clinical (i.e., cardiac history, hypertension, diabetes mellitus, family history of CAD, 
and prescribed cardiac discharge medications (i.e., beta-blockers, calcium-antagonists, 
and statins)), and psychological (i.e., anxiety, depression, and Type D personality) baseline 
characteristics. Covariates were selected a priori based on the literature 13-16. 
RESULTS
In the current study, at 12 months follow-up 70.8% (n=802) of patients were classified 
as completers and 29.2% (n=330) as drop-outs. Completers and drop-outs differed on 
several baseline characteristics, with drop-outs being younger (61.2 years vs. 63.2 years), 
more likely to smoke (27.5% vs. 17.4%), but less likely to be prescribed calcium-antagonists 
(18.9% vs. 34.1%) and ACE-inhibitors (28.4% vs. 39.6%) as compared with completers. 
Drop-outs were more likely to be depressed (28.5% vs. 20.5%), anxious (30.0% vs. 23.2%), 
and to report negative affectivity (mean score 9.3 vs. mean score 8.1) at baseline as 
compared with completers (Table 1). At a median follow-up of 4.3±1.2 years, the incidence 
of all-cause mortality was 6.5% (52/802) in completers versus 7.3% (24/330) in drop-outs. 
Cumulative hazard functions were not significantly different for completers versus drop-
outs (log-rank X2=.435, p=.51). In univariable and multivariable Cox regression analyses, 
there were no significant differences in all-cause mortality risk between completers and 
drop-outs (crude HR=1.18; 95%CI [.74-1.89], p=.48 and adjusted HR=1.34; 95%CI [.82-
2.19], p=.24, respectively).
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Male gender 863 (76.2) 618 (77.1) 245 (74.2) .31
Age, mean (SD) 62.8 (10.8) 63.2 (10.6) 61.2 (11.1) .004**
Clinical characteristics
Multi-vessel disease 613 (54.3) 438 (54.8) 175 (53.0) .58
Cardiac history c 517 (46.7) 366 (46.7) 151 (46.5) .93
Indication for PCI .86
   Stable angina/ Silent ischemia 519 (46.3) 367 (46.2) 152 (46.8)
   Unstable angina 370 (33.0) 268 (33.7) 102 (31.4)
   MI 219 (19.6) 152 (19.1) 67 (20.6)
Hypertension 512 (47.2) 361 (46.5) 151 (46.5) .49
Diabetes mellitus 198 (17.5) 141 (17.6) 75 (17.6) .90
Family history of CAD 491 (45.3) 352 (45.4) 139 (45.0) .91
Self-reported smoking 220 (20.3) 135 (17.4) 85 (27.5) <.001***
BMI, mean (SD) 27.3 (4.4) 27.2 (4.3) 27.4 (4.7) .63
Cardiac medication
Aspirin 1098 (97.3) 776 (96.6) 322 (98.2) .23
ACE-inhibitors 410 (36.3) 317 (39.6) 93 (28.4) <.001***
Beta-blockers 857 (75.9) 617 (77.0) 240 (73.2) .17
Calcium-antagonists 335 (29.7) 273 (34.1) 62 (18.9) <.001***
Diuretics 112 (9.9) 83 (10.4) 29 (8.8) .44
Oral nitrates 211 (18.7) 149 (18.6) 62 (18.9) .91
Statins 1001 (88.7) 712 (88.9) 289 (88.1) .71
Psychological characteristics
Depression
   Dichotomous (HADS-D≥8) 257 (22.7) 163 (20.3) 94 (28.5) .003**













   Dichotomous (HADS-A≥8) 285 (25.2) 186 (23.2) 99 (30.0) .017*
   Continuous, mean (SD) 5.3 (3.8) 5.1 (3.7) 5.8 (4.2) .009**
Type D personality 288 (25.5) 196 (24.5) 92 (28.0) .22
   Negative affectivity, mean (SD) 8.4 (6.5) 8.1 (6.3) 9.3 (6.9) .005**
   Social inhibition, mean (SD) 9.0 (6.4) 8.9 (6.5) 9.3 (6.3) .38
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b Patients who completed the questionnaires at baseline, but dropped out of the study at 12-months post-PCI.
c Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft 
(CABG) surgery 
ACE = angiotensin converter enzyme, BMI = body mass index (kg/m2), CAD = coronary artery disease, HADS-A = 
Hospital Anxiety and Depression Scale - Anxiety, HADS-D = Hospital Anxiety and Depression Scale - Depression
DISCUSSION
The current study extends previous research by showing that a healthy volunteer effect 
might also be applicable to completers versus drop-outs, with drop-outs being more likely 
to smoke, experiencing higher levels of psychological distress (i.e., anxiety, depression, and 
negative affectivity), and less often being prescribed some cardiac discharge medications. 
Although one previous study in post-MI patients and one population-based study 
demonstrated that drop-out during follow-up was associated with a higher mortality risk 
15, 16, our results did not corroborate this finding. This discrepancy may be explained by the 
fact that previous studies used a larger study sample (2690 post-MI patients and 14.121 
Civil Service workers, respectively) and differences in follow-up duration (3 and 14 years, 
respectively). An increased mortality risk has also been repeatedly observed among non-
participants in population-based studies 7, 10, 13 and clinical trials 12, 14. As only one previous 
study focused on systematic differences between completers and drop-outs in CAD, 
future studies on this topic are warranted.
Limitations of the current study must be acknowledged. First, although we had 
information on all-cause mortality, we had no information on other reasons for drop-out. 
Second, no information on left ventricular ejection fraction (LVEF) was collected, which 
is an important marker for disease severity in CAD 20. However, we addressed possible 
differences in disease severity by comparing completers and drop-outs on multi-vessel 
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disease and cardiac history. Third, we were not able to compare completers and drop-outs 
on use of psychotropic medication, as information on this type of medication was not 
collected. Finally, the current study was single-center.
In conclusion, in the current study a possible attrition bias occurred, as drop-
outs and completers differed systematically on some socio-demographic, clinical, and 
psychological baseline characteristics. Despite these differences, this did not translate into 
a poorer prognosis, as there were no differences in the mortality risk of completers versus 
drop-outs. In future prospective studies, using serial assessments of patient-reported 
outcomes, attention should be paid to attrition bias, and its possible impact on study 
results and implications should be discussed.
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Background: Coronary artery bypass graft (CABG) surgery is considered the optimal 
revascularization strategy for patients with complex coronary artery disease (CAD), 
whereas in patients with less severe CAD percutaneous coronary intervention (PCI) is 
recommended. As a more invasive procedure may be associated with increased use of 
psychotropic medications, we compared antidepressant and anxiolytic medication use 
between patients treated with CABG or PCI, using data from the Danish Heart Registry.
Methods: All patients treated with a first-time CABG or PCI between 1999 and 2012 in 
Denmark were identified. Antidepressant and anxiolytic medication use was determined 
by claimed prescriptions up to 12 months post-index event. Analyses were conducted 
in the total sample and a propensity-score matched sample. In addition to statistical 
significance, clinical relevance was evaluated by calculating absolute risk differences 
(ARD’s) and risk ratios (RR’s).
Results: We identified 62.912 patients, of whom 10.347 (16.4%) were treated with CABG 
and 52.565 (83.6%) with PCI. After propensity-score matching, the use of antidepressants 
(particularly selective serotonin reuptake inhibitors (SSRI’s)) was significantly higher 
in CABG patients at 6 and 12 months post-index event as compared with PCI patients, 
although no difference was found on anxiolytic medication use. ARD’s ranged between 
1.0-1.8%, with corresponding RR’s ranging between 1.1-1.2. 
Conclusion: CABG patients were more often than PCI patients prescribed antidepressants 
(in particular SSRI’s) up to 12 months. Given the small ARD’s and RR’s, these differences did 
not seem to be clinically relevant, possibly reflecting comparable underlying psychological 
distress levels in CABG and PCI patients. 
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INTRODUCTION
Since its introduction in 1968, coronary artery bypass graft (CABG) surgery rapidly became 
the treatment of choice for patients with advanced coronary artery disease (CAD) needing 
revascularization 1. When percutaneous coronary intervention (PCI) was introduced in 
1977, this method was thought to be appropriate only for patients with single-vessel 
disease 2. However, increased experience with PCI and improved technology expanded 
its use to patients with more complex CAD, such as multi-vessel disease and left main 
coronary disease 3. 
The optimal revascularization strategy for CAD has been subject of some debate. 
Several randomized controlled trials have compared clinical outcomes between CABG and 
PCI patients, showing similar survival rates but higher repeated revascularization rates 
among patients treated with PCI with drug-eluting stents as compared with CABG surgery 
patients 3-7. These findings were also confirmed in systematic reviews 8, 9 and recent meta-
analyses 10, 11. 
Little is known about potential differences in patient-centered outcomes, such as 
anxiety and depression, between CABG and PCI patients. Previous studies indicated that 
anxiety and depression are common in both CABG and PCI patients, with prevalence rates 
ranging from 20-50%, and are associated with increased cardiovascular morbidity and 
mortality 12-15 and impaired health-related quality of life 16, 17. Psychotropic medications 
are widely used treatments for anxiety and depression, but to our knowledge no study 
to date has directly compared the prevalence of psychotropic medication use between 
CABG and PCI patients. Hence, the aim of the current study was to examine differences in 
antidepressant and anxiolytic medication use between CABG and PCI patients up to 12 
months post-index event, using data from the Danish Heart Registry.
METHODS
Data sources 
In Denmark, all citizens are registered with a unique and permanent civil registration 
number in the Central Population Register, which enables linkage of information at the 
individual level across different registers. In the current study, 3 nationwide administrative 
registers were used and linked at an anonymous and individual level: 
1) The Danish Heart Register, which contains information on patients undergoing 
the following invasive cardiac procedures and thoracic surgeries: Coronary 
angiography (CAG), PCI, CABG, and valve surgeries. The procedures are classified 
according to the Nordic Medico-Statistical Committee (NOMESCO) Classification 
of Surgical Procedures (NCSP) 18. 
154
Chapter 10
2) The Danish National Patient Register, which contains information on all 
hospitalizations in Denmark since 1978. Each hospitalization is registered with 
1 primary diagnosis and, if appropriate, a secondary diagnosis according to the 
World Health Organization’s International Classification of Diseases, 10th Revision 
(ICD-10) 19. 
3) The Danish Register of Medicinal Product Statistics (or the Danish Prescription 
Register), which holds information on all prescriptions dispensed from Danish 
pharmacies since 1995. Each prescription is coded according to the international 
classification of pharmaceuticals (Anatomic Therapeutical Chemical (ATC) system) 
and includes information on dispensing date, strength, formulation, quantity 
dispensed, and affiliation of the physician issuing the prescription. As the Danish 
health care system partially reimburses prescribed medications, pharmacies are 
requested to register all dispensed prescriptions, ensuring complete registration 
nationwide 20.
Study population
Using the Danish Heart Registry, we identified all patients admitted to Danish hospitals 
who underwent a first-time CABG surgery or PCI between 1999 and 2012. Information 
on socio-demographic characteristics (i.e., gender, age, and marital status) was obtained 
from the Central Population Register, whereas information on clinical characteristics 
(i.e., smoking status and body mass index (BMI)) was obtained from the Danish Heart 
Registry. Charlson’s comorbidity index was calculated based on information from the 
Danish National Patient Register and included information on 19 comorbidities (i.e., 
acute myocardial infarction (MI), AIDS, any tumor, cerebrovascular disease, congestive 
heart failure, chronic pulmonary disease, connective tissue disease, dementia, diabetes 
mellitus, diabetes mellitus with chronic complications, hemiplegia, leukemia, lymphoma, 
metastatic solid tumor, mild liver disease, moderate/severe liver disease, moderate/severe 
renal disease, peripheral vascular disease, and ulcer disease) 21. 
ATC codes from the Danish Prescription Register were used to identify all 
prescriptions for aspirin (B01AA04), angiotensin-converting enzyme (ACE)-inhibitors 
(C09), beta-blockers (C07), calcium-antagonists (C08), clopidogrel (B01AC04), digoxin 
(C01AA05), loop diuretics (C03), statins (C10), spironolactone (C03), and thiazide diuretics 
(C03). In line with previous Danish studies 22, 23, baseline medication use was defined as at 
least 1 claimed prescription within 3 months post-index event to ensure equal time for all 
patients to claim prescriptions for new medications after hospitalization.
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Antidepressant and anxiolytic medication use
ATC codes were also used to identify prescriptions for antidepressants (N06A) and anxiolytics 
(N05B). Five different types of antidepressants were identified, including selective 
serotonin reuptake inhibitors (SSRI’s) (N06AB), tricyclic antidepressants (TCA’s) (N06AA), 
serotonin and noradrenaline reuptake inhibitors (SNRI’s) (N06AX), noradrenergic and 
specific serotonergic antidepressants (NaSSA’s) (N06AX), and tetracyclic antidepressants 
(N06AX). With regard to anxiolytic medication use, 3 different types of anxiolytics were 
identified, including benzodiazepines (N05BA), diphenylmethan derivatives (N05BB), 
and azaspirodecanedion derivatives (N05BE). As for the cardiac medications, baseline 
antidepressant and anxiolytic medication use was defined as at least 1 claimed prescription 
within 3 months post-index event. Besides baseline use, information on antidepressant 
and anxiolytic medication use at 6 and 12 months post-index event was collected to get 
insight into the evolution of psychotropic medication use.
Ethics
The current study was approved by the Danish Data Protection Agency (Ref. No. 2007-58-
0015 / I. suite no. 00916 GEH-2010-001). Retrospective register studies in which individual 
patients cannot be identified do not require ethical approval in Denmark.
Statistical analyses
Prior to analyses, antidepressants were categorized into 4 groups: 1) any antidepressant 
(including all different types of antidepressants), 2) SSRI’s, 3) TCA’s, and 4) other 
antidepressants (i.e., SNRI’s, NaSSA’s, and tetracyclic antidepressants). Anxiolytics were 
categorized into 3 groups: 1) any anxiolytic (including all different types of anxiolytics), 
2) benzodiazepines, and 3) other anxiolytics (i.e., diphenylmethan derivatives and 
azaspirodecanedion derivatives).
In the total sample, group differences on baseline characteristics and 
antidepressant and anxiolytic categories between CABG and PCI patients were examined 
using the Chi-square test for nominal variables and Student’s t-test for independent 
samples for continuous variables. Second, in order to enhance comparability between 
CABG and PCI patients, CABG and PCI patients were matched on the propensity score. 
The propensity score was calculated by using logistic regression analysis conditional on 
baseline characteristics, using the Greedy match algorithm on a 1:1 ratio 24. Only matched 
controls were included in the analyses, preserving the case-group (CABG patients) as 
originally identified. To ensure that matching was successful, group differences on baseline 
characteristics between the matched CABG and PCI patients were examined using the 
Chi-square test for nominal variables and Student’s t-test for independent samples for 
continuous variables. These same tests were also used to examine group differences on 
antidepressant and anxiolytic categories between the matched CABG and PCI patients.
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All results were based on 2-tailed tests and a p-value <.05 was used to indicate 
statistical significance. Clinical relevance of the results was also evaluated using absolute 
risk differences (ARD’s) and risk ratios (RR’s). Statistical analyses were performed using SAS 




In the current study, a total of 62.912 patients were included, of whom 10.347 (16.4%) 
underwent a CABG surgery and 52.565 (83.6%) patients were treated with PCI. Patient 
characteristics for the total sample and stratified by treatment are presented in Table 1. 
CABG and PCI patients differed systematically on all baseline characteristics.










Male gender 45810 (73.6) 8152 (78.8) 37658 (72.6) <.001***
Age, mean (SD) 65.85 (11.4) 68.41 (9.3) 65.93 (11.7) <.001***
Married 32951 (52.4) 5683 (54.9) 27268 (51.9) <.001***
Clinical characteristics
Smoking 17905 (28.5) 1761 (17.0) 16144 (30.7) <.001***
Obesity b 12720 (20.2) 2430 (23.5) 10290 (19.6) <.001***
Charlson’s comorbidity index c <.001***
   0 26415 (42.0) 5508 (53.2) 20907 (39.8)
   1 26473 (42.1) 2773 (26.8) 23700 (45.1)
   2 4807 (7.6) 892 (8.6) 3915 (7.5)
   3 2550 (4.1) 588 (5.7) 1962 (3.7)
   4 1543 (2.5) 333 (3.2) 1210 (2.3)
   ≥5 1124 (1.8) 253 (2.5) 871 (1.7)
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Cardiac medication use at 
baseline
Aspirin 40757 (64.8) 6015 (58.1) 34742 (66.1) <.001***
ACE-inhibitors 27027 (43.0) 4331 (41.9) 22696 (43.2) .013*
Beta-blockers 39152 (62.2) 6015 (58.1) 33137 (63.0) <.001***
Calcium-antagonists 11381 (18.1) 2216 (21.4) 9165 (17.4) <.001***
Clopidogrel 40704 (64.7) 2194 (21.2) 38510 (73.3) <.001***
Digoxin 1658 (2.7) 332 (3.2) 1353 (2.6) <.001***
Loop diuretics 11233 (17.9) 3456 (33.4) 7777 (14.8) <.001***
Statins 43684 (69.4) 6625 (64.0) 37059 (70.5) <.001***
Spironolactone 3161 (5.0) 790 (7.6) 2371 (4.5) <.001***
Thiazide diuretics 5927 (9.4) 1268 (12.3) 4659 (8.9) <.001***
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b BMI ≥30; c included information on 19 comorbidities: Acute myocardial infarction (MI), AIDS, any tumor, 
cerebrovascular disease, congestive heart failure, chronic pulmonary disease, connective tissue disease, 
dementia, diabetes mellitus, diabetes mellitus with chronic complications, hemiplegia, leukemia, lymphoma, 
metastatic solid tumor, mild liver disease, moderate/severe liver disease, moderate/severe renal disease, 
peripheral vascular disease, and ulcer disease
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CABG = coronary artery bypass graft, PCI 
= percutaneous coronary intervention
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Differences in antidepressant medication use between CABG and PCI patients in the 12 
months post-index event
Overall, the prevalence rate of antidepressant medication use increased over time in both 
CABG and PCI patients, with prevalence rates increasing from 8.6% at baseline to 13.0% at 
12 months in CABG patients and 7.7% at 3 months to 12.1% at 12 months in PCI patients. 
Statistically significant differences emerged between CABG and PCI patients, with any 
antidepressant use at baseline, 6, and 12 months post-index event being significantly 
higher in CABG patients as compared with PCI patients. When looking at the different 
types of antidepressants, CABG patients were more often using SSRI’s at baseline, 6, and 
12 months post-index event as compared with PCI patients. The ARD’s at the different 
time points ranged between .9–1.2%, with corresponding RR’s ranging between 1.1-1.2 
(Table 2).
Differences in anxiolytic medication use between CABG and PCI patients in the 12 
months post-index event
Overall, the prevalence rate of anxiolytic medication use increased over time in both 
CABG and PCI patients, with prevalence rates increasing from 5.1% at baseline to 7.4% at 
12 months in CABG patients and 5.2% at baseline to 8.1% at 12 months in PCI patients. 
Statistically significant differences emerged between CABG and PCI patients, with the use 
of any anxiolytic at 12 months being significantly lower in CABG patients as compared 
with PCI patients. When looking at the different types of anxiolytics, CABG patients were 
less likely to use benzodiazepines at 12 months post-index event as compared with PCI 
patients. At baseline, 6, and 12 months post-index event, CABG patients were more often 
using other anxiolytics as compared with PCI patients. The ARD’s for any anxiolytic and 
benzodiazepines at the different time points ranged between -.9- -.7%, with corresponding 
RR’s of .9. For other anxiolytics, the ARD’s were .1% at the different time points. The 
corresponding RR’s were rather large, ranging between 1.6-1.9, but with wide CI’s (Table 
2).
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Differences in antidepressant and anxiolytic medication use in a propensity-score 
matched sample of CABG and PCI patients, up to 12 months post-index event
After propensity score matching, a total of 14.042 patients were included, equally divided 
between 7.021 CABG and 7.021 PCI patients, respectively. Baseline characteristics were 
well balanced between CABG and PCI patients (Table 3). 
As for the total sample, we found an increase in antidepressant and anxiolytic 
medication use over time in both CABG and PCI patients in the matched sample. Significant 
differences emerged between CABG and PCI patients, with the use of any antidepressant 
at 6 and 12 months post-index event being significantly higher in CABG patients as 
compared with PCI patients. When looking at the different types of antidepressants, CABG 
patients were more often using SSRI’s at 6 and 12 months post-index event as compared 
with PCI patients. The ARD’s at the different time points ranged between 1.0-1.8%, with 
corresponding RR’s ranging between 1.1-1.2. There were no statistically significant 
differences in anxiolytic medication use between CABG and PCI patients (Table 4). 











Male gender 10753 (76.6) 5377 (76.6) 5376 (76.6) .98
Age, mean (SD) 68.06 (10.1) 67.93 (9.5) 68.18 (10.7) .14
Married 7461 (53.1) 3743 (53.3) 3718 (53.0) .67
Clinical characteristics
Smoking 2822 (20.1) 1406 (20.0) 1416 (20.2) .83
Obesity b 3128 (22.3) 1571 (22.4) 1557 (22.2) .78
Charlson’s comorbidity index c .032*
   0 7364 (52.4) 3640 (51.8) 3724 (53.0)
   1 4021 (28.6) 1980 (28.2) 2041 (29.1)
   2 1148 (8.2) 627 (8.9) 521 (7.4)
   3 716 (5.1) 365 (5.2) 351 (5.0)
   4 440 (3.1) 243 (3.5) 197 (2.8)











Cardiac medication use at 
baseline
Aspirin 7322 (52.1) 3624 (51.6) 3698 (52.7) .21
ACE-inhibitors 5320 (37.9) 2637 (37.6) 2683 (38.2) .42
Beta-blockers 7350 (52.3) 3708 (52.8) 3642 (51.9) .27
Calcium-antagonists 2702 (19.2) 1334 (19.0) 1368 (19.5) .47
Clopidogrel 4495 (32.0) 2194 (31.3) 2301 (32.8) .05
Digoxin 410 (2.9) 209 (3.0) 201 (2.9) .69
Loop diuretics 3293 (23.5) 1748 (24.9) 1545 (22.0) <.001***
Statins 8086 (57.6) 3987 (56.8) 4099 (58.4) .056
Spironolactone 836 (6.0) 443 (6.3) 393 (5.6) .075
Thiazide diuretics 1383 (9.9) 706 (10.1) 677 (9.6) .41
*p≤.05; ** p≤.01; ***p≤.001
a Results are presented as n (%) unless otherwise stated
b BMI ≥30
c included information on 19 comorbidities: Acute myocardial infarction (MI), AIDS, any tumor, cerebrovascular 
disease, congestive heart failure, chronic pulmonary disease, connective tissue disease, dementia, diabetes 
mellitus, diabetes mellitus with chronic complications, hemiplegia, leukemia, lymphoma, metastatic solid tumor, 
mild liver disease, moderate/severe liver disease, moderate/severe renal disease, peripheral vascular disease, 
and ulcer disease
ACE = angiotensin-converting enzyme, BMI = body mass index (kg/m2), CABG = coronary artery bypass graft, PCI 
= percutaneous coronary intervention
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DISCUSSION
To our knowledge, this is the first study to compare psychotropic medication use between 
CABG and PCI patients. Overall, the use of antidepressant and anxiolytic medications 
increased over time in both CABG and PCI patients. In the total sample, the use of 
antidepressants, and SSRI’s in particular, was significantly higher in CABG patients at all 
time points as compared with PCI patients. The use of anxiolytics, and benzodiazepines 
in particular, was significantly higher in PCI patients at 12-months post-index event as 
compared with CABG patients, whereas the use of other anxiolytics was higher in CABG 
patients at all time points. After propensity-score matching, there was still a significant 
difference in antidepressant medication use between CABG and PCI patients, but not in 
anxiolytic medication use. However, given that corresponding ARD’s and RR’s were rather 
small, these statistically significant differences did not seem to be clinically relevant, 
possibly reflecting comparable levels of anxiety and depression up to 12 months post-
index event. 
The overall increase in antidepressant and anxiolytic medication use up to 
12 months post-index event found in the current study is in line with findings from a 
previous study in post-MI patients, showing an increase in the rate of antidepressant 
prescription, and SSRI’s in particular, over the past decade 25. In the latter study, 7.8% 
of patients were prescribed antidepressants within 6 months post-MI, which is in line 
with the baseline prevalence rates found in the current study. Previous studies in CABG 
patients mainly reported on antidepressant medication use before surgery, indicating 
that 2.5-12% of patients are prescribed SSRI’s prior to surgery 26-28. As we did not take 
psychotropic medication use before revascularization into account, we cannot compare 
these prevalence rates with those of the current study. Our baseline prevalence rates of 
antidepressant and anxiolytic medication use in PCI patients were comparable to rates 
ranging between 6-13% reported in previous studies on psychological functioning post-
PCI 29, 30.
So far, the efficacy of pharmacological treatment for psychological distress remains 
unclear. Results of pharmacological intervention trials for depression demonstrated 
that antidepressants could (modestly) reduce symptoms of depression in CAD patients 
31-33, but this did not translate into enhanced survival 32. Besides, cardiotoxic effects of 
antidepressants were reported, as in several studies antidepressant medication use before 
CABG surgery was associated with an increased risk for long-term mortality 26, 28 and 
rehospitalization 28. In another study, use of SSRI’s or SNRI’s was associated with a higher 
risk for in-hospital morbidity but not with increased bleeding events or mortality after 
CABG surgery 27. To date no studies have focused on potential differences in the impact of 
antidepressant and anxiolytic medication use on patient-reported and clinical outcomes 
between CABG and PCI patients, so future studies on this topic are warranted.
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Chapter 10
As indicated by the American Institute of Medicine in their recommendations for 
the optimal health care system in the 21st century, patient-centeredness is 1 of 6 criteria 
that should guide clinical trials, guidelines, and treatment decisions 34. Current guidelines 
recommend that CABG surgery should be the treatment of choice for patients with complex 
CAD, such as three-vessel disease, left main coronary disease, and anatomically complex 
and extensive lesions, while PCI may be considered an alternative strategy in patients 
with less severe CAD 35. The guidelines also recommend that risks and benefits of each 
procedure should be weighed in the decision-making process, taking also into account 
the patient baseline risk profile and patient preferences 3, 35. Given that psychological 
distress is associated with an increased risk for cardiovascular morbidity and mortality 
12-15 and impaired health-related quality of life 16, 17, it might be worthwhile to consider 
psychological consequences of each treatment strategy in the decision-making process 
in addition to clinical outcomes. 
In the current study, we used antidepressant and anxiolytic medication use 
as a proxy for underlying levels of anxiety and depression. However, future studies are 
warranted to examine the congruence between psychological morbidity and psychotropic 
medication use in CABG and PCI patients, as the claimed prescriptions may not correspond 
with the actual underlying levels of psychological distress. Previous population-based 
studies have identified a mismatch between the prevalence of mental health problems and 
received treatment, with two thirds of patients not receiving pharmacological treatment 
for their mental problems 36-38. In a recent study in implantable cardioverter defibrillator 
patients, this gap between the need for psychological treatment and actual delivery of 
treatment was also confirmed 39. To our knowledge, no such study has been conducted in 
neither CABG nor PCI patients, although it warrants information on both clinical diagnoses 
of anxiety and depression and antidepressant and anxiolytic medication use. 
The main strength of the current study is the completeness of the data and the 
generalizability of the results, with our sample comprising a nationwide unselected cohort 
of Danish CABG and PCI patients and data on antidepressant and anxiolytic medication use 
being complete. The data in the registries has been shown to be accurate 18-20. Limitations 
of the current study should also be acknowledged. First, the registries do not include 
information on clinical diagnoses of anxiety and depression. The use of antidepressant 
and anxiolytic medication use as a proxy for anxiety and depression may imply bias, 
as the claimed prescriptions may not correspond with the actual underlying levels of 
psychological distress. Second, the use of claimed prescriptions as a proxy of medical 
treatment in the study population may imply bias as well, as the claimed prescriptions 
may not accurately reflect consumed medication. However, in Denmark the medications 
of interest are dispensed only with a valid prescription and all pharmacies must report 
every claimed prescription because of a national reimbursement scheme, which ensures 
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complete registration of dispensed drugs and diminishes the patient’s incentive to 
obtain medications through other sources. Moreover, the Danish Prescription Register 
has been shown to be highly accurate, with concordance between drug dispensing and 
consumption likely to be high 20. Third, we did not have information on indicators of 
disease severity, such as multi-vessel disease or left ventricular ejection fraction. Finally, 
generalizing these results to other health care systems and to other countries should be 
done with caution 40. 
In conclusion, the current study showed that in both the total sample and a 
propensity-score matched cohort of CABG and PCI patients, CABG patients were more 
often being prescribed antidepressants, and SSRI’s in particular, up to 12 months post-
index event. After propensity-score matching, no significant differences were found in 
anxiolytic medication use between CABG and PCI patients. Given the small ARD’s and RR’s, 
the statistically significant differences found on antidepressant medication use did not 
seem to be clinically relevant, possibly reflecting comparable underlying psychological 
distress levels in CABG and PCI patients. As this is the first study to compare psychotropic 
medication use between CABG and PCI patients, future studies are warranted to replicate 
our findings and further investigate the clinical and psychological impact of both CABG 
and PCI in order to enhance patient-centered care.
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Coronary artery disease (CAD), generally caused by atherosclerosis, is the leading cause 
of death in the Western world and refers to abnormalities in the coronary arteries that 
facilitate the supply of blood and oxygen to the heart 1, 2. Due to plaque growth inside 
the lumen of coronary arteries, they may become narrowed, which may lead to ischemic 
chest pain (i.e., angina pectoris). If a coronary artery becomes fully blocked due to plaque 
rupture and the subsequent formation of thrombosis, this may result in an acute coronary 
syndrome (ACS), such as myocardial infarction (MI) 1, 2. In patients with CAD, coronary 
revascularization, medication, or a combination are the mainstays of treatment to restore 
coronary blood flow. Coronary artery bypass graft (CABG) surgery and percutaneous 
coronary intervention (PCI) comprise the 2 primary means of coronary revascularization 
3, 4.
Over the past decades, interest has increased in the role of psychological factors 
in the onset and progression of CAD, which has also led to the inclusion of psychological 
factors in the 2012 European Guidelines for Prevention of Cardiovascular Diseases of the 
European Society of Cardiology 5. Psychological distress, such as anxiety and depression, 
is highly prevalent in CAD, affecting 1 in 4 patients, and has been linked to increased 
cardiovascular morbidity and mortality 6, 7 and poorer patient-reported outcomes, such as 
impaired health status and quality of life 8-10. So far, the majority of studies on psychological 
distress in CAD have focused on post-MI, CABG, or general CAD patients. Although PCI 
is currently the most commonly used coronary revascularization procedure, few studies 
have focused on the patient perspective in PCI. Hence, little is known about the impact of 
psychological distress in PCI patients and whether it is similar to that reported in post-MI, 
CABG, or general CAD populations, or whether disease- and treatment-specific processes 
play a role in this context. The current dissertation extends previous research by focusing 
on the psychological well-being of patients treated with PCI, the impact of psychological 
distress on long-term prognosis, potential underlying mechanisms, and the occurrence 
and consequence of attrition bias in prospective cohort studies. In this chapter, the main 
findings of this dissertation will be discussed and their implications for future research 
and clinical practice will be outlined. 
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OVERVIEW AND DISCUSSION OF MAIN FINDINGS
Indications for PCI include MI, unstable angina pectoris, and stable angina pectoris 4. 
Previous studies have demonstrated that indication for PCI is associated with different 
cardiovascular morbidity and mortality rates 11, 12, but little is known about the influence 
of indication for PCI on psychological distress 13. In Chapter 2, we examined the association 
between indication for PCI and anxiety and depression levels in 791 patients in the first 
year post-PCI. Patients treated with PCI due to MI, unstable angina pectoris, or stable 
angina pectoris did not differ significantly on anxiety and depression levels. It is plausible 
that especially psychological factors related to the subjective experience of the cardiac 
event are predictive of psychological distress in the long-term rather than the nature of 
the event and objective measures of disease severity 14. 
In Chapter 3, we reported on changes in anxiety and depression in 715 patients over a 
12-month period post-PCI using an intra-individual approach, and examined possible 
demographic and clinical correlates of these changes. There was a decline in distress scores 
over time, with a mean individual change from baseline to 12 months of -.16 (±3.0) for 
anxiety and -.02 (±2.8) for depression. In linear regression analyses, only baseline anxiety 
and depression levels were significant correlates of individual change scores in anxiety and 
depression. In other words, the higher the baseline distress levels, the lower the change in 
anxiety and depression scores over the 12-month follow-up period. Secondary analyses 
showed that anxiety remained stable in 76% of patients and depression in 81%. A stable 
pattern of anxiety and depression up to 1 year post-index event has been demonstrated 
previously in other cardiac patients groups, including post-MI 15 and CABG patients 16.  
Although substantial research has focused on the impact of psychological distress 
on prognosis in patients with CAD, there is a gap in our understanding of the impact 
of psychological distress on long-term prognosis (≥5 years). The paucity of studies 
in CAD patients that examined the impact of depression on long-term mortality has 
yielded mixed results 16-20. The aim of Chapter 4 was to examine the association between 
depression and long-term mortality in 1234 PCI patients. Given that there has been a 
tendency in the literature to focus on one psychological risk factor at a time, also called 
'risk factor of the month approach' 21, we also examined whether the effect of depression 
on mortality was independent of anxiety and the distressed (Type D) personality (i.e., the 
combination of negative affectivity and social inhibition traits 22). After a median follow-
up of 7 years, depression was independently associated with a 1.6-fold increased risk for 
all-cause mortality (HR=1.63; 95%CI [1.05-2.71], p=.038), after adjusting for relevant socio-
demographic and clinical characteristics, anxiety, and Type D personality. Neither anxiety 
nor Type D personality were associated with mortality. 11
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In contrast to the vast amount of research focusing on the impact of negative emotions 
on CAD outcomes, the role of positive emotions has received less attention 23, 24. Studies 
focusing on anhedonia (i.e., reduced positive affect) have shown that anhedonia is 
associated with a higher risk for mortality and adverse cardiac events up to 2 years 
follow-up 23, 25. In Chapter 5, results on the impact of anhedonia on long-term mortality 
in 1206 PCI patients were presented. After a median follow-up of 7 years, anhedonia 
was independently associated with a 1.5-fold increased risk for all-cause mortality 
(HR=1.51; 95%CI [1.03-2.22], p=.036), after adjusting for socio-demographic and clinical 
characteristics, and negative and relaxed affect. This study extends previous research by 
showing that anhedonia is not only associated with short-term but also with long-term 
prognosis in CAD, independent of negative affect. This supports the notion that positive 
and negative affect are not merely opposites on the same continuum 26. 
Medical explanations, such as differences in medication prescriptions 27, 28, do not provide 
a clear understanding of the better survival rates reported in overweight or obese CAD 
patients, a phenomenon referred to as the “obesity paradox” 27, 28. Impaired health status 
has been linked to poor prognosis in CAD 29, 30, and a paucity of studies focused on the 
association between obesity and health status 31, 32, but the role of health status in the 
context of obesity and mortality in CAD has not yet been examined. Hence, in Chapter 6 we 
pursued health status as a potential explanation for the obesity paradox. After a median 
follow-up of 7 years, overweight but not obesity was significantly associated with a 40% 
lower risk for all-cause mortality in 1019 patients treated with PCI (HR=.60; 95%CI [.42-.86], 
p=.005). Health status did not seem to play a role in explaining the obesity paradox, as 
after adding the health status domains to the multivariable Cox regression model, the 
association between overweight and mortality remained unchanged. 
Both Type D personality and dysfunctional parenting styles, like overprotection or 
coldness, have been associated with anxiety and depression 13, 33. As parenting styles have 
been related to personality development 34, 35, dysfunctional parenting styles may also be 
associated with Type D personality, which in turn may increase the risk for anxiety and 
depression. Hence, the aim of Chapter 7 was to examine whether remembered parenting 
was associated with anxiety and depression in cardiac patients and whether Type D 
personality mediated this relationship. To examine whether the effects differed between 
stages of heart disease, we used 2 cohorts of patients, namely 435 patients treated with 
PCI and 123 congestive heart failure patients. In both cohorts, remembered parenting 
was significantly associated with higher anxiety and depression levels and with Type D 
personality. In multivariable linear regression analyses, Type D personality accounted 
for 25-29% of the variance in anxiety and 23-46% of the variance in depression, while 
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remembered parenting was no longer significantly associated with these domains. Sobel 
tests and bootstrapping confirmed that Type D personality mediated the relationship 
between remembered parenting and anxiety and depression in both PCI and congestive 
heart failure patients. 
Chapter 8 elaborated on inflammation and the extent of coronary plaque burden as 
potential mechanisms underlying the relationship between psychological distress 
and prognosis in 183 patients treated with PCI. There were consistent, although small, 
inverse associations between psychological distress and serum levels of C-reactive 
protein (CRP) and tumor-necrosis factor alpha (TNF-α). Further, anxiety and negative 
affectivity were inversely associated with IVUS-derived coronary plaque burden. These 
findings are counterintuitive, as increased levels of distress were related to lower levels 
of inflammatory markers and coronary plaque burden. There were neither statistically 
significant associations between depression and inflammatory biomarkers nor between 
depression and coronary plaque burden. Overall, these results do not support increased 
inflammation and the extent of coronary plaque burden as likely mechanisms underlying 
the relationship between psychological distress and prognosis in PCI patients. Possibly, 
other biological (e.g., altered activity of the autonomic nervous system 36, 37) or behavioral 
(e.g., less optimal health related behaviors 36, 38, 39) mechanisms might provide a more 
robust explanation for this link. 
In Chapter 9, the possible occurrence and consequence of attrition bias was investigated in 
a prospective cohort study in 1132 PCI patients. At 12 months follow-up, 71% of patients 
were classified as completers and 29% as drop-outs. A possible attrition bias occurred, 
as we observed significant differences in socio-demographic, clinical, and psychological 
baseline characteristics between completers and drop-outs. Drop-outs were younger, 
more likely to smoke, but less often prescribed some cardiovascular medications, 
including calcium-antagonists and ACE-inhibitors as compared with completers. Drop-
outs also more often had depression, anxiety, and negative affectivity, as compared with 
completers. In post-MI patients and the general population, drop-out during follow-up 
has been associated with a higher mortality risk 40, 41, while our results found no support 
for this notion after a median follow-up of 4 years. In future prospective studies, using 
serial assessments of patient-reported outcomes, attention should be paid to attrition 




As aforementioned, besides PCI, CABG surgery is a common coronary revascularization 
procedure 3, 4. Little is known about potential differences in patient well-being between 
CABG and PCI patients. A more invasive procedure may be associated with increased use 
of psychotropic medications. Hence, the aim of Chapter 10 was to prospectively examine 
differences in antidepressant and anxiolytic medication use between CABG and PCI patients 
up to 12 months post-index event, using data from the national Danish Heart Registry. In 
this study, a total of 62.912 patients was included, of whom 10.347 (16%) underwent a 
CABG surgery and 52.565 (84%) patients were treated with PCI. In both the total sample 
and a propensity-score matched cohort of CABG and PCI patients, CABG patients were 
more often being prescribed antidepressants, and selective serotonin reuptake inhibitors 
(SSRI’s) in particular, up to 12 months post-index event. After propensity-score matching, 
no significant differences were found in anxiolytic medication use between CABG and 
PCI patients. Given that corresponding absolute risk differences (ARD’s) and risk ratios 
(RR’s) were rather small, the statistically significant differences found on antidepressant 
medication use did not seem to be clinically relevant, possibly reflecting comparable 
underlying psychological distress levels in CABG and PCI patients, up to 12 months post-
index event. 
Figure 1 provides a conceptual model of the relationships between socio-demographic, 
clinical, and psychological factors, and long-term outcomes, as discussed in the current 
dissertation and previous studies. Taken together, the findings of this dissertation suggest 
that there is more to PCI than just coronary arteries, and that it seems worthwhile to take 
the patient perspective into account in order to optimize the management and care of 
PCI patients in clinical practice. Specific suggestions and recommendations for future 












































































OPTIMALIZATION OF THE MANAGEMENT AND CARE OF PCI PATIENTS
Identification of patients with a high-risk psychological profile
As presented in this dissertation, psychological distress, such as anxiety, depression, and 
Type D personality, is prevalent in 24-29% of PCI patients (Chapters 4, 5, 8, and 9), which is 
comparable to average rates reported in recent meta-analyses in post-MI 6, 7 and general 
CAD patients 42. In about 80% of PCI patients, levels of anxiety and depression remain 
stable over time and seem to be best predicted by baseline distress levels (Chapter 3) 
rather than by objective measures of disease severity, such as indication for PCI (Chapter 2). 
The current dissertation also indicated that psychological distress is related to long-term 
prognosis in addition to short-term prognosis, as both depression and anhedonia were 
associated with a 1.5-fold increased risk for 7-year mortality, after adjusting for baseline 
characteristics and other psychological risk factors (Chapters 4 and 5). Hence, there is a need 
for the identification and monitoring of patients at high-risk for psychological distress, to 
provide them with appropriate treatment in order to reduce their psychological distress 
levels. The 2012 European Guidelines for Prevention of Cardiovascular Diseases of the 
European Society of Cardiology state that patients with established CAD but also those at 
risk for incident CAD should be screened for psychological distress factors, such as anxiety, 
depression, and Type D personality 5.
With regard to depression, there is an ongoing debate whether routine screening 
for depression in CAD patients should be implemented in clinical practice 43-50. In 2008, an 
advisory from the American Heart Association (AHA) recommended routine depression 
screening in all CAD patients, using a 2-step screening protocol including the 2-item 
Patient Health Questionnaire (PHQ-2) and the 9-item Patient Health Questionnaire (PHQ-
9) 48. However, based on results from systematic reviews, to date there is no evidence 
that routine screening for depression – in combination with appropriate treatment when 
indicated - improves depression and clinical outcomes 43, 50. Since the AHA advisory, 
studies have examined the feasibility of implemented screening as part of standard clinical 
practice, with mixed results 45, 46. For example, an evaluation of the implementation of the 
2-step screening protocol in MI patients showed that feasibility of the protocol was low, 
as about 25% of eligible patients did not get screened, and only had a modest impact on 
depression recognition 46. 
Cardiac rehabilitation
Although there is no hard evidence that routine screening for psychological distress may 
result in improved CAD outcomes, appropriate monitoring and treatment of patients at 
high-risk for psychological distress seems important, given the high prevalence of distress 
in CAD patients and its risk associated with morbidity and mortality 6, 7. 
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In standard clinical practice, cardiac rehabilitation comprises an important part of 
the armamentarium of secondary prevention options for MI and coronary revascularization 
patients, combining exercise training with risk factor modification and psychological 
counseling 51, 52. The beneficial effects of CR are unequivocal, as CR is associated with 
reductions in cardiovascular morbidity and mortality 53, 54 as well as improved patient-
reported outcomes, such as anxiety, depression, and quality of life 53, 55, 56. In several national 
guidelines, CR is included as a class I indication for post-MI or coronary revascularization 
patients 4, 57-59, and according to the current performance measures for CR, all patients 
hospitalized for a cardiac event, including MI, CABG, and PCI, should be referred to CR 
before hospital discharge 51. Nevertheless, CR remains widely under-utilized, with overall 
referral rates ranging between 30-60% 60, 61 and over 50% of patients referred to CR not 
enrolling in the program 62, 63. 
Previous studies have shown that participation rates are particularly low in 
patients treated with PCI, with PCI patients being about half as less likely to attend CR 
as compared with CABG or MI patients 64, 65 and with over one third of patients not being 
referred to CR 66. There could be several reasons for the low attendance rates of PCI patients. 
First, it is possible that the very short hospital stay of PCI patients (i.e., 1-3 days) reduces 
the opportunity for arranging a referral to an outpatient CR program. Second, both 
patients and physicians may believe that standard CR programs are unnecessary for PCI 
patients, due to the less invasive, non-surgical nature of the procedure and patients often 
experiencing improved functional status immediately after PCI 65, 67. However, findings 
from the current dissertation indicate that psychological distress is highly prevalent in 
patients treated with PCI and associated with poorer long-term prognosis (Chapters 4, 5, 
8, and 9), emphasizing the need for appropriate follow-up care for this specific patient 
group.
Besides low referral and attendance rates, high drop-out rates of 20-50% have 
been reported in CR programs 68, 69. Patients not completing CR seem to be more likely to be 
depressed or anxious and report poorer quality of life as compared to patients completing 
CR 68-70. In order to increase CR adherence and to improve outcomes for distressed CAD 
patients, initial screening for psychological distress upon admission to CR, monitoring of 
distress, and referral to appropriate psychological care if indicated may be paramount 68, 
71.
Treatment of psychological distress
A variety of treatments have been suggested to target psychological distress in CAD 
patients, including both psychological and pharmacological treatments. Cognitive-
behavioral therapy (CBT) is one of the mainstays of psychological treatment, and aims 




Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) randomized trial and 
the EXhaustion Intervention Trial (EXIT) demonstrated that CBT was associated with a 
modest reduction in psychological distress and improved social support in CAD patients, 
but this did not translate into a better prognosis 73, 74. However, the more recent Secondary 
Prevention in Uppsala Primary Health Care Project (SUPRIM) showed that a 1-year CBT 
program reduced the risk for recurrent cardiovascular events 75. Inconsistent results have 
also been reported from pharmacological intervention trials for depression, indicating 
that antidepressants could modestly reduce symptoms of depression in CAD patients 76, 77 
but with no associated survival benefits 76. The Canadian Cardiac Randomized Evaluation 
of Antidepressant and Psychotherapy Efficacy (CREATE) trial evaluated the efficacy of 
combined antidepressant and psychological treatment, showing that antidepressant 
therapy with citalopram (i.e., SSRI) was associated with a reduction in depression scores, 
but there was no added value of short-term interpersonal psychotherapy over clinical 
management 78.
A lesson to be learned from these trials is that one size fits some but not all patients. 
Hence, more recently developed psychological intervention trials, such as the Coronary 
Psychosocial Evaluation Studies (COPES) and the Bypassing the Blues trial 79, 80, aimed to 
address several potential reasons for previous trials having shown modest to negligible 
results. One way forward may be to build in a 3-month observation period after an acute 
cardiac event to eliminate patients whose depressive symptoms might spontaneously 
remit due to symptoms being a reaction to an acute event. Second, in these recent 
trials interventions were tailored to patients’ individual needs and preferences, allowing 
patients to choose between several treatment options. Further, a stepped-care approach 
was adopted, with symptom severity being reviewed regularly and depression treatment 
being adjusted when indicated. Finally, these trials used a collaborative care approach, 
with trained non-physician “care managers” closely monitoring patients’ response to 
treatment, in close collaboration with the clinical management team 79, 80. These patient-
tailored, collaborative, stepped-care approaches led to significant improvements in 
depressed mood and health status 81, 82, a substantial improvement in satisfaction with 
depression care 82, and a promising reduction in major adverse cardiac events (i.e., non-
fatal MI or hospitalization for unstable angina pectoris) and all-cause mortality 82. 
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RECOMMENDATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH
Over the past decades, incorporation of the patient perspective into research and clinical 
practice has gained increased importance. As indicated by the American Institute of 
Medicine in their recommendations for an optimal health care system in the 21st century, 
patient-centeredness is 1 of 6 criteria that should guide clinical trials, guidelines, and 
treatment decisions 83. The findings from the current dissertation extend previous research 
by indicating that psychological distress is prevalent in about 1 in 4 patients treated with 
PCI and associated with poorer long-term prognosis. In the majority of patients, levels 
of distress remain stable over time and seem to be best predicted by baseline distress 
levels rather than by objective measures of disease severity, such as indication for PCI. 
Hence, it is important that clinicians take into account the patient perspective in this 
specific CAD subgroup and focus on the early identification of patients at high-risk for 
psychological distress by means of screening and monitoring, and hereby looking beyond 
factors related to disease severity and treatment. Follow-up care for PCI patients should 
be tailored to patients’ individual needs and preferences. Clinicians should refer PCI 
patients to CR, monitor their adherence to the program, and address potential reasons for 
non-adherence. When indicated, adjunctive psychological treatment should be provided 
(Table 1).  
In addition to recommendations for clinical practice, Table 1 further outlines 
recommendations for future research. Future large-scale randomized controlled trials 
are needed to evaluate the benefit of screening for psychological distress in CAD, as it 
is still unclear whether routine screening (combined with psychological treatment) 
results in improved levels of distress and clinical outcomes 43. Despite this controversy, a 
patient-tailored, collaborative, stepped-care approach of psychological treatment seems 
one avenue to pursue, as promising results were found in the first trials evaluating these 
approaches for the treatment of depression. Future psychological intervention trials are 
needed to further examine the impact of these approaches on distress levels, quality of 
life, and clinical outcomes. 
Besides depression, future trials should seek to broaden the scope by targeting 
other psychological factors, such as anxiety and Type D personality, as they have also been 
related to poorer prognosis in CAD 6, 42. A recent psychological intervention trial in Dutch 
community residents specifically targeted Type D personality, showing that a mindfulness-
based stress reduction intervention was associated with a significant decrease in both NA 
and SI dimensions 84. As indicated in Chapter 5, anhedonia is also of importance in the 
context of CAD both for short- and long-term prognosis. Therefore, future psychological 
intervention trials and clinical practice should not only target the reduction of negative 




promising, with CBT having been shown to improve positive affect in older depressed 
patients at increased cardiovascular risk 85, and mindfulness-based stress reduction 
programs improving positive affect in medically ill patients 86.  
Finally, the complex nature of psychological distress in the context of CAD 
warrants further investigation. Besides adopting a 'risk factor of the month approach' and 
examining the impact of one psychological risk factor at a time, also their co-occurrence 
seems worthwhile considering in future research, as risk factors tend to cluster together 
and may dispose patients to a higher risk as compared to the presence of a single factor 
21, 87, 88. Future research should also seek to unravel whether it is incident or recurrent 
distress that leads to the highest risk for morbidity and mortality. For example, it has 
been suggested that post-MI patients with a first episode of major depression had poorer 
survival than those with recurrent depressive episodes 89, 90. Lastly, it is important to enhance 
our understanding of the potential biological and behavioral pathways underlying the 
relationship between psychological distress and poorer prognosis in CAD, as this might 
point towards targets for secondary prevention. 
Table 1. Recommendations for future patient-centered initiatives in PCI patients 
Recommendations for clinical practice
•	 Incorporate	the	patient	perspective
•	 Identify	patients	at	high-risk	for	psychological	distress	–	look	beyond	factors	related	to	




Recommendations for future research
•	 Evaluate	the	benefit	of	routine	screening	for	psychological	distress	
•	 Evaluate	 patient-tailored,	 collaborative,	 stepped-care	 approaches	 to	 treatment	 for	
psychological distress
•	 Examine	appropriate	timing	of	psychological	interventions




CR = cardiac rehabilitation, PCI = percutaneous coronary intervention
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LIMITATIONS AND STRENGTHS OF THE CURRENT DISSERTATION
Some limitations of the findings presented in the current dissertation should be 
acknowledged. First, although the majority of studies included in this dissertation had 
a prospective cohort design, in Chapters 7 and 8 we report on cross-sectional data. 
The findings from these cross-sectional studies should be interpreted with caution, as 
the study design does not allow for causal inferences and generalizability of the study 
findings might be limited. Second, data on psychological distress was obtained from self-
report questionnaires and therefore, common method variance may have contributed 
to the significant results. However, we only used validated and reliable questionnaires to 
assess the psychological constructs studied, which have been used frequently in different 
cardiovascular patient groups 7, 42. Besides, even minimal symptoms of distress, as assessed 
by a questionnaire, have been shown to predict poorer prognosis 91. Third, although a 
variety of psychological distress factors have been addressed in this dissertation, we were 
not able to cover the whole spectrum of psychological factors that may be of importance 
in patients with CAD, such as a clinical diagnosis of anxiety and depression or other 
personality traits. Fourth, the majority of studies presented in this dissertation had a 
single-center design.
Strengths of the studies presented in the current dissertation comprise the 
relatively large samples of patients treated with PCI, ranging from 183 to 1234 patients. 
In addition, in Chapter 10 we present unique data on a nationwide unselected cohort of 
62.912 Danish CABG and PCI patients. A second strength includes the information on 
long-term mortality as presented in Chapters 4 and 5. In these chapters, we were able to 
examine the association between psychological distress and all-cause mortality after a 
median follow-up of 7 years, whereas previous studies have mainly followed patients for 
up to 5 years. Third, we had information on a wide range of socio-demographic and clinical 






The findings of the current dissertation suggest that the question of whether there is 
more to PCI than just coronary arteries could be answered with a whole-hearted “Yes”. 
Although PCI is considered to be a minimally invasive procedure, psychological distress 
is prevalent in about 25% of patients, tends to be stable over time, and is associated with 
poorer prognosis. Hence, in order to optimize the management and care of PCI patients 
in clinical practice, it is important to incorporate the patient perspective and focus on 
the early identification and monitoring of patients at high-risk for psychological distress, 
hereby looking beyond factors related to disease severity and treatment. It is crucial not 
only to acknowledge the low referral and participation rates of PCI patients to CR, but also 
to take action. This is particularly important given that patients with high distress levels 
are less likely to consent to participate and more likely to drop-out, while paradoxically 
they are likely to benefit the most. When indicated, adjunctive psychological care should 
be provided. Throughout the management and care of PCI patients, their voices should be 
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Op dit moment leven meer dan 1 miljoen mensen in Nederland met een hart- of 
vaatziekte en bijna 1 op de 3 Nederlanders overlijdt aan deze ziekte. Coronaire hartziekten 
(CHZ), zoals een acuut hartinfarct, zijn de meest voorkomende vormen van hart- en 
vaatziekten. CHZ zijn aandoeningen die worden veroorzaakt door afwijkingen in de 
kransslagaderen, de slagaderen die het hart van bloed en zuurstof voorzien. Door een 
ziekteproces dat slagaderverkalking, ofwel “atherosclerose”, genoemd wordt, kunnen 
vettige, verkalkte ophopingen in de wand van een kransslagader ontstaan (plaques) 
waardoor deze vernauwd raakt, wat kan leiden tot pijn op de borst. Een zogenaamde 
“atherosclerotische plaque” kan vervolgens openbarsten, waardoor de inhoud ervan in 
de bloedbaan terecht komt en bloedstolselvorming optreedt. Wanneer een kransslagader 
door dit proces volledig afgesloten wordt, kan een acuut hartinfarct ontstaan. Hoewel 
de kans op overlijden aan CHZ in de afgelopen jaren is gedaald – met name dankzij 
verbeterde behandelmogelijkheden - zijn CHZ nog steeds één van de belangrijkste 
oorzaken van overlijden en ziekte wereldwijd en doen daarmee een groot beroep op de 
gezondheidszorg.
Naast medicatie zijn een dotterbehandeling (PCI) of bypassoperatie (CABG) 
de meest gebruikte methoden om vernauwde of verstopte kransslagaderen te 
behandelen en de bloedtoevoer naar het hart te herstellen bij CHZ patiënten. Tijdens 
een dotterbehandeling wordt via een katheter een ballonnetje in de vernauwde of 
verstopte kransslagader gebracht en opgeblazen om de slagader te openen. Om 
ervoor te zorgen dat de kransslagader open blijft en de kans op het terugkeren van een 
vernauwing of verstopping te verkleinen, wordt tevens een zogenaamde stent geplaatst: 
een cilindervormige gaasstructuur met een doorsnede die gelijk is aan het bloedvat. 
Om het risico op een nieuwe vernauwing nog meer te verkleinen, worden er sinds 2001 
stents gebruikt die medicijnen afgeven, de zogenaamde “drug-eluting stents”. De meer 
invasieve bypassoperatie is een openhartoperatie, waarbij de vernauwing of verstopping 
in de kransslagader wordt omzeild door het aanleggen van een “omleiding”. Een 
“gezonde” slagader, meestal uit de borstkas of het been, wordt gebruikt om een nieuwe 
vaatverbinding te maken en zo de bloedtoevoer naar het hart te herstellen.
Aanvankelijk werd een dotterbehandeling vooral toegepast bij patiënten met 
vernauwingen of verstoppingen in slechts 1 kransslagader, terwijl bypassoperaties werden 
toegepast bij patiënten met complexere problemen. In de loop der jaren is veel ervaring 
opgebouwd met het toepassen van dotterbehandelingen, is de techniek verbeterd en 
zijn medicijnen ontwikkeld die de schadelijke gevolgen van procedure-gerelateerde 
complicaties beperken, waardoor het indicatiegebied voor dotterbehandelingen 
kon worden uitgebreid: in 2012 ondergingen 45.305 patiënten in Nederland een 
dotterbehandeling, vergeleken met 11.240 bypassoperaties in datzelfde jaar.
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Er zijn verschillende risicofactoren voor het ontstaan van CHZ bekend, zoals roken, 
suikerziekte, een hoog cholesterol gehalte en een hoge bloeddruk. Deze factoren kunnen 
ook het ziektebeloop (de prognose) bij patiënten die al CHZ hebben verslechteren. De 
laatste jaren is er steeds meer aandacht voor de rol van psychologische factoren, zoals 
angst, depressie en Type D persoonlijkheid. Type D persoonlijkheid wordt gekenmerkt door 
de gelijktijdige aanwezigheid van 2 persoonlijkheidskenmerken: negatieve affectiviteit 
en sociale inhibitie. Met andere woorden, patiënten met een Type D persoonlijkheid (ook 
wel “binnenvetters” genoemd) ervaren veel verschillende negatieve emoties, maar zijn 
niet geneigd deze te uiten in sociale situaties uit angst voor afwijzing of afkeuring door 
anderen. Uit eerdere onderzoeken blijkt dat psychische klachten, zoals angst, depressie 
en Type D persoonlijkheid, voorkomen bij ongeveer 1 op de 4 CHZ patiënten en dat deze 
het ziektebeloop negatief kunnen beïnvloeden. Zo hebben CHZ patiënten die psychische 
klachten ervaren een verhoogd risico op vroegtijdig overlijden en ziekenhuisopnames en 
rapporteren zij een lagere kwaliteit van leven. 
DOEL VAN DIT PROEFSCHRIFT
De meeste onderzoeken die tot nu toe gedaan zijn naar de invloed van psychologische 
factoren op de prognose van patiënten met CHZ, hebben zich gericht op patiënten 
die een bypassoperatie hebben ondergaan of op hartinfarctpatiënten. De rol van 
psychologische factoren bij patiënten die een dotterbehandeling ondergaan is tot nu toe 
onderbelicht gebleven. Komen psychische klachten net zo vaak voor bij dotterpatiënten 
als bij andere groepen hartpatiënten of bestaan er verschillen? Welke factoren dragen 
bij aan het ontstaan van psychische klachten bij dotterpatiënten? Wat is de invloed van 
psychologische factoren op de langetermijnprognose van dotterpatiënten? Deze vragen 
staan centraal in dit proefschrift. 
Figuur 1 geeft een overzicht van demografische, klinische en psychologische 
factoren die mogelijk een rol spelen bij het ziektebeloop van CHZ patiënten, gebaseerd 
op eerder onderzoek. In dit proefschrift wordt onderzocht in hoeverre enkele van deze 



































































VOORNAAMSTE BEVINDINGEN VAN DIT PROEFSCHRIFT
Met uitzondering van hoofdstuk 10, zijn alle onderzoeken in dit proefschrift gebaseerd op 
gegevens verzameld bij patiënten die gedotterd zijn in het Erasmus MC in Rotterdam. Op 
verschillende momenten na de dotterbehandeling zijn vragenlijsten afgenomen, waarmee 
informatie is verkregen over demografische, klinische en psychologische kenmerken van 
deze patiënten. Hoofdstuk 10 is gebaseerd op data die verkregen is uit nationale registers 
in Denemarken.
Zowel (min of meer chronische) pijn op de borst als een hartinfarct kunnen indicaties 
zijn voor een dotterbehandeling. Vanwege het meer acute karakter van een hartinfarct, 
wordt vaak gedacht dat deze patiënten meer psychische klachten ervaren na een 
dotterbehandeling dan patiënten die gedotterd worden naar aanleiding van klachten 
van pijn op de borst. Echter, uit de resultaten van hoofdstuk 2 van dit proefschrift blijkt 
dat er geen relevante verschillen zijn in de mate van angst en depressie tussen patiënten 
die gedotterd zijn na het doormaken van een hartinfarct of naar aanleiding van pijn op 
de borst. 
Hoofdstuk 3 beschrijft het beloop van angst en depressie over tijd in dotterpatiënten. 
Uit dit onderzoek blijkt dat angst en depressie bij ongeveer 80% van de patiënten 
stabiel blijven, tot een jaar na de dotterbehandeling. Wanneer patiënten ten tijde van de 
dotterbehandeling klachten van angst en depressie ervaren, bestaat er dus een grote kans 
dat deze klachten een jaar na de behandeling nog steeds bestaan. Anderzijds, wanneer 
patiënten ten tijde van de dotterbehandeling geen psychische klachten ervaren, is de 
kans groot dat zij geen klachten van angst en depressie ontwikkelen. 
Zoals eerder beschreven is er bij patiënten met CHZ veel onderzoek gedaan naar de invloed 
van psychologische factoren op de prognose van patiënten. Een klein aantal van deze 
onderzoeken heeft onderzocht of depressie ook de langetermijnprognose beïnvloedt, 
maar resultaten van deze onderzoeken zijn wisselend. Uit de bevindingen van hoofdstuk 
4 blijkt dat depressie voorkomt bij 26% van de dotterpatiënten en dat patiënten die 
depressieve klachten ervaren ten tijde van de dotterbehandeling een 50% hogere kans 
hebben om te overlijden na 7 jaar, dan patiënten zonder depressieve klachten. Tevens 
toont dit onderzoek aan dat het effect van depressie op overlijden onafhankelijk is van 
andere psychologische factoren, zoals angst en Type D persoonlijkheid. Zowel angst als 
Type D persoonlijkheid komen in dit onderzoek bij 29% van de dotterpatiënten voor.
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Binnen het onderzoek naar de rol van psychologische factoren bij CHZ wordt voornamelijk 
aandacht geschonken aan de rol van negatieve emoties, zoals angst en depressie. Over 
de invloed van positieve emoties is veel minder bekend. Enkele onderzoeken hebben zich 
gericht op de rol van anhedonie, ofwel het gebrek aan het ervaren van positieve emoties, 
in CHZ. Uit de resultaten van deze onderzoeken blijkt dat patiënten met anhedonie een 
hoger risico hebben op overlijden binnen 2 jaar na een cardiale gebeurtenis (zoals een 
hartinfarct) en een lagere kwaliteit van leven rapporteren, dan patiënten zonder anhedonie. 
De invloed van anhedonie op de langetermijnprognose is nog niet eerder onderzocht. 
Hoofdstuk 5 richt zich op de vraag of anhedonie invloed heeft op de langetermijnsterfte 
onder dotterpatiënten. De resultaten van dit onderzoek laten zien dat anhedonie 
voorkomt bij 24% van de dotterpatiënten en dat patiënten met anhedonie klachten ten 
tijde van de dotterbehandeling een 60% hogere kans hebben om te overlijden na 7 jaar, 
in vergelijking met patiënten zonder anhedonie klachten. 
Uit eerdere onderzoeken blijkt dat de invloed van obesitas (BMI >30) op overlijden in 
CHZ patiënten paradoxaal is: mensen met obesitas overlijden minder snel dan mensen 
met een gezond gewicht. De verklaring voor dit fenomeen is tot op heden onbekend. 
In hoofdstuk 6 wordt onderzocht of er bij dotterpatiënten ook sprake is van deze 
zogenaamde “obesitas paradox” en of de gezondheidstoestand van patiënten hiervoor 
een mogelijke verklaring kan bieden. Gezondheidstoestand wordt gedefinieerd als de 
“perceptie van de patiënt met betrekking tot de invloed van een ziekte of behandeling op 
zijn of haar symptomen, functioneren en kwaliteit van leven”. Het zou zo kunnen zijn dat 
obese patienten een betere gezondheidstoestand rapporteren dan niet-obese patienten 
en dat dit mogelijk leidt tot een betere prognose. Uit dit onderzoek blijkt dat patiënten 
met overgewicht (BMI 25-30), maar niet de obese patiënten, een 40% lager risico hebben 
om te overlijden 7 jaar na de dotterbehandeling, in vergelijking met patiënten met een 
gezond gewicht (BMI 18.5-25). Er lijkt dus geen sprake van een obesitas paradox, maar wel 
van een “overgewicht paradox”. Uit het onderzoek blijkt ook dat de patiëntgerapporteerde 
gezondheidstoestand geen verklaring biedt voor deze paradox. 
In hoofdstuk 7 staat de relatie tussen opvoedingsstijl, angst en depressie en Type D 
persoonlijkheid centraal. Uit de bevindingen blijkt dat een overbezorgde of verwaarlozende 
opvoedingsstijl door ouders (zoals herinnerd door patiënten) samenhangt met angst, 
depressie en Type D persoonlijkheid bij patiënten die een dotterbehandeling hebben 
ondergaan. Op basis van de resultaten wordt gesuggereerd dat een disfunctionele 
opvoedingsstijl kan bijdragen aan het ontstaan van een Type D persoonlijkheidstype en 
dat dit vervolgens kan leiden tot verhoogde angst en depressie (Figuur 2). Echter, deze 








Figuur 2. Samenhang tussen disfunctionele opvoedingsstijl, angst en depressie en Type D 
persoonlijkheid 
Verschillende onderzoeken hebben zich gericht op mogelijke biologische en 
gedragsmatige mechanismen die de relatie tussen psychische klachten en de prognose 
van CHZ patiënten kunnen verklaren (zie ook Figuur 1). Vaak onderzochte biologische 
mechanismen zijn inflammatie en de mate van atherosclerose (slagaderverkalking). 
Inflammatie is een verzamelnaam voor de afweerreactie van het lichaam tegen vreemde 
organismen (zoals virussen en bacteriën) en treedt op bij verwonding en ziekte. De 
mate van inflammatie kan gemeten worden aan de hand van bepaalde markers in het 
bloed, de zogenaamde “cytokines”. Zowel inflammatie als de mate van atherosclerose 
zijn gerelateerd aan het ontstaan en de progressie van CHZ. Eerder onderzoek heeft 
verbanden aangetoond tussen psychische klachten, zoals angst, depressie en Type D 
persoonlijkheid, en een verhoogde inflammatie in CHZ. Ook blijken psychische klachten 
samen te hangen met een verhoogde mate van atherosclerose. Echter, in andere studies 
werden deze relaties niet gevonden. In hoofdstuk 8 worden inflammatie en de mate van 
atherosclerose onderzocht als mogelijke verklaringen voor de relatie tussen psychische 
klachten en prognose bij patiënten die een dotterbehandeling hebben ondergaan. 
In dit hoofdstuk worden geen duidelijke verbanden gevonden tussen psychische 
klachten en inflammatie of de mate van atherosclerose, dus deze beide mechanismen 
lijken bij dotterpatiënten geen belangrijke rol te spelen. Mogelijk spelen andere, meer 
gedragsmatige, mechanismen een grotere rol in deze patiëntengroep, maar meer 
onderzoek op dit gebied is nodig.
In hoofdstuk 9 wordt het fenomeen “attritie-bias” onderzocht in een prospectieve studie 
bij dotterpatiënten. Er is sprake van een mogelijke attritie-bias in een wetenschappelijk 
onderzoek als studiedeelnemers die het onderzoek helemaal afronden verschillen 
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van deelnemers die voortijdig uitvallen (“uitvallers”), waardoor de resultaten van 
het onderzoek mogelijk vertekend kunnen worden. Uit hoofdstuk 9 blijkt dat er 
inderdaad verschillen bestaan tussen patiënten die zowel een maand als een jaar na 
de dotterbehandeling de vragenlijsten hebben ingevuld en patiënten die dit wel een 
maand na de dotterbehandeling hebben gedaan, maar niet na een jaar (uitvallers). De 
uitvallers zijn jonger, roken vaker, maar krijgen minder vaak bepaalde hartmedicijnen 
voorgeschreven (calcium-antagonisten en ACE-remmers), in vergelijking met patiënten 
die op beide momenten de vragenlijsten hebben ingevuld. Daarnaast ervaren uitvallers 
vaker psychische klachten, zoals angst en depressie. Tot slot is onderzocht of uitvallers 
een slechtere prognose hebben en eerder overlijden dan patiënten die de gehele 
onderzoeksduur betrokken blijven bij het onderzoek, maar hierin zijn geen verschillen 
gevonden. De resultaten van dit onderzoek suggereren dat het in vervolgonderzoeken 
zinvol is om aandacht te besteden aan deze zogenoemde attritie-bias en er bij stil te staan 
dat dit mogelijk de bevindingen van een onderzoek kan vertekenen. 
Tot slot is in hoofdstuk 10 het nationale Deense Hart Register gebruikt om informatie 
op te vragen over alle patiënten die tussen 1999 en 2012 opgenomen zijn geweest in 
een Deens ziekenhuis en een dotterbehandeling of bypassoperatie hebben ondergaan. 
Daarnaast is informatie opgevraagd met betrekking tot het gebruik van medicatie voor 
angst en depressie (anxiolytica en antidepressiva) in beide patiëntengroepen, tot aan een 
jaar na de behandeling. Uit dit onderzoek blijkt dat er geen klinisch relevante verschillen 
bestaan in het gebruik van antidepressiva en anxiolytica tussen patiënten die gedotterd 
zijn en patiënten die een bypassoperatie hebben ondergaan. Deze bevindingen duiden 
er mogelijk op dat er geen grote verschillen bestaan in de mate waarin zij klachten van 
angst en depressie ervaren, maar meer onderzoek op dit gebied is nodig. 
CONCLUSIES EN AANBEVELINGEN 
Een dotterbehandeling wordt in vergelijking met een bypassoperatie doorgaans 
beschouwd als een niet-invasieve procedure, waarbij na de behandeling meestal 
meteen een verbetering in lichamelijke klachten, zoals benauwdheid en vermoeidheid, 
optreedt. Echter, de resultaten van dit proefschrift suggereren dat niet alleen de medische 
situatie met betrekking tot de kransslagaderen van belang is voor het welbevinden van 
dotterpatiënten, maar dat ook psychologische factoren een rol spelen. Uit dit proefschrift 
blijkt namelijk dat psychische klachten, zoals angst, depressie en Type D persoonlijkheid, 
voorkomen bij 25-29% van de dotterpatiënten. Deze percentages komen overeen met 
bevindingen in andere CHZ groepen (zoals hartinfarctpatiënten en patiënten die een 
bypassoperatie hebben ondergaan). Hoewel de gevonden prevalentie van psychische 
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klachten in de onderzoeken dus vrij hoog is, zou dit toch nog een onderschatting kunnen 
zijn gezien het feit dat patiënten met psychische klachten minder geneigd zijn mee te 
doen aan onderzoek of, zoals aangetoond in dit proefschrift, vaker voortijdig uitvallen 
(attritie-bias) dan patiënten zonder psychische klachten. 
Bij de meerderheid van de dotterpatiënten (ongeveer 80%) blijven psychische 
klachten stabiel over tijd: wanneer patiënten ten tijde van de dotterbehandeling psychische 
klachten ervaren, bestaat er een grote kans dat deze klachten een jaar na de behandeling 
nog steeds aanwezig zijn. De resultaten in dit proefschrift laten verder zien dat het ervaren 
van psychische klachten na een cardiale gebeurtenis niet zozeer samenhangt met ziekte-
ernst, type behandeling (dotterbehandeling vs. bypassoperatie) of de indicatie voor 
behandeling (hartinfarct vs. pijn op de borst), maar meer met psychologische factoren 
die relateren aan de “subjectieve ervaring” van de hartziekte. Zo blijkt dat het ervaren van 
psychische klachten na een dotterbehandeling vooral voorspeld wordt door het wel of 
niet aanwezig zijn van deze klachten ten tijde van de behandeling. Daarnaast lijkt er een 
positief verband te bestaan tussen Type D persoonlijkheid en het ervaren van angst en 
depressie bij dotterpatiënten. Uit dit proefschrift blijkt tevens dat dotterpatiënten met 
klachten als depressie en anhedonie een slechtere langetermijnprognose hebben en 
eerder overlijden dan patiënten zonder deze klachten. Tot slot suggereren de resultaten 
dat inflammatie en de mate van atherosclerose geen duidelijke verklaring bieden voor de 
samenhang tussen psychische klachten en prognose bij dotterpatiënten; mogelijk spelen 
meer gedragsmatige mechanismen een grotere rol in deze patiëntengroep. 
Om de zorg voor dotterpatiënten in de klinische praktijk te optimaliseren, is het 
dus van belang om niet alleen aandacht te besteden aan medische factoren, zoals ziekte-
ernst, maar ook het psychologisch welbevinden van dotterpatiënten in ogenschouw 
te nemen. Hartrevalidatie is een belangrijke vorm van nazorg voor patiënten met CHZ, 
waarin fysieke training gecombineerd wordt met leefstijladviezen en psychologische 
begeleiding. Het is bekend dat het volgen van een hartrevalidatie programma na een 
cardiale gebeurtenis positieve effecten heeft en kan zorgen voor een vermindering van 
psychische klachten, een betere kwaliteit van leven en een gunstigere prognose. Echter, 
uit onderzoek blijkt dat meer dan één derde van de patiënten die een dotterbehandeling 
heeft ondergaan niet deelneemt aan een hartrevalidatie programma. Daarnaast is de uitval 
in hartrevalidatieprogramma’s hoog, waarbij vooral patiënten uitvallen die het mogelijk 
het hardst nodig hebben, zoals patiënten die angst en depressie ervaren en een lage 
kwaliteit van leven rapporteren. Het is dus zinvol om patiënten met psychische klachten 
in een vroegtijdig stadium te identificeren en gepaste nazorg te bieden, eventueel in de 
vorm van een aanvullende psychologische behandeling, toegespitst op de behoeften en 







Het duurt even een paar jaar, maar dan heb je ook wat: het proefschrift is klaar! Via deze 
weg wil ik een aantal mensen bedanken die hebben bijgedragen aan de totstandkoming 
van dit boekje.
Allereerst wil ik alle patiënten bedanken die hebben meegewerkt aan de 
verschillende studies van dit proefschrift. Bedankt voor jullie bereidheid om alle 
vragenlijsten in te vullen, zonder jullie bijdrage was dit proefschrift er nooit geweest!
Ook gaat mijn dank uit naar mijn promotoren: Prof. dr. Susanne Pedersen en 
Prof. dr. Eric Boersma en mijn copromotor dr. Henneke Versteeg. Bedankt voor jullie fijne 
begeleiding en voor alles wat jullie mij geleerd hebben. Jullie enthousiasme voor de 
wetenschap werkt aanstekelijk! Ik mag dan misschien niet zo in de wieg gelegd zijn als 
“praat-psycholoog”, maar mijn enthousiasme voor het onderzoek is dankzij jullie des te 
groter geworden.
Susanne, bedankt dat je me ruim 3 jaar geleden de kans bood om bij jou als AIO 
aan de slag te gaan. Ik heb onze samenwerking als erg prettig ervaren en heb ontzettend 
veel van je geleerd! Bedankt voor het vertrouwen dat je altijd in me gehad hebt en voor 
het feit dat ik altijd bij je terecht kon, zowel op werk als op persoonlijk vlak. Ik ben blij dat 
ik jou op mijn beurt af en toe wat Didi-kleding aan heb kunnen smeren :-). Ik vind het knap 
dat je de stap hebt gemaakt om naar Denemarken te gaan en wens je daar alle goeds. 
Ik hoop dat we in de toekomst nog regelmatig een “Chardonnaytje” met elkaar kunnen 
drinken en wellicht nog eens een bezoekje kunnen brengen aan jouw geliefde Christiania 
in Kopenhagen?! 
Eric, dank je wel voor je begeleiding vanuit het Erasmus MC. Ik vind het fijn dat 
jouw deur altijd voor me open stond en ik heb veel van je geleerd. Jouw kritische blik hielp 
me om dingen soms net vanuit een ander perspectief te zien, wat mijn proefschrift zeker 
ten goede is gekomen! 
Henneke, mijn allerliefste roomie, wat hebben we samen een leuke tijd gehad 
op de universiteit: In P604 was het altijd een feestje!. Bedankt voor je begeleiding bij mijn 
proefschrift, ik vind het heel fijn dat ik altijd bij je terecht kon met mijn vragen, al was het 
maar om soms alleen even te horen "ja dat is goed" :-). Ik wil je ook heel erg bedanken 
voor alle gezelligheid buiten de universiteit, zoals tijdens congressen of onze vele etentjes 
en borrelavondjes. Ik ben heel blij met jouw vriendschap en zou je niet meer kunnen 
missen!
Aline, zonder jou was ik nooit als AIO op de universiteit terecht gekomen. 
Bedankt dat je me tijdens mijn afstudeerstage kennis hebt laten maken met wat een 
promotieonderzoek inhoudt en dat je me aan deze baan hebt geholpen. Jouw fijne 
begeleiding tijdens mijn eerste jaar zorgde ervoor dat ik me al snel thuis voelde op de 
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universiteit. Ook zal ik mijn eerste congres in Brussel nooit vergeten, waarbij ik mijn “spa 
rood sur les montagnes” heel charmant over jullie uitspuugde omdat ik zo moest lachen 
om jou!
Johan, bedankt voor de fijne tijd op de afdeling en je betrokkenheid bij een 
aantal van mijn artikelen. Ik heb bewondering voor jouw eindeloze kennis over tal van 
onderwerpen en heb daar veel van geleerd. Ik hoop dat onze wegen elkaar in de toekomst 
nog eens zullen kruisen!
Verder wil ik graag mijn promotiecommissie bedanken, bestaande uit Prof. 
dr. Guus van Heck, Prof. dr. Victor Pop, Prof. dr. Felix Zijlstra, dr. Christina Bode, dr. Nina 
Kupper en dr. Ken Redekop. Bedankt voor jullie bereidheid zitting te nemen in mijn 
promotiecommissie en mijn proefschrift te beoordelen. Christina, het ARPH congres dat 
we samen in Twente hebben georganiseerd zal ik nooit vergeten! Ons motto “als jij er niet 
aan hebt gedacht en ik ook niet, dan zal het wel niet belangrijk zijn” heeft het congres tot 
een waar succes gemaakt! Bedankt dat je deur altijd voor me open stond in Twente en ik 
hoop dat we elkaar in de toekomst nog regelmatig zullen blijven zien.
De interventiecardiologen van het Thoraxcentrum van het Erasmus MC wil ik 
bedanken voor het feit dat ik heb mogen werken met databestanden gebaseerd op jullie 
patiënten. Ron, bedankt voor het ter beschikking stellen van de data en je feedback op 
mijn artikelen. Ook de overige coauteurs wil ik bedanken voor hun kritische en waardevolle 
feedback op mijn manuscripten.
Gunnar and Stefan, thank you for your kind hospitality and supervision during 
our stay in Copenhagen. Although SAS and STATA sometimes "drove us crazy", we had a 
wonderful time!
Remco, bedankt dat jij het ontwerp voor de cover van dit proefschrift en de 
uitnodigingen hebt willen verzorgen. Fijn dat jij na 3 zinnen wist wat ik ongeveer voor 
ogen had! Als het van mijn eigen creativiteit af had moeten hangen, was het waarschijnlijk 
een heel saai boekje geworden. Sean, bedankt voor je bereidheid om ondanks je eigen 
drukke agenda de lay-out van mijn proefschrift te verzorgen en mijn "correctiebijbeltjes" 
en "beschouwingen" te verwerken. Zonder jullie beide had dit proefschrift er nooit zo 
mooi uitgezien, ik ben erg blij met het eindresultaat!
Mijn ex-collega’s van Tilburg University en het Erasmus MC wil ik graag bedanken 
voor de fijne samenwerking van de afgelopen jaren. In het bijzonder wil ik de “device-
ladies” Corline, Henneke, Madelein, Mirjam en Mirela bedanken voor alle fijne en leuke 
momenten op de universiteit en daarbuiten, ik ben blij dat jullie mij als “niet-device-AIO” 
wilden adopteren. Mirjam, ik heb genoten van onze gezamenlijke congressen in Parijs 
en Bordeaux. Corline, bedankt voor de supertijd die we samen in Kopenhagen hebben 
gehad! Bewoners van de 6e verdieping, de gezellige lunches en borrels op onze “party-
gang” waren onvergetelijk! Bedankt voor alle gezelligheid en het luisterend oor wat ik 
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altijd bij jullie vond, ik ga jullie missen! 
Ik wil mijn collega’s van het NIVEL bedanken voor de warme ontvangst. In het 
bijzonder mijn leidinggevende Prof. dr. Cordula Wagner en mijn “mede-patiëntveiligheid-
collega’s”: ik heb veel zin om aan mijn nieuwe project te gaan beginnen en ik kijk uit naar 
onze verdere samenwerking! Kamergenootjes Sanneke, Stef en Paul, bedankt voor het 
beantwoorden van de vele vragen op mijn eerste dagen, mede dankzij jullie voelde ik me 
al gauw thuis binnen het NIVEL! 
Lieve Saar en Miep, ik ben heel erg blij dat jullie als paranimfen achter me staan, 
ik had me geen betere “nimfjes” kunnen wensen! Met jullie talloze one-liners over het hart 
weet ik zeker dat het met die verdediging wel goed gaat komen, jullie hebben het hart op 
de juiste plek zitten! Nu maar hopen dat ik niet ziek wordt…
Saar, ik ken je zo ongeveer al mijn hele leven en van kleins af aan hebben we 
lief en leed gedeeld. Over wat wij allemaal samen hebben meegemaakt, zou ik een boek 
kunnen schrijven! Stapavondjes, shoppen, sauna, concerten, weekendjes weg, mooie 
reizen en vooral uren en uren kletsen over alles wat ons bezighoudt. Bedankt dat je er 
altijd voor me bent, ook al vertel ik 10x hetzelfde verhaal. Ik kijk uit naar alle dingen die 
we samen nog gaan meemaken, met om te beginnen een mooie reis in het najaar. Je bent 
een super vriendin!
Marieke, miepie, gompie, jouw beslissing om een master in Tilburg te gaan 
volgen en bij ons in “huisje-boompje-feestje” te komen wonen is wat mij betreft één van 
de beste uit je leven geweest, want ik zou je nooit meer kunnen missen! Ook al wonen we 
niet meer in hetzelfde huis, we spreken elkaar bijna dagelijks en delen elk klein detail van 
ons leven. Voordat ik het zelf weet, weet jij vaak al hoe ik me voel of ergens over denk...
zo bijzonder! Fijn dat jij me er zo nu en dan op wijst dat ik ook wel eens de stoptrein kan 
pakken :-). Ik geniet enorm van onze vriendschap, alle leuke dingen die we samen doen en 
onze eindeloze gesprekken (met name over eten). Weet dat ik heel erg trots op je ben! 
Lieve Mark, vanaf het moment dat wij elkaar hebben ontmoet in de TIK-week 
zijn we onafscheidelijk. Jij hebt mijn studententijd in Tilburg tot een onvergetelijke tijd 
gemaakt! Ik ben je ontzettend dankbaar voor het feit dat je nooit te beroerd was om me 
af te melden voor college als “Dikkie Laurina Mathilda Damen”. Maar de kers op de taart 
van onze avonturen is toch wel de fantastische tijd die we in Zuid-Afrika hebben gehad! 
Wat hebben we daar veel leuke dingen gedaan en wat was het fijn om dat samen met jou 
te delen! Ik ben heel blij met jou als mijn maatje en ik hoop dat we in de toekomst nog 
veel mooie momenten samen zullen meemaken, met meer vals spelen tijdens een potje 
Tai-pan, meer wijn en meer borrelhapjes!
Lieve Lon, zonder jou zou het leven er een stuk saaier uitzien! Wat begon als een 
onzeker “Papa, mag Lonneke misschien bij mij komen spelen na de hockey?” is uitgegroeid 
tot een hechte vriendschap. Bedankt voor alle fijne en gezellige momenten die we samen 
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hebben meegemaakt. Vooral van de avonden dat we zeker-weten-op-stap-gaan-maar-
uiteindelijk-toch-op-de-bank-belanden geniet ik volop! Ook op winkelgebied vullen wij 
elkaar naadloos aan en stoken we elkaar altijd heerlijk op om dingen te kopen die we van 
tevoren niet van plan waren :-). Bedankt dat ik altijd met mijn verhalen bij je terecht kan, 
ik vind je een super vriendin!
HKGD, ofwel Els, Renske, Roos en Terri, bedankt voor alle DOLFijne dingen die we 
met elkaar hebben beleefd tijdens de studie en daarna. Ik geniet erg van onze gezellige 
uitjes, zoals high tea’en, high wine’en, sinterkerst vieren en natuurlijk onze DOLdwaze 
weekendjes weg! 
“Etten-Leur gang”, Saar, Soof, Anja en Kaat, we go waaaaaaay back! Ik vind het 
heel erg leuk dat we elkaar nog altijd weten te vinden en zoveel gezellige dingen met 
elkaar doen. Ik zeg, dat houden we erin!
Annefleur, een potje tennissen in Goirle leidde tot het volledig uitstippelen van 
jouw leven, met gezellig samen werken op de uni, gezellig samen in een tennisteam en 
wie weet ooit nog gezellig als buufies naast elkaar wonen ;-). Bedankt voor de lol die we 
altijd samen hebben, op of buiten de tennisbaan, maar ook voor de serieuze gesprekken 
die we zo nu en dan ook nog wel eens voeren :-). 
Maria, bedankt voor de jarenlange gezelligheid in ons huisje aan de Prof. 
Cobbenhagenlaan. Ik zal alle series die wij samen hebben gekeken, wijntjes en wodka-
limes die we hebben gedronken en de “couple of M&M’s” die we hebben gegeten, niet 
snel vergeten! 
Ingrid en Margo, ik ben blij met jullie als mijn liebe grosse Schwestern! Een 
wintersport met jullie staat garant voor heel veel gemutlichkeit….en owja, af en toe ook 
wat skiplezier! Weet dat kleine Schwester altijd klaarstaat om jullie om 7.30u uit bed te 
trommelen en natuurlijk om Drei Grosse Bier te halen! 
Cindy, mijn andere grote zus, ik vind het bijzonder hoeveel wij op elkaar lijken! Van 
jurkjes, jassen, schoenen, armbanden en huisinrichting tot aan het delen van gerechten in 
een restaurant…dit is meant to be! :-) Ik ben blij dat we elkaar hebben ontmoet en hoop 
dat we elkaar veel zullen blijven zien!
Lieve papa en mama, alias “de zwervertjes”, bedankt dat jullie altijd voor me 
klaarstaan. Jullie vormen samen de ideale combi: Mama, bedankt dat ik bij jou altijd 
terecht kan met dingen waar “wij vrouwen” ons nou eenmaal soms druk om maken. Papa, 
jouw nuchtere kijk op het leven zorgt ervoor dat ik met beide benen op de grond blijf, 
bedankt dat je me altijd met raad en daad bijstaat! Wie had gedacht je ook nog eens kijk 
op mode had ;-). Ik heb veel bewondering voor hoe jullie in het leven staan en ik hoop dat 
jullie de komende jaren lekker blijven genieten en rondzwerven over de wereld, laat dat 
werken maar aan ons over! Ad en Elly, bedankt dat jullie er altijd voor Stijn en mij zijn, ik 
had me geen leukere en lievere schoonouders kunnen wensen!
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Pim, lief klein broertje, inmiddels toren je hoog boven me uit en ligt de tijd dat 
ik volop over jou kon moederen ver achter ons (al probeer ik dat soms natuurlijk stiekem 
toch nog even :-)). Ik ben blij dat onze familie over een heuse “Dokter Mc Dreamy-in spe” 
beschikt, weet dat ik erg trots op je ben!
Lieve opa en oma, ik ben er trots op dat jullie bij mijn promotie aanwezig zijn! 
Speciaal voor jullie nu ook een deel van het boekje in het Nederlands, zodat jullie meer 
kunnen lezen dan alleen de namen van de referenties. En ja…ik heb het allemaal zelf 
geschreven! ;-)
En tot slot lieve, lieve Stijn, wat zou ik toch zonder jou moeten?! Je eindeloze 
geduld en gevoel voor humor in combinatie met je fantastische skills om knopen aan te 
zetten, de lekkerste maaltijden op tafel te toveren en klusjes in huis te doen (“Stijn, wil je 
even komen, het lukt niet”) maken jou tot de beste en liefste vriend die ik me maar kan 
wensen! Bedankt dat je er altijd voor me bent en ik hoop dat ik ooit je droom om huisman 
te worden uit kan laten komen :-). Ik houd van je!
Nikki, februari 2014
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